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Abstract
Emerging evidence implicates the regulation of higher-order chromatin structure in brain
development, maturation, and function. Human mutations in two important regulators of
chromatin structure, ATRX and CTCF, cause microcephaly and intellectual disability and
have been identified in several cancers, suggesting an important role for these proteins in
the developing brain and to suppress tumourigenesis. This thesis demonstrates that
chromatin structure is critical to the differentiation and survival of neural progenitor cells,
and explores the mechanisms of ATRX and CTCF function in brain development. The
first chapter identifies that Atrx deficiency induces replicative DNA damage at telomeres
and pericentromeric heterochromatin, and the mutant mice display signs of premature
aging, providing novel evidence that genetic damage restricted to the central nervous
system can result in systemic defects that resemble aging. The second chapter
demonstrates that the genome organizer CTCF is required for neural progenitor survival
and to maintain the correct balance between proliferative and differentiative divisions in
the mouse neocortex. The third chapter investigates the mechanism underlying p53- and
PUMA-dependent apoptosis in Ctcf-null neural progenitor cells, focusing on a role for
the protein in preventing replicative stress-induced apoptosis. Together, the findings
presented here indicate that chromatin architectural proteins, such as ATRX and CTCF,
are required for genomic stability to promote neural progenitor cell survival and support
correct brain development.
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Chapter 1
1 General Introduction
Our knowledge of the genome has expanded considerably in the past decades, with the
decreasing costs of high-throughput sequencing technologies and the completion of the
human genome project. We now know that DNA sequence does not simply dictate
function, but rather that protein factors and chemical modifications “above” the genome
can dramatically alter the organization of DNA within the nucleus and constitute a major
mechanism underlying transcriptional regulation, DNA replication, and DNA repair
dynamics.
Sequencing of the human genome has also greatly expanded our understanding of human
disease etiology, and new technologies continue to drive progress in the field. Recent
advances in exome sequencing, i.e. sequencing of codon sequences that constitute 1% of
the genome, has demonstrated that neuropsychiatric diseases, such as those on the autism
spectrum, are primarily caused by mutations in synaptic proteins and epigenetic factors
(De Rubeis et al., 2014; Pinto et al., 2014). This highlights the importance of chromatin
regulation in brain development and function. Moreover, microcephaly and intellectual
disability (ID) are caused by disruptions in the DNA damage response and cell cycle
regulatory pathways, which coalesce at the level of chromatin regulation. However, the
dynamic interplay between DNA damage signaling and chromatin structure, and how
they are integrated into cell cycle regulation is not well understood, especially in the
context of brain development.
The work herein describes a role for two important regulators of chromatin structure,
ATRX and CTCF, in genomic stability to promote neuroprogenitor cell survival and
correct brain development, and explores the functional means by which these essential
proteins exert their actions.
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1.1 ATRX is essential for brain development and the suppression of
tumourigenesis
1.1.1 The ATRX Gene and Protein
The alpha thalassemia mental retardation, X-linked (ATRX) protein was first cloned over
twenty years ago and described as a putative helicase protein due to sequence homology
with the Rad54 helicase (Stayton et al., 1994). ATRX is comprised of 36 exons and spans
approximately 300 kilobases (kb) of DNA sequence located on the long arm of the
human X chromosome (Xq21.1) (Picketts et al., 1996; Villard et al., 1997). The gene is
conserved between mouse and human (85% homologous), and homologs of the protein
have been identified in Drosophila melanogaster (dATRX; 66% homologous), and
Caenorhabditis elegans (xnp-1; 52% homologous) (Lee et al., 2007; Picketts et al., 1996;
Villard et al., 1999). In vivo expression patterns demonstrated that ATRX is a ubiquitous
nuclear protein that may play an important role in neuronal differentiation since protein
levels were highest in fetal brain (Gecz et al., 1994). ATRX is a member of the SNF2
subgroup of the SWI/SNF protein superfamily that can incorporate themselves into multisubunit complexes and utilize the energy of ATP to remodel chromatin (Picketts et al.,
1996). SWI/SNF members are involved in transcriptional regulation, DNA repair, and
mitotic recombination (Carlson and Laurent, 1994; Eisen et al., 1995; Picketts et al.,
1996).
ATRX contains two highly conserved domains: a globular ATRX-DNMT3-DNMT3L
(ADD) domain in the amino (N)-terminus, and a carboxy (C)-terminal helicase domain
(Aapola et al., 2000; Argentaro et al., 2007; Picketts et al., 1998; Xie et al., 1999) (Figure
1-1a). The ADD domain is cysteine-rich and contains two types of zinc finger motifs: a
plant homeodomain (PHD) finger flanked by a GATA-1-like C2C2 motif (Gibbons et al.,
1997). The de novo DNA methyltransferases (DNMT) DNMT3A, DNMT3B, and
DNMT3L are the only other proteins that contain this type of domain (Xie et al., 1999).
ADD can bind both DNA and RNA, and has an affinity for H3K9me3-containing
nucleosomes in the absence of H3K4 methylation (Argentaro et al., 2007; Dhayalan et
al., 2011; Eustermann et al., 2011; Iwase et al., 2011; Mitson et al., 2011; Sarma et al.,
2014) (Figure 1-1b). Furthermore, the ADD domain is one of the only known readers of
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the H3K9me3-S10ph combinatorial modification (Eustermann et al., 2011; Kunowska et
al., 2015; Noh et al., 2014). H3K9me3-S10ph has been shown to modulate binding of
polycomb proteins during differentiation (Sabbattini et al., 2014), and H3S10ph is
induced under periods of high neuronal activity at the promoter of immediate early genes
(Crosio et al., 2003). The ATRX helicase domain exhibits ATPase chromatin remodeling
activity that can be stimulated by nucleosomes or DNA (Tang et al., 2004; Xue et al.,
2003).
Characterization of the full-length ATRX gene revealed that it gives rise to at least three
alternative transcripts (Berube et al., 2000; Garrick et al., 2004; Picketts et al., 1996).
Two of the transcripts depend on alternative splicing of exon 6, which lies upstream of
the ADD domain, and generate transcripts of approximately 10.5 kb that give rise to
proteins of 265 and 280 kDa, respectively (Picketts et al., 1996; Villard et al., 1997). The
third isoform of ATRX results from a failure to remove intron 11, generating a premature
stop codon and C-terminal truncated protein (ATRXt) of approximately 180 kDa (Berube
et al., 2000; Garrick et al., 2004). The functional significance of different ATRX isoforms
is not understood, however ATRXt likely does not perform identical activities as fulllength ATRX since it lacks the ATPase domain.
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Figure 1-1 The ATRX protein and function
(A) Structure of the ATRX protein. Conserved domains and relevant protein interaction
sites are indicated. (B) Model of ATRX recruitment to heterochromatin. The ADD
domain of ATRX recognizes the combinatorial signature of H3K4me0 (white circle)H3K9me3 (navy circle), the LxVxL motif within the linker domain interacts with HP1
(Lechner et al., 2005), and DAXX interacts with the ATPase domain of ATRX. ATRXDAXX deposits H3.3 in heterochromatin (Drane et al., 2010; Goldberg et al., 2010;
Lewis et al., 2010; Pathak et al., 2014), while restricting incorporation of macro H2A
(Ratnakumar et al., 2012).
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1.1.2 ATRX is a heterochromatin-associated protein
ATRX is an exclusively nuclear protein that associates with the nuclear matrix during
interphase (Berube et al., 2000). At the onset of mitosis ATRX is phosphorylated and
released from the nuclear matrix (Berube et al., 2000). Throughout the cell cycle ATRX
localizes to pericentromeric heterochromatin (PCH) and interacts directly with
heterochromatin protein 1 α (HP1α) (Berube et al., 2000; Lechner et al., 2005; McDowell
et al., 1999). Depletion of ATRX has minimal effect on HP1 localization (Huh et al.,
2012; Ritchie et al., 2008; Wong et al., 2010), while loss of HP1 results in abnormal
targeting of ATRX to heterochromatin (Kourmouli et al., 2005), suggesting that HP1 is
involved in recruitment or stabilization of ATRX. Mutation to the LxVxL HP1
interaction motif (Figure 1-1a) reduced ATRX localization at heterochromatin to a lesser
extent than mutations in the ADD domain (Eustermann et al., 2011), pointing to a
stabilization role for HP1 in ATRX localization rather than recruitment per se.
ATRX can also interact with the methyl CpG binding protein 2 (MeCP2) through its Cterminal helicase domain, and together the proteins co-localize at DAPI-bright
heterochromatin bundles in the nucleus (Kernohan et al., 2010; Nan et al., 2007).
MeCP2-deficient neurons display abnormal targeting of ATRX to heterochromatin
(Baker et al., 2013; Nan et al., 2007). C-terminal fragments of ATRX require MeCP2 for
heterochromatic localization while N-terminal fragments of the protein localize to DAPIbright heterochromatin in a MeCP2-independent manner (Nan et al., 2007), indicating
that the N-terminus contains elements required for ATRX targeting. Further support for
this stems from the fact that the short isoform of ATRX (ATRXt) is capable of localizing
to PCH despite lacking the C-terminal MeCP2-interaction domain (Garrick et al., 2004).
Indeed, the N-terminal ADD domain of ATRX can recognize the H3K4me0-H3K9me3
repressive histone signature that is often enriched at heterochromatin (Dhayalan et al.,
2011; Eustermann et al., 2011; Iwase et al., 2011; Mitson et al., 2011) (Figure 1-1b).
ATRX depletion does not alter cellular H3K9me3 distribution (Ritchie et al., 2008),
however more precise techniques like chromatin immunoprecipitation followed by high
throughput sequencing (ChIP-sequencing) will be required to determine if ATRX is
required for establishment or maintenance of this type of chromatin modification. ATRX
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also localizes to the heterochromatic inactive X chromosome and can interact with the
repressive histone variant macroH2A following the onset of X chromosome inactivation
(Baumann and De La Fuente, 2009; Ratnakumar et al., 2012; Sarma et al., 2014).
ChIP-sequencing has demonstrated that ATRX binds intergenic regions and within gene
bodies, in addition to highly repetitive DNA sequences such as telomeres, rDNA, and
PCH (Law et al., 2010). Repetitive elements are susceptible to the formation of complex
secondary structures such as hairpins/cruciforms, Z-DNA, triplexes, and tetraplexes,
especially when the DNA is unwound during transcription or replication (Zhao et al.,
2010). Telomeric DNA is particularly prone to the formation of G-quadruplex (G4) DNA
structures, since the sequences of telomeres are GC-rich (Biffi et al., 2013; Lipps and
Rhodes, 2009). In fact, ATRX is enriched at predicted G4-DNA-forming sequences and
recombinant ATRX can interact with G4-DNA oligonucleotides in vitro (Law et al.,
2010).
Taken together, these data indicate that ATRX targeting to heterochromatin is likely
mediated through direct interaction and recognition of modifications on the histone H3
tail by the ADD domain, and that stabilization of ATRX at heterochromatin requires
protein-protein interaction with MeCP2 and HP1. ATRX may also be capable of
recognizing complex secondary G4-DNA structures in vivo, resulting in ATRX
recruitment to specific sites enriched in G4-DNA, such as telomeres. However, the
precise biochemical interaction between G4-DNA structures and ATRX is not well
understood and deems clarification. Furthermore, the relationship between ATRX and
macroH2A in the context of heterochromatin requires further characterization, as it may
also play an important role in ATRX targeting.

1.1.3 ATRX forms a chromatin-remodeling complex with DAXX
An unbiased proteomic analysis to isolate ATRX interacting partners identified the deathassociated protein 6 (DAXX) (Xue et al., 2003). The majority of ATRX molecules are in
complex with DAXX (Xue et al., 2003), indicating that DAXX likely participates in
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ATRX cellular functions. DAXX interacts with the linker region of ATRX located
between the ADD and ATPase domains (Figure 1-1a,b) (Tang et al., 2004). Together,
ATRX/DAXX exhibits ATP-dependent chromatin remodeling activities such as
disruption of DNA-histone interactions and translocation of histones on DNA, but does
not display helicase activity (Tang et al., 2004; Xue et al., 2003). However, DAXX is not
required for the chromatin remodeling ability of the complex (Tang et al., 2004), which is
consistent with the fact that ATRX, and not DAXX, contains an ATPase domain (Figure
1-1a). At imprinting control regions (ICRs), ATRX mediates nucleosome remodeling to
facilitate recruitment of the chromatin architecture protein CCCTC-binding factor
(CTCF), likely through its ATPase domain (Kernohan et al., 2014). The relationship
between ATRX and CTCF will be touched upon in section 1.3.3 and 5.9.
All activities that involve the DNA template, such as transcription, replication, and repair,
must be accomplished in the context of chromatin and require extensive remodeling of
the nucleosome. Together, ATRX and DAXX are responsible for replication-independent
deposition of the histone H3 variant H3.3 at telomeres, PCH, and rDNA (Drane et al.,
2010; Goldberg et al., 2010; Lewis et al., 2010). DAXX acts as a chaperone through
direct interaction with H3.3, and deposition requires the chromatin remodeling activities
of ATRX (Drane et al., 2010; Lewis et al., 2010). The significance of ATRX/DAXXdependent H3.3 deposition at repetitive elements is not well understood. H3.3 is typically
enriched at transcriptionally active sites, which is believed to be a consequence of the
inherent instability of nucleosomes containing H4-H3.3 dimers (Jin and Felsenfeld,
2007). ATRX loss results in a failure to incorporate H3.3 and induces a DNA damage
response at telomeres and PCH, suggesting that H3.3 incorporation is required to
maintain stability of these elements (Goldberg et al., 2010; Huh et al., 2012; Watson et
al., 2013; Wong et al., 2010). However, this idea is difficult to reconcile with the inherent
instability of H3.3-containing nucleosome, which is consistent with the finding that
ATRX facilitates RNA polymerase elongation through intragenic deposition of H3.3 in a
small subset of genes that contain predicted G4-DNA structures (Levy et al., 2014).
Transcription of repetitive elements is important for maintenance of heterochromatin
(Buhler et al., 2007; Schoeftner and Blasco, 2009). Despite a failure to incorporate H3.3
at telomeres and PCH in ATRX- or DAXX-depleted cells, there have been conflicting
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reports of transcriptional dysregulation of pericentromeric and telomeric (TERRA)
transcripts (Drane et al., 2010; Goldberg et al., 2010; Levy et al., 2014). A recent study
demonstrated G2/M-specific upregulation of TERRA in HeLa cells depleted for ATRX
(Flynn et al., 2015), providing an explanation for the discrepancies in earlier findings of
TERRA regulation. Together these data suggest a potential role for ATRX in resolution
of G4-DNA to facilitate transcriptional elongation and replication of heterochromatin
(Figure 1-1b), however future efforts will be necessary to dissect the functional
significance of ATRX/DAXX-dependent H3.3 incorporation at repetitive elements and
other locations.
ATRX and DAXX localize to promyelocytic leukaemia nuclear bodies (PML-NBs),
which are subnuclear structures implicated in transcriptional activation, DNA replication,
apoptosis, and viral infection (Bernardi and Pandolfi, 2007; Ishov et al., 1999; Ishov et
al., 2004). PML-NBs can be found in most cell lines and tissue types; in a normal
mammalian cell there are approximately 5-30 PML-NBs (Melnick and Licht, 1999). Over
100 proteins have been associated with PML-NBs, many of which show dynamic
localization (Weidtkamp-Peters et al., 2008). In contrast to heterochromatic localization,
ATRX localization at PML-NBs is DAXX-dependent (Ishov et al., 2004). It is
hypothesized that PML-NBs serve as platforms for heterochromatin remodeling post
replication in G2 phase of the cell cycle, which is supported by the dynamic
colocalization of ATRX/DAXX/H3.3, heterochromatin, and PML-NBs during this time
(Chang et al., 2013; Ishov et al., 2004). Furthermore, PML-NBs have been suggested to
be sites of H3.3 storage within the nucleus and function as a gathering point for proteins
involved in replication-independent H3.3 assembly (Corpet et al., 2014). In fact, PML
depletion results in dissociation of PML-NBs and decreased ATRX/H3.3 at telomeres,
suggesting that the subnuclear structures are important for maintaining H3.3 at telomeres
(Chang et al., 2013).
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1.1.4 ATRX regulates DNA replication and cell division
Subnuclear distribution of ATRX is cell cycle-dependent. As mentioned previously,
ATRX is phosphorylated at the onset of mitosis resulting in its dissociation from the
nuclear matrix (Berube et al., 2000). ATRX is enriched at DAPI-bright heterochromatin
throughout all stages of the cell cycle (McDowell et al., 1999; Nan et al., 2007). ATRX
localization at telomeres of embryonic stem (ES) cells occurs primarily during mid-tolate S phase, which may indicate a specific requirement for ATRX in facilitating
replication or remodeling of telomeric heterochromatin (Wong et al., 2010). This is
consistent with its localization pattern in replicating myoblasts: pulse-labeling cells with
the thymidine analog bromodeoxyuridine (BrdU) demonstrated colocalization of ATRX
with large BrdU foci characteristic of late-replicating heterochromatin (Huh et al., 2012).
Replication of heterochromatin and S phase progression are tightly interrelated (Quivy et
al., 2008), which may explain the increased DNA damage response observed in latereplicating chromatin and S phase lengthening of Atrx-null cells (Clynes et al., 2014; Huh
et al., 2012; Watson et al., 2013). The mechanism of ATRX function in replication is not
well characterized. A prevalent hypothesis is that ATRX resolves G4-DNA to allow
progression of the replication fork through regions prone to forming the complex
secondary structures, such as telomeres (Clynes et al., 2013; Gibbons and Higgs, 2010),
which is supported by the finding that Atrx-null cells are sensitive to chemically induced
G4 stabilization (Watson et al., 2013). However, there is also evidence to suggest a more
direct function for ATRX in replication, as Atrx-null cells show reduced origin firing and
ATRX interacts with components of the MRE11-RAD50-NBS1 (MRN) complex that
facilitates replication fork restart (Clynes et al., 2014; Leung et al., 2013). The MRNATRX interaction may occur in the context of telomeric chromatin, as the ataxia
telangiectasia-mutated (ATM) kinase, MRN, and homologous recombination (HR)
machinery are all recruited to newly replicated telomeres for reformation of the protective
t-loop structure (Verdun et al., 2005; Verdun and Karlseder, 2006).
Enrichment of ATRX at pericentromeric heterochromatin (PCH) and highly condensed
mitotic chromosomes suggests a function for the protein during cell division (Berube et
al., 2000; McDowell et al., 1999). Indeed, studies have demonstrated a requirement for
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ATRX in both meiosis and mitosis (Baumann et al., 2010; De La Fuente et al., 2004;
Ritchie et al., 2008; Ritchie et al., 2014). In human HeLa cells and mouse
neuroprogenitors, ATRX loss causes chromosome congression defects and a prolonged
prometaphase-to-metaphase transition that ultimately results in increased mitotic defects
such as anaphase bridging and micronuclei formation (Ritchie et al., 2008; Ritchie et al.,
2014). In mouse oocytes, ATRX depletion disrupts alignment of chromosomes at the
metaphase II spindle and causes defective chromosome cohesion, similarly resulting in
micronuclei formation and centromere instability (Baumann et al., 2010; De La Fuente et
al., 2004).
Replicative stress, or DNA damage that occurs during replication, can be carried over
into mitosis if the damage is not severe enough to induce checkpoint activation and cell
cycle arrest (Wilhelm et al., 2014). Ultimately, this can result in abnormal cell division,
as under-replicated regions of chromosomes remain physically joined and eventually
break or shatter to cause micronuclei or chromothripsis, respectively (Crasta et al., 2012).
Therefore, it is possible that the mitotic/meiotic defects associated with ATRX loss could
be a consequence of increased stress during replication. However, replicative stress and
increased DNA damage can also result from abnormal cell division (Ganem and Pellman,
2012). It remains unclear whether ATRX deficiency causes replicative stress that
precedes mitotic/meiotic dysfunction or vice versa. Nevertheless, there is ample evidence
to conclude that ATRX is required throughout the cell cycle for both replication and cell
division.

1.1.5 Inherited hypomorphic ATRX mutations cause syndromic and
non-syndromic intellectual disability
The ATRX gene was originally identified through genetic linkage studies indicating that
numerous mutations within the coding region of ATRX cause a rare mental retardation
syndrome (ATR-X; OMIM#301040) characterized by a wide array of developmental
abnormalities, alpha-thalassemia, and severe cognitive deficits (Gibbons, 1995). ATRX
mutations have also been identified in patients with Chudley-Lowry (OMIM#303600),
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Juberg-Marsidi, Carpenter-Waziri, and other less well-characterized X-linked intellectual
disability (ID; OMIM#309580) (Abidi et al., 1999; Lossi et al., 1999; Villard et al., 1999;
Villard et al., 1996). Interestingly, ATR-X syndrome is the first identified human disease
caused by mutations in a chromatin remodeling factor, establishing the functional
significance of epigenetic regulation in human disease pathogenesis (Gibbons et al.,
1997).
Patients with ATRX mutations show profound intellectual disability (95% of patients),
microcephaly (76%), seizures (35%), characteristic facial features (94%), skeletal
abnormalities (90%), HbH inclusions (87%), and genital abnormalities (80%) (Gibbons
and Higgs, 2000). Magnetic resonance imaging of ATR-X patients identified
abnormalities in grey and white matter of the brain, implicating ATRX in the production
of neuronal/glial cells and myelination, respectively (Wada et al., 2013). Modeling of
patient mutations demonstrated that missense mutations often had little effect on protein
levels, however point mutations affecting the zinc-coordinating cysteines, surface
residues, and the structural core of the ADD domain resulted in a 50-90% reduction in
ATRX levels, likely due to protein destabilization (Argentaro et al., 2007; McDowell et
al., 1999).
Our understanding of ATR-X pathogenesis has been aided through genotype-phenotype
correlations. Over 95% of identified ATRX mutations lie within the conserved ADD and
ATPase domains of ATRX, indicating that these domains are essential for correct
function (Gibbons, 2006). The lack of identified mutations outside of these domains
suggests that mutations elsewhere are non-viable or that regions outside of the ADD and
ATPase domains are dispensable for ATRX function. Patient mutations in the ATPase
domain of ATRX result in abnormal targeting to PML-NBs, implicating the subnuclear
structures in disease pathogenesis (Berube et al., 2008). Additionally, patient mutations
within the ADD domain result in abnormal targeting to heterochromatin (Eustermann et
al., 2011; Iwase et al., 2011; Mitson et al., 2011). Together these data emphasize the
importance of ATRX targeting to PML-NBs and heterochromatin, and indicate that
defects in these pathways can contribute to ATR-X pathogenesis. Truncating mutations in
the C-terminus consistently result in patients with severe urogenital abnormalities,
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suggesting that this region may play a key role in urogenital development (Gibbons and
Higgs, 2000). While genotype-phenotype correlations have been informative, there exists
phenotypic variability even in patients with the same mutation: 15 unrelated individuals
with the same mutations showed variable levels of HbH inclusions (Gibbons et al., 1997).
Variability in the degree α-thalassemia presentation in ATR-X patients has been
correlated with the length of the ψζ variable nucleotide tandem repeat (VNTR) adjacent
to the α-globin gene cluster that is predicted to form G4-DNA structures and is enriched
for ATRX binding in normal individuals (Law et al., 2010). This finding implies that
ATRX is likely targeted to this VNTR sequence due to its propensity to form non-β G4DNA structures, and that it is required to prevent repression of nearby pathologically
relevant genes. This function of ATRX may also have consequences for DNA replication
and repair, as a failure to resolve G4-DNA could cause replication fork stalling and
collapse into DNA double-strand breaks (DSBs) (Lipps and Rhodes, 2009). Indeed,
ATR-X patient lymphocytes exhibited phosphorylation of the histone H2A variant H2AX
(γH2AXS139) and of p53 (pp53S15), suggestive of an increased DNA damage response
(Huh et al., 2012).
The study of X-linked intellectual disability syndromes resulting from ATRX mutations
has been pivotal in furthering our knowledge of ATRX function. These human disorders
clearly demonstrate a requirement for ATRX in development of the brain, urogenital and
skeletal systems, and provide evidence that ATRX is necessary for transcriptional
regulation of the α-globin gene cluster.

1.1.6 ATRX is required for mouse brain development
The overt neurological dysfunction associated with human ATRX mutations implies a
requirement for ATRX in brain development, maturation, and/or function. Mouse models
have been useful in studying the effects of genetically altering ATRX levels globally and
specifically in the brain.
Overexpression of ATRX causes neurodevelopmental and craniofacial defects,
suggesting that ATRX is required in correct stoichiometric amounts for normal
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development (Berube et al., 2002). Forebrain-specific deletion of the full-length Atrx
isoform causes increased p53-dependent apoptosis of neuroprogenitor cells (NPCs),
resulting in decreased neonatal cortical size and hippocampal dysgenesis (Berube et al.,
2005; Seah et al., 2008). ATRX is required to specify the correct number of GABAergic
interneurons and hippocampal dentate granule precursors, and this function contributes to
the abnormal cortical and hippocampal development of forebrain-specific mutants (Seah
et al., 2008). Generation of p53/ATRX double mutant mice effectively rescued apoptosis,
however failed to completely restore neonatal forebrain size, indicating that ATRX
functions outside of promoting cellular survival to regulate brain size (Seah et al., 2008).
Indeed, Atrx-null NPCs exhibit premature differentiation into neurons, resulting in early
depletion of the progenitor pool and a failure to sustain birth of late-born neurons (Ritchie
et al., 2014).
AtrxΔE2 mice were generated to mimic an ATR-X patient mutation and study the
consequence of Atrx exon 2 deletion in brain development and function (Nogami et al.,
2011). AtrxΔE2 mice were smaller than controls, displayed normal spatial learning and
memory by the Morris water maze test, and did not display any overt differences in brain
morphology (Nogami et al., 2011). However, the AtrxΔE2 mice exhibited impaired
contextual fear memory and long-term potentiation (LTP), which was attributed to
aberrant activation of the LTP effectors calcium/calmodulin-dependent protein kinase II
(CaMKII) and the glutamate receptor 1 (GluR1) in the hippocampus and medial
prefrontal cortex, and associated with abnormal dendritic spines (Nogami et al., 2011;
Shioda et al., 2011).
Collectively, animal models of ATRX dysfunction have illustrated a requirement for the
protein in both brain development and maturation and provide some insight into the
mechanisms underlying developmental abnormalities, such as intellectual disability and
microcephaly, associated with ATRX mutations.
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1.1.7 Somatic ATRX
progression

loss-of-function

mutations

drive

cancer

The first clue that ATRX may be required to prevent malignancy came from the
identification that alpha-thalassemia myelodysplasia syndrome, somatic (ATMDS;
OMIM#300448), a rare pre-leukemic condition, is caused by acquired somatic ATRX
mutations (Gibbons et al., 2003).
Somatic ATRX loss-of-function mutations have been identified in numerous tumour types
by exome sequencing, such as neuroblastoma, glioma, pancreatic neuroendocrine
tumours (PanNETs), and paediatric osteosarcoma (Chen et al., 2014; Jiao et al., 2012;
Jiao et al., 2011; Kannan et al., 2012; Liu et al., 2012; Molenaar et al., 2012;
Schwartzentruber et al., 2012). The ATRX mutational landscape includes point mutations
scattered throughout the coding sequence, as well as large deletions of the N terminus.
Mutations in DAXX, a protein partner of ATRX, were also reported in the tumour
subtypes but never overlapped ATRX mutations, implying that they function in the same
pathway. ATRX/DAXX mutations commonly occurred in conjunction with mutations in
the tumour suppressors p53 or IDH1 (Liu et al., 2012; Schwartzentruber et al., 2012).
These findings invoke a model whereby epigenetic factors like ATRX may act as
“backseat drivers” in a tissue-specific manner to suppress oncogenic pathways upstream
of master regulators common to a broad range to tumours, like p53 (Elsasser et al., 2011).
An inverse relationship between ATRX and macroH2A levels is associated with
melanoma progression, and ATRX can interact with macroH2A to negatively regulate its
deposition (Kapoor et al., 2010; Qadeer et al., 2014; Ratnakumar et al., 2012). Further
analysis of the full spectrum of ATRX mutations in cancer and the different tumour
subtypes that are defined based on ATRX/DAXX perturbations will help to uncover the
mechanism underlying tumourigenesis stemming from mutations in these epigenetic
factors.
In addition to mutations in ATRX/DAXX, sequencing of paediatric glioma tumour samples
identified K27M missense mutations in the gene encoding histone H3.3 (H3F3A)
(Khuong-Quang et al., 2012; Schwartzentruber et al., 2012; Wu et al., 2012). This
provides direct evidence that in addition to the proteins involved in the histone deposition
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pathway, alterations in the histone proteins themselves can promote cancer. Analysis of
the H3.3K27M mutant demonstrated alterations in genome-wide H3K27me3 levels
through inhibition of the Polycomb repressive complex 2 (PRC2) enzymatic component
EZH2 (Bender et al., 2013; Chan et al., 2013; Lewis et al., 2013). These findings are
particularly intriguing given that ATRX is responsible for H3.3 deposition at specific
genomic positions, and that ATRX interacts with EZH2 (Cardoso et al., 1998; Drane et
al., 2010; Goldberg et al., 2010; Lewis et al., 2010; Sarma et al., 2014). Furthermore, the
K27M mutation synergizes with p53 loss in neural progenitor cells resulting in neoplastic
transformation (Funato et al., 2014). Together, the data suggests that the ATRX-DAXXH3.3 pathway may genetically interact with the PRC2-H3K27me3 pathway in cancer
progression.
A common theme in tumour samples with mutations in ATRX/DAXX is the appearance of
the alternative lengthening of telomeres (ALT) phenotype (Bower et al., 2012; Heaphy et
al., 2011a; Lovejoy et al., 2012; Schwartzentruber et al., 2012). Tumourigenesis, or
uncontrolled cell growth, is limited by replicative senescence that occurs as a
consequence of telomere shortening every S phase (Hastie et al., 1990). Most tumour
cells overcome this hurdle by hijacking telomerase to maintain telomere length and
suppress senescence (Counter et al., 1994). Interestingly, telomerase reverse transcriptase
(TERT) promoter mutations that result in increased telomerase expression are mutually
exclusive with ATRX mutations in glioma, suggesting that the growth advantage afforded
by TERT mutation would be equivalent to that of ATRX mutation (Killela et al., 2013).
Approximately 5% of human cancers will instead utilize the ALT pathway to lengthen
their telomeres via homologous recombination (Cesare and Reddel, 2010). ALT is
prevalent in specific cancer types that can arise from mutations in ATRX, such as
osteosarcoma and glioma (Heaphy et al., 2011b), however the mechanism by which
ATRX mutations result in the ALT phenotype and drive cancer progression is largely
unknown. Although ATRX loss has been correlated with telomere dysfunction (Flynn et
al., 2015; Goldberg et al., 2010; Huh et al., 2012; Watson et al., 2013; Wong et al., 2010),
its loss is not sufficient to drive ALT (Clynes et al., 2014; Flynn et al., 2015; Lovejoy et
al., 2012), suggesting that additional genetic or epigenetic changes are necessary to
establish the phenotype. ATRX may function rather to poise telomeres for ALT, as its
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loss results in persistent association of replication protein A (RPA) with telomeric
ssDNA, a key intermediate of homologous recombination (HR), as well as increased
TERRA levels at telomeres (Flynn et al., 2015).
Interestingly, ALT is associated with the appearance of large PML-NBs (referred to as
ALT-associated PML-NBs, or APBs) that contain telomeric DNA, the DNA repair MRN
complex, replication factor A (RPA), and telomeric-repeat binding proteins TRF1 and
TRF2 (Luciani et al., 2006; Wu et al., 2003; Wu et al., 2000; Yeager et al., 1999). The
appearance of APBs is a robust marker for tumours that utilize ALT, and APBs rapidly
assemble upon ALT induction (Costa et al., 2006; Henson et al., 2005; Perrem et al.,
2001), suggesting that APBs may be involved in the mechanism underlying ALT. This is
intriguing since ATRX/DAXX/H3.3 are PML-associated factors and mutations in this
pathway drive cancers with a high frequency of ALT. It is possible that defects in the
ATRX/DAXX pathway results in a loss of heterochromatic features at telomeres, such as
H3.3 enrichment, leading to increased homologous recombination rates that are
associated with ALT activity, but it remains unclear as to how PML-NBs fit into this
picture exactly.

1.2 CTCF is a multifunctional and essential protein
1.2.1 The CTCF gene and protein
CCCTC-binding factor (CTCF) is a conserved zinc finger (ZF) DNA binding protein that
can interact with highly divergent genomic targets through the combinatorial use of its
eleven ZFs (Burcin et al., 1997; Filippova et al., 1996) (Figure 1-1a). The ZF domain of
CTCF is 100% identical between human, mouse, and chicken, and the full-length protein
shows 93% conservation across species (Filippova et al., 1996). CTCF is conserved in
most bilaterial phyla but is absent in yeast, Caenorhabditis elegans and plants (Heger et
al., 2012). The promoter of CTCF contains a binding site for the transcription factor yingyang 1 (YY1), and elements that are conserved in cell cycle-regulated genes (Klenova et
al., 1998). In fact, CTCF mRNA levels oscillate during the cell cycle, peaking in S/G2
phase, and decreasing in terminally differentiated cells (Delgado et al., 1999; Klenova et
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al., 1998). Exons 2 to 8 contain the ZF domains, with several individual fingers being
split between intron-exon boundaries (Ohlsson et al., 2001). The stop codon resides in
exon 10, followed by a long 3’UTR that likely regulates CTCF translation (Klenova et
al., 1997). The first 10 ZFs are typical units of 30 residues containing a pair of cysteines
invariantly separated by 12 amino acids from the pair of histidines that inserts into the
major groove of DNA (el-Baradi and Pieler, 1991; Klug and Schwabe, 1995). The
eleventh C-terminal ZF is structurally similar to the friend of GATA (FOG) proteins that
can interact with GATA-containing proteins (Fox et al., 1999).
CTCF is a nuclear protein that is generally restricted from heterochromatin, and can
interact with the nuclear matrix (Dunn et al., 2003). Unlike many other DNA-binding
proteins, CTCF remains associated with chromatin during mitosis through its C-terminal
domain (Burke et al., 2005), yet this appears to be locus-specific since CTCF binding is
no longer detected at the MYC insulator element during this time (Komura et al., 2007).
The molecular mass of CTCF is 82 kDa, however due to amino acid sequences in the Nand C-terminus, CTCF migrates aberrantly in SDS-PAGE gels at around 130 kDa, and
truncation of the C-terminus results in a 70 kDa isoform (Klenova et al., 1997;
Lobanenkov et al., 1990).
CTCF was initially characterized as a transcription factor capable of activating or
repressing gene expression in heterologous reporter assays (Baniahmad et al., 1990;
Lobanenkov et al., 1990), and was later found to exhibit insulator activity (Bell et al.,
1999). Insulator proteins are capable of buffering position effect variegation caused by
heterochromatin spreading (barrier activity) and/or the communication between cis
regulatory elements, such as enhancers and promoters (enhancer blocker function) (Bell
et al., 2001). Recently, however, the broad properties of CTCF and its ability to mediate
long-range chromatin interactions have led to its description as an architectural rather
than insulator protein per se (Ong and Corces, 2014).
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Figure 1-2 The CTCF protein, binding partners, and model of function in genome
organization
(A) Structure of the CTCF protein. Nucleic acid-binding domains highlighted in orange
and protein partners highlighted in purple text. Known sites of post-translational
modification (SUMOylation and CKII-dependent phosphorylation) are indicated in
green. Intellectual disability (ID)/autism patient mutations are indicated in pink (Gregor
et al., 2013; Iossifov et al., 2014). (B) CTCF binding sites at TAD borders are potentially
involved in organizing the domains (left), while binding sites within TAD interiors often
colocalize with cohesin (orange ring) and facilitate gene expression by mediating
interactions between distal enhancers (E) and promoters (P). Over 90% of chromatin
loops are anchored by CTCF motifs in convergent orientation (Rao et al., 2014).
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1.2.2 Regulation of CTCF functions
The ZFs of CTCF are capable to binding to both DNA and protein; for example, ZFs 5-7
mediate CTCF binding to the amyloid precursor protein (APP) promoter and the ZF
domain also mediates CTCF interaction with the chromodomain helicase DNA binding
protein 8 (CHD8) (Ishihara et al., 2006; Quitschke et al., 2000) (Figure 1-2a). Mapping of
CTCF binding sites in numerous cell lines and tissues have provided functional insights:
CTCF is enriched at ~55,000-65,000 sites in mammalian genomes with a genomic
distribution of ~50% intergenic, ~35% intragenic, and ~15% at promoters (Chen et al.,
2012; Chen et al., 2008; Kim et al., 2007b). Of CTCF binding sites, ~5,000 are highly
conserved between mammalian species and tissues and correspond to high affinity sites
(Schmidt et al., 2012), while 30-60% of sites are cell-type specific and tend to exhibit low
occupancy of CTCF (Barski et al., 2007; Chen et al., 2008; Essien et al., 2009; Kim et al.,
2007b). Paradoxically, CTCF is enriched at enhancer elements, which in stark contrast to
its originally identified role as an enhancer-blocker, indicating that CTCF sites likely play
different functional roles in a context-dependent manner and some sites may be involved
in establishing cell type-specific transcriptional programs (DeMare et al., 2013; Song et
al., 2011). Interestingly, CTCF binding sites are carried in transposable elements and
evidence points to the expansion of repetitive elements as a driver of new CTCF binding
events in diverse mammalian lineages (Bourque et al., 2008; Schmidt et al., 2012).
CTCF binding sites contain a 12- to 20-bp consensus motif (Bell and Felsenfeld, 2000;
Kim et al., 2007b), however the basis of CTCF recruitment to genomic sites is not well
understood. The CTCF consensus motif is not present in all binding sites and not all such
motifs bind CTCF (Kim et al., 2007b), suggesting that CTCF recruitment is more
complicated. DNA methylation plays a widespread role in modulating CTCF binding:
41% of cell type-specific CTCF binding events are linked to differential methylation
concentrated at base pairs (bp) 1 and 11 of the consensus motif (Mukhopadhyay et al.,
2004; Wang et al., 2012). CTCF can also directly affect DNA methylation through
interaction and activation of poly(ADP-ribose) polymerase 1 (PARP1), which inhibits
DNA (cytosine-5)-methyltransferase 1 (DNMT1) through poly(ADP-ribosyl)ation
(Guastafierro et al., 2008; Zampieri et al., 2012). Despite this, the presence of cell-type
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specific CTCF binding sites that are not differentially methylated suggests additional
mechanisms that affect CTCF occupancy. CTCF is typically located in nucleosomedepleted linker regions surrounded by well-positioned nucleosomes, suggesting that
nucleosome phasing is an essential upstream factor that regulates CTCF enrichment
(Cuddapah et al., 2009; Fu et al., 2008). This idea is supported by evidence that CTCF
recruitment or maintenance at the H19-Igf2 and Gtl2-Dlk1 ICRs requires local
nucleosome remodeling by ATRX (Kernohan et al., 2014). Furthermore, the interaction
of CTCF and CHD8 suggests that CHD8 may facilitate local chromatin remodeling to
mediate CTCF binding, however this idea has not been tested experimentally (Ishihara et
al., 2006). While DNA methylation and nucleosome phasing are important regulators of
CTCF binding, it is likely that additional contributing mechanisms have not yet been
identified.
The addition of covalent post-translational modifications has been linked to differential
binding and functions of CTCF. For instance, CTCF itself can be poly(ADP-ribosyl)ated,
which has been linked to its insulator (Yu et al., 2004) and barrier functions (Witcher and
Emerson, 2009), as well as subnuclear localization (Guastafierro et al., 2013; Ong et al.,
2013; Torrano et al., 2006). Four serines in the C-terminus of CTCF are phosphorylated
by casein kinase II (CKII; Figure 1-2a), potentiating its growth suppressive functions
(Klenova et al., 2001). Interestingly, mutation at this same motif present in the p53
tumour suppressor protein abrogates its growth inhibition function, and selective
phosphorylation of the motif is regulated in response to genotoxic stress by the CKIIFACT (facilitates chromatin transcription) complex (Keller et al., 2001; Milne et al.,
1992). The PC2 small ubiquitin-like modifier (SUMO) ligase can SUMOylate residues in
the N-terminus of CTCF, contributing to its repression of MYC transcription without
affecting its ability to bind DNA (MacPherson et al., 2009) (Figure 1-2a). Together,
analysis of CTCF post-translational modifications demonstrates the complexity of CTCF
regulation.
Interactions between CTCF and other proteins may also represent an additional
mechanism by which the protein achieves functional diversity (Zlatanova and Caiafa,
2009). CTCF interacts with the large subunit of RNA polymerase II (RNAPII) through its
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C terminal domain (Figure 1-2a) and intragenic peaks of RNAPII overlap sites of CTCF
enrichment (Chernukhin et al., 2007; Wada et al., 2009). Functionally, this may be a
consequence of a role for CTCF in promoting polymerase pausing, rather than
recruitment per se, since on a global scale CTCF binding has been implicated in
generating a “poised” promoter state (promoter-proximal pausing) and in the pre-mRNA
processing decisions associated with alternative splicing (Paredes et al., 2013; Shukla et
al., 2011). In addition to RNAPII, CTCF can interact with numerous protein partners
such as zinc finger protein 143 (ZNF143), the Kaiso transcription factor, nucleophosmin,
lamin A/C, ying yang 1 (YY1), and CHD8 to name a few (Zlatanova and Caiafa, 2009)
(Figure 1-2a). Further complicating this issue is the recent finding that the C-terminus of
CTCF can interact with RNA, which is important for its role in transcriptional regulation
of p53, X chromosome inactivation, and in stabilizing protein-protein interactions (Kung
et al., 2015; Saldana-Meyer et al., 2014; Sun et al., 2013; Yao et al., 2010) (Figure 1-2a).
RNA-immunoprecipitation followed by high throughput sequencing (RIP-sequencing)
identified that CTCF can interact with ~15,000 different RNA species (Kung et al., 2015;
Saldana-Meyer et al., 2014), indicating that the interaction likely represents a more
widespread mechanism of CTCF function.
While the aforementioned partners can influence CTCF activities at specific loci, a
pervasive relationship has been established with the cohesin complex (Parelho et al.,
2008; Rubio et al., 2008; Wendt et al., 2008). The cohesin complex is composed of four
subunits: the structural maintenance of chromosomes 1 (SMC1) and SMC3, radiation
mutant 21 (Rad21), and stromal antigen 1 or 2 (SA1 or SA2), and was initially
characterized as being required for sister chromatid cohesion during mitosis (Barbero,
2011; Michaelis et al., 1997; Moser and Swedlow, 2011; Uhlmann and Nasmyth, 1998).
The high degree of overlap between cohesin and CTCF binding sites genome-wide
suggests a functional relationship: depending on the cell type, ~50-80% of CTCF binding
sites are co-occupied by cohesin, and there is a mutualistic relationship between their
binding (Parelho et al., 2008; Rubio et al., 2008; Wendt et al., 2008). By-and-large CTCF
is required for cohesin recruitment, while cohesin appears to be required to stabilize most
CTCF-mediated chromosomal contacts and to be essential for CTCF function at most
genomic sites (Hou et al., 2010; Nativio et al., 2009). Physical interaction of the proteins

22
occurs between the SA1/2 subunit of cohesin and the C terminus of CTCF (Xiao et al.,
2011) (Figure 1-2a). Despite this close relationship, evidence suggests that the
CTCF/cohesin interaction is independent from cohesin’s role in mediating sister
chromatid cohesion, as CTCF-depleted cells do not exhibit cohesion defects (Parelho et
al., 2008).

1.2.3 CTCF regulates higher-order chromatin organization
CTCF can mediate long-range intra- and inter-chromosomal interactions in mammalian
cells (Kurukuti et al., 2006; Ling et al., 2006; Splinter et al., 2006) (Figure 1-2b). This
function of CTCF is best characterized at the imprinted H19-Igf2 locus where allelespecific binding of CTCF at the maternal H19 ICR results in expression of H19 and
paternal expression of Igf2 through physical interactions with the differentially
methylated regions upstream of the Igf2 promoter (Kurukuti et al., 2006; Murrell et al.,
2004). CTCF is also required for interchromosomal interaction between the H19-Igf2 and
Wsb1/Nf1 imprinted clusters (Ling et al., 2006), which is thought to help establish coregulation of an imprinted gene network (Andrade et al., 2010; Kernohan and Berube,
2010; Varrault et al., 2006).
The discovery that CTCF interacts with the cohesin ring complex led to a model wherein
long-range interactions mediated by CTCF are clamped together and stabilized by
cohesin (Haering et al., 2008; Ohlsson et al., 2010b) (Figure 1-2b). This matches with the
finding that CTCF binding to the DNA duplex asymmetrically bends the DNA but is
unable to form a loop alone (Liu and Heermann, 2015). Indeed, cohesin is required for
higher-order chromosome conformation at H19-Igf2 (Nativio et al., 2009) and many
other sites co-occupied with CTCF (Merkenschlager and Odom, 2013). Despite this, it
remains unclear whether CTCF and cohesin work independently or in concert to define
loop interactions; in general, cohesin depletion affects larger loops (100-200 kb
interaction range), while CTCF depletion affects shorter loops (<100 kb) (Zuin et al.,
2014). Moreover, CTCF depletion resulted in a gain of chromatin interactions (Zuin et
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al., 2014), further complicating our understanding of the mechanisms underlying genome
organization.
Hi-C maps of global chromatin interactions have identified that the genome is partitioned
into large (~1 Mb) domains referred to as topologically associating domains (TADs) that
are defined based on a higher interaction frequency within domains that between domains
(Dixon et al., 2012; Lieberman-Aiden et al., 2009). Intriguingly, domain boundaries are
enriched for housekeeping genes, short interspersed elements (SINEs), and CTCF
binding sites in convergent orientation, implicating these features in the establishment of
TADs (Dixon et al., 2012; Rao et al., 2014) (Figure 1-2b). CTCF depletion does not
dramatically alter global domain organization, suggesting that it is likely not the sole
determinant of TAD formation (Zuin et al., 2014). However, deletion of specific CTCF
binding sites on the X chromosome or within the HoxA cluster results in structural TAD
reorganization, indicating that at least in some contexts CTCF is required to delimit TAD
boundaries (Nora et al., 2012). The influence of CTCF on other features regulated by
TAD organization, such as replication timing (Pope et al., 2014), has yet to be
characterized.
Chromatin interaction analysis by paired-end sequencing (ChIA-PET) analysis of CTCFmediated chromatin interactions in ES cells identified ~1,800 interactions involving
~3,300 CTCF binding sites (~5-10% of total CTCF binding sites). In contrast to its
characterized role as an insulator protein, the majority of CTCF/cohesin sites facilitate
enhancer-promoter interactions (Handoko et al., 2011; Sanyal et al., 2012). The finding
that only a small proportion of CTCF sites are involved in higher-order interactions
suggests additional DNA-dependent functions for CTCF. Furthermore, the average cell
contains ~200,000 CTCF molecules but only ~30,000-60,000 CTCF binding sites,
perhaps indicating DNA-independent functions for the protein as well (Heath, 2007).
Together, global analysis of chromatin interactions in the context of CTCF binding
suggests that enhancer blocking or barrier insulation activities of CTCF may only occur
in a context-dependent manner as a consequence its primary role in mediating long-range
interactions (Handoko et al., 2011; Phillips-Cremins et al., 2013; Sanyal et al., 2012)
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(Figure 1-2b). Analysis of CTCF function in TAD architecture is still in its infancy, but
emerging technologies to study large-scale chromatin interactions such as Hi-C and
ChIA-PET will indisputably uncover the functional significance of higher-order genome
organization.

1.2.4 Evidence of CTCF function during replication
In addition to its well-characterized functions in transcriptional regulation, transcriptionindependent roles for CTCF have also been described in the literature. For instance,
CTCF regulates stability of numerous regions implicated in trinucleotide repeat
expansion disorders such as spinocerebellar ataxia type 7 (SCA7) and myotonic
dystrophy type I (DM1) (Filippova et al., 2001; Libby et al., 2008; Sopher et al., 2011).
At the DM1 locus, CTCF binding upstream of the repeat is required to slow DNA
polymerase before replication of the repetitive tract, and mutations in the CTCF binding
site results in repeat expansion likely due to strand slippage (Cleary et al., 2010).
Intriguingly, DM1 is asymmetrically replicated (Rajcan-Separovic 1998) and CTCF
regulates asymmetric replication of the H19/Igf2 imprinted domain (Bergstrom et al.,
2007). Therefore, the effect of CTCF on replication may be limited to certain loci, as
direct roles for the protein have only been described at asymmetrically replicated regions.
CTCF has also been implicated in replication origin firing, as overexpression of the
oncogenic replication licensing factor Cdc6 causes CTCF dissociation from the
promoters of the tumour-suppressor genes CDH1 and INK4/ARF, resulting in reduced
expression and activation of adjacent replication origins (Sideridou et al., 2011). It was
suggested that because replication origins are defined by structural chromatin context
rather than DNA sequence (Antequera, 2004; Cvetic and Walter, 2005), CTCF might
facilitate higher-order organization of replication origins.
The CTCF partner cohesin is implicated in organizing replication factories and
controlling S phase progression, however CTCF depletion had little effect on cell cycle
dynamics or the overall size of replicon units identified by the DNA halo assay (Guillou
et al., 2010). A more global role for CTCF in DNA replication and/or organizing
replication factories has not yet been thoroughly investigated, but is of interest given the
importance of CTCF in replication timing, progression, and origin firing at individual
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loci. Furthermore, the finding that TADs regulate replication timing suggests that CTCF
may participate in this process if indeed CTCF is involved in orchestrating TAD
organization (Dixon et al., 2012; Pope et al., 2014) (Figure 1-3).

26

Figure 1-3 The relationship between chromosome territory organization in the
nucleus, topologically associating domains (TADs), and replication timing
(Left) Chromosome territory organization within the nucleus represented by four
chromosomes of different colours for simplicity. (Right) The replication domain model
described in (Pope et al., 2014): TADs within the nuclear interior (green) actively fire
origins and replication proceeds passively into TADs at the nuclear exterior (red). CTCF
(yellow) binding at TAD borders is shown.
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1.2.5 In vivo functions of CTCF
Most of our knowledge of CTCF activities has been derived from in vitro studies using
immortalized cell lines (Ohlsson et al., 2010a), yet CTCF function has rarely been
approached in an organismal context. Using transgenic RNA interference (RNAi),
Fedoriw and colleagues demonstrated that both zygotic and maternal stores of CTCF are
essential for preimplantation development (Fedoriw et al., 2004; Wan et al., 2008). These
studies also indicated a requirement for CTCF in cellular survival since CTCF depletion
caused meiotic and mitotic defects that culminated in apoptosis (Wan et al., 2008).
Generation of a Ctcf-null allele (Ctcf-/-) confirmed the essential nature of CTCF in early
development, as homozygous mutants are lethal prior to E3.5 (Heath et al., 2008).
Heterozygotes (Ctcf+/-) are viable, fertile, and do not exhibit any overt phenotypes,
however the decreased ratio of wild type to heterozygote mice suggests that
heterozygosity of Ctcf does compromise survival to some extent (Heath et al., 2008).
Tissue-specific deletion of CTCF has yielded more insight into its function in
development and has pointed to an essential role for the protein in cell survival and cell
cycle progression. For instance, Ctcf deletion in the developing limb bud resulted in
upregulation of the pro-apoptotic p53 upregulated modulator of apoptosis (PUMA),
massive apoptosis, and a complete loss of forelimb structure (Soshnikova et al., 2010),
while deletion of Ctcf in post-mitotic neurons did not cause apoptosis (Hirayama et al.,
2012). Deletion of Ctcf in T cells resulted in a decreased number of cells, suggestive of
increased cell death, and caused a cell cycle block due to transcriptional upregulation of
p21 and p27 (Heath et al., 2008).
A requirement for CTCF in neuron-specific gene expression programs has recently been
demonstrated (Chang et al., 2010; Hirayama et al., 2012). Brain derived neurotrophic
factor (BDNF) is a critical mediator of neurogenesis, synaptic plasticity, and neuronal
survival (Greenberg et al., 2009). Methylation-sensitive binding of CTCF to the Bdnf
gene is required for its activity-dependent transcriptional activation (Chang et al., 2010).
Additionally, CTCF is an important transcriptional regulator of the protocadherin cluster
of genes (Hirayama et al., 2012). Protocadherins are largely expressed in the nervous
system and encode cell adhesion molecules located at the pre- and post-synaptic
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membrane. Cells express variable sets of protocadherin proteins, and each set may serve
as a molecular barcode for neuron identity (Frank and Kemler, 2002). Therefore, at least
in neurons, CTCF is required for the establishment of transcriptional programs that help
to shape individual cell-specific identity (Dekker, 2012).

1.2.6 CTCF mutations linked to cancer and neuropsychiatric disease
Few human CTCF mutations have been reported, which likely reflects the essential
nature of the protein (Fedoriw et al., 2004; Heath et al., 2008; Moore et al., 2012; Wan et
al., 2008; Watson et al., 2014). Chromosomal deletion at 16q22.1, however, is well
documented in several human cancers and is one of the most common genetic events in
breast cancer (Filippova et al., 1998; Rakha et al., 2006). CTCF maps to 16q22.1 and has
been demonstrated to function as a haploinsufficient tumour suppressor in mice, as Ctcf+/mice are susceptible to spontaneous and chemical/radiation-induced tumours of
epithelial, mesenchymal, and hematopoietic origin (Kemp et al., 2014). Furthermore,
analysis of ~5,000 tumours across 21 cancer types revealed that CTCF was one of the
most frequently mutated genes (Lawrence et al., 2014). A high proportion (21%) of
CTCF mutations identified in human cancers were missense mutations in the ZF domain
predicted to alter DNA sequence recognition, implicating this domain in the suppression
of tumourigenesis (Kemp et al., 2014). Together, these data implicate a broad role for
CTCF in tumour suppression, yet the mechanism of CTCF function in cancer prevention
is not fully understood. Hemizygous loss of Ctcf destabilized DNA methylation in mouse
tumours, however it remains unclear as to whether this is a direct or secondary cause of
CTCF loss (Kemp et al., 2014).
Recently, de novo mutations in CTCF were identified in patients with intellectual
disability (ID), microcephaly, and autistic features (Gregor et al., 2013; Iossifov et al.,
2014) (Figure 1-2a) and single nucleotide polymorphisms at the CTCF locus have been
associated with schizophrenia (Juraeva et al., 2014). This adds to the growing list of
epigenetic regulators implicated in neuropsychiatric disease and suggests that CTCF
function is particularly important in the developing brain, as evidence suggests that
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autism and schizophrenia are developmental in origin (Cook and Scherer, 2008;
Guilmatre et al., 2009; Millan, 2013; Mitchell, 2011; Pinto et al., 2014; Sebat et al.,
2009). Since there have been very few patients identified with CTCF mutations it is
difficult to generate conclusions based on genotype-phenotype correlations. However,
one patient has a missense mutation (R567W) located in the eleventh ZF that does not
affect mRNA or protein levels, implicating abnormal targeting of CTCF in the
pathogenesis of ID (Gregor et al., 2013). Identification of the full spectrum of CTCF
mutations in the human population will undoubtedly expand our understanding of CTCF
function and the pathogenesis of ID.

1.3 The regulation of higher-order chromatin structure
1.3.1 Higher-order chromatin architecture
Nuclear architecture is a key regulator of transcription, replication, and repair (Misteli,
2007). The term nuclear architecture refers to higher-order chromatin structure, nuclear
compartments, and non-random spatial genome organization (Bickmore and van
Steensel, 2013). Nuclear compartmentalization has been shown to be critical in the
regulation of DNA metabolism: for instance, artificial tethering of genes to the nuclear
periphery results in transcriptional silencing (Finlan et al., 2008; Reddy et al., 2008), and
nuclear positioning has been linked to replication timing (Gilbert, 2001; Pope et al.,
2014).
The fundamental unit of chromatin is the nucleosome, which is comprised of ~147 base
pairs of DNA wrapped around a (H3-H4)2-(H2A-H2B)2 histone octamer. The
nucleosome is organized into a fiber, which is further condensed to generate
chromosomes. Within the nucleus chromosomes occupy distinct territories, and
chromatin folds in cis to mediate interactions between regulatory elements as well as
bring genomic regions from long distances or different chromosomes into close spatial
proximity for co-regulation (Cremer and Cremer, 2001). Large-scale genome
organization was later confirmed by 3C-based experiments, demonstrating that different
chromosomes display different propensity to form inter-chromosomal interactions:
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chromosomes of similar size and density have a higher likelihood of interaction
(Lieberman-Aiden et al., 2009; Zhang et al., 2012). Nuclear compartments differ with
regards to chromatin and genic features: DNAse I hypersensitive, active, and gene-rich
loci cluster together and are separate from gene-poor, transcriptionally silent chromatin
(Lieberman-Aiden et al., 2009; Zhang et al., 2012). The compartments primarily appear
to relate to gene expression and as such are cell-type specific.
Chromosome compartments are further organized into domains of 100 kb-1 Mb that are
topologically separated from one another (TADs) and flanked by insulators (Dixon et al.,
2012; Rao et al., 2014; Sexton et al., 2012). As opposed to chromosome territories, which
are related to gene expression, TADs are largely conserved across cell types (Dixon et al.,
2012; Nora et al., 2012). Deletion of a TAD boundary region in the X chromosome
inactivation center resulted in partial fusion of the flanking TADs, suggesting that TAD
boundaries are genetically defined (Nora et al., 2012). This, in conjunction with the
finding that TAD boundaries are enriched for particular genomic features i.e. CTCF
binding sites (Dixon et al., 2012), begs the question of whether specific elements are
involved in the formation of TADs (Figure 1-3).
Global comparisons between genome topological organization and replication timing
programs support a model that TADs (i.e. regions of the genome that interact with
themselves more often than they interact with neighbouring regions) regulate replication
timing (Dixon et al., 2012; Pope et al., 2014) (Figure 1-3). Since CTCF has been
implicated in the establishment of TADs, it may play an important role in regulating the
replication timing program (Dixon et al., 2012). Depletion of Ctcf by RNAi resulted in
subtle relaxation of TAD organization and increased inter-TAD interactions (Zuin et al.,
2014), however the consequences of these changes on global replication timing are
unknown and the effects of complete CTCF loss rather than depletion have not been
assessed. CTCF is necessary for asynchronous replication of the H19-Igf2 imprinted
domain, demonstrating that it is important for replication timing in some capacity
(Bergstrom et al., 2007).
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The significance of higher-order chromatin organization and TAD formation is not well
understood, however the finding that compartments are correlated with transcription and
that domains are units of DNA replication suggests functional importance (Markaki et al.,
2010; Pope et al., 2014).

1.3.2 Interplay between CTCF, cohesin and ATRX
The first indication of a relationship between ATRX and cohesin was the finding that
ATRX depletion in HeLa cells causes chromosome cohesion defects (Ritchie et al.,
2008). An interaction between ATRX and the SMC1 and SMC3 subunits of cohesin can
be detected by co-immunoprecipitation in neonatal mouse brain extracts (Kernohan et al.,
2010), and recruitment of CTCF and cohesin to imprinting control regions is dependent
on nucleosome-remodeling activities of ATRX (Kernohan et al., 2010; Kernohan et al.,
2014). Preliminary analysis of ATRX-dependent CTCF recruitment indicates that ATRX
is required for enrichment at a number of sites in the postnatal mouse brain (Levy et al.,
unpublished data), raising the intriguing possibility that ATRX may help recruit CTCF to
specific sites through nucleosome remodeling and/or interaction with the cohesin
complex.

1.4 Genome stability in the context of brain development
1.4.1 The response to DNA damage
The genome is constantly bombarded with sources of stress, both exogenous and
endogenous, that can result in the accumulation of genetic lesions (Ciccia and Elledge,
2010). It is estimated that tens of thousands of damaging events occur daily in each cell
(De Bont and van Larebeke, 2004). Chemotherapeutic agents, ultra-violet (UV) radiation
from the sun, and other frequencies of radiation such as x- and gamma (γ)-rays, are all
examples of exogenous sources of DNA damage, while damage can also result from
endogenous sources such as replication errors and oxidative stress caused by metabolic
by-products (Mirkin and Mirkin, 2007; Ward, 1988). The type of damage lesion can vary
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widely from single- to double-strand breaks, interstrand cross-links, and base
modifications i.e. alkylation, depurination, oxidation. The strategy for repair depends on
the type and location of the lesion as well as cell cycle stage. The cell has evolved a
complex DNA damage response (DDR) that is responsible not only for detection and
repair of damage, but also to coordinate repair with other cellular processes such as
chromatin remodeling, transcription, cell-cycle progression, and apoptosis (Jackson and
Bartek, 2009). Following detection of DNA damage, genome surveillance pathways
become activated to block progression through the cell cycle in order to repair damaged
DNA prior to cell division and ensure that daughter cells do not inherit the damage.
The most common type of lesion is likely single-strand breaks (SSBs), which can occur
during base excision repair (BER) or from abortive topoisomerase I (TOP1) reactions
(Caldecott, 2008). TOP1 generates a nick, also known as a cleavage complex
intermediate, to relax DNA during transcription and replication (Wang, 2002). These
intermediates are usually transient and rapidly resealed by TOP1, however collision with
DNA/RNA polymerases can convert them into TOP1-linked SSBs (Pommier et al.,
2003). Repair of single-strand breaks requires the generation of a 3’ hydroxyl and 5’
phosphate compatible for ligation by a DNA ligase, such as DNA ligase 1 (LIG1). Base
modifications, such as oxidation or alkylation, are another common source of DNA
damage. Organs with high metabolic demand, such as the brain, are particularly
vulnerable to oxidative base modifications caused by reactive oxygen species (ROS),
such as 8-oxo-dG (Iyama and Wilson, 2013). Oxidative lesions are repaired by the base
excision repair (BER) pathway, in which DNA glycosylases cleave the N-glycosidic
bond of modified bases (Lindahl, 1974) and processing occurs through the action of
APE1, DNA polymerase β, and XRCC1 (Hegde et al., 2008; Mitra et al., 2001).
Structural distortions of the DNA, such as “bulky” pyrimidine dimers and DNA adducts
are repaired by nucleotide excision repair (NER). NER can be broadly characterized into
global-genome NER, which scans the genome for helix-distorting lesions, and
transcription-coupled NER, which is activated in response to damage on the transcribed
stand of active genes (de Laat et al., 1999). Both BER and NER utilize the same general
program: detection, excision, gap-filling synthesis, and ligation (Kamileri et al., 2012a).
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DNA damage associated with replication, commonly referred to as replication stress,
requires signaling of the ATM and Rad3 related (ATR) kinase, which responds to
replication protein A (RPA)-coated ssDNA found at stalled or collapsed replication forks
(Cimprich and Cortez, 2008) (Figure 1-4). Interstrand cross-link repair and mismatch
repair also function to overcome errors that can occur during DNA replication (Deans
and West, 2011; Jiricny, 2006). Replication-associated damage and other sources of
endogenous damage will be further discussed in Section 1.4.3.
The most deleterious form of DNA damage is a double-strand break (DSB) since they
can result in the loss of a substantial amount of genetic information and/or cause large
chromosomal rearrangements that can lead to cell death or tumourigenesis. DSBs can
arise endogenously as a result of abortive topoisomerase II activity, replication fork
collapse, and even neuronal activity (Gomez-Herreros et al., 2013; Nitiss, 2009; SalehGohari et al., 2005; Suberbielle et al., 2013), as well as exogenous sources such as
ionizing radiation and chemotherapy agents (Jekimovs et al., 2014; Ward, 1988). DSBs
are detected by the MRN complex, which promotes recruitment of repair factors and
activation of cell cycle checkpoints through activation of the ATM kinase (Stracker and
Petrini, 2011) (Figure 1-4). The strategy of repair is dependent on cell cycle stage: while
the majority of DSBs are repaired through non-homologous end joining (NHEJ), the
extra copy of genetic information that exists in S/G2-phase cells allows for homologydirected repair (also referred to as homologous recombination; HR) (Lombard et al.,
2005). In NHEJ, DSB ends are recognized by Ku70/Ku80 heterodimers that recruit and
activate the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs), which
facilitates recruitment of end processing proteins that prepare the DNA ends for ligation
by DNA ligase IV (Waters et al., 2014). Deletions can be introduced during the end
processing stage of NHEJ, making this type of repair strategy error-prone. HR, however,
is virtually error-free since it utilizes the homologous sister chromatid as a template for
repair. HR repair is initiated through dsDNA end resection to generate 3’ ssDNA end on
which the RAD51 recombinase is loaded, resulting in invasion of a homologous DNA
duplex that primes DNA synthesis and DNA polymerase-mediated copying of the intact
DNA molecule (Li and Heyer, 2008). Many other molecules also play key roles in HR
repair, such as breast cancer 1, early onset (BRCA1) and BRCA2, Rad54, and XRCC2
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(Chen et al., 1999; Liu et al., 1998). Furthermore, the cohesin complex is important for
activation of DNA damage-induced intra-S phase and G2/M checkpoints downstream of
DSB signaling (Kim et al., 2002; Luo et al., 2008; Qiu et al., 2015; Watrin and Peters,
2009; Yazdi et al., 2002), and replication-associated cohesion generated by cohesin is
required for post-replicative HR repair (Sjogren and Nasmyth, 2001). This role of cohesin
has not been investigated with respect to its interaction with CTCF or ATRX.
The DNA damage repair and response cascade is an energy-consuming process that can
in itself perturb cellular homeostasis if over activated. It is estimated that 104 ATP
molecules are required to repair one DSB (Hoeijmakers, 2009), and PARP1 activation
during the DDR can lead to nicotinamide adenine dinucleotide (NAD+) depletion,
disrupting NAD-dependent enzymes like sirtuins and/or promote cell death through the
release of apoptosis-inducing factor (AIF) (Alano et al., 2010). Timely and accurate
repair of DNA damage is therefore essential for cellular survival and homeostasis.
Cell cycle arrest and apoptotic pathways are largely intertwined, and the p53 protein is an
upstream master regulator of both facets of tumour suppression (Lane, 1992) (Figure 14). DNA damage, oncogene activation, hypoxia, and oxidative stress are cellular stressors
that induce activation of p53, a transcription factor that binds to target gene promoters in
a sequence-specific manner (Kern et al., 1991). The cellular outcome of the p53 pathway
is contingent on the target activated: p21 is a major mediator of p53-dependent cell cycle
arrest (Vogelstein et al., 2000), while Puma is responsible for apoptotic activation
downstream of p53 (Jeffers et al., 2003; Villunger et al., 2003) (Figure 1-4). p21 induces
cell cycle arrest by inhibiting cyclin D/cyclin-dependent kinase (Cdk) 4, 6 and cyclin
E/Cdk2 complexes, resulting in retinoblastoma (Rb) hyperphosphorylation and arrest at
the G1/S phase transition (Stewart and Pietenpol, 2001). G2 phase arrest can also be
mediated by p21-dependent inactivation of cyclin B1 and Cdc2 (Flatt et al., 2000;
Innocente et al., 1999). PUMA promotes cell death through BAX activation, resulting in
apoptosis-inducing factor and cytochrome c release from the mitochondria and activation
of the caspase cascade (Sionov and Haupt, 1999).
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Figure 1-4 Cellular response to telomere uncapping, DNA double-strand breaks
(DSBs), and replication stress
In the CNS, telomere uncapping results in ATR-to-ATM signaling, checkpoint activation
and cell cycle arrest or apoptotic induction (Lee et al., 2014). DSBs cause MRN
activation, resulting in ATM-dependent signaling (pATMS1981) to induce cell cycle
arrest via Chk2 (pChk2T68) activation or p53-dependent apoptosis (pp53S18).
Replicative stress typically causes an accumulation of RPA (pRPAS33), which activates
ATR-dependent checkpoint activation via Chk1 (pChk1S317/345) or apoptotic induction
via p53 (pp53S18). Genotoxic stress-induced apoptosis in neuroprogenitor cells is
primarily mediated by p53-dependent transcriptional induction of Puma (Jeffers et al.,
2003). Incorporation and phosphorylation of H2AX (S139; γH2AX) is a common event
in response to many types of damage and is mediated by ATM and ATR kinases.
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1.4.2 DNA damage response and repair in the context of chromatin
Since virtually all DNA damage occurs in the context of chromatin, interplay between
higher-order chromatin structure and the DDR is crucial for timely detection and repair of
damage. Historically, chromatin has been viewed as a barrier that has to be alleviated
during repair and then restored afterwards (Smerdon, 1991). However, chromatin
components have also been shown to promote DNA damage repair and signaling,
resulting in the proposition of a “prime-repair-restore” model that suggests a more active
role for chromatin in the DDR (Soria et al., 2012).
Several types of chromatin remodeling are important for DNA repair such as chaperonemediated incorporation of histone variants, histone post-translational modifications, and
ATP-dependent chromatin remodeling. There is also crosstalk between these
mechanisms, as ATP-dependent chromatin remodeling is necessary for nucleosome
eviction to allow for histone chaperone-mediated deposition of variants, underscoring the
complexity of chromatin contributions to the DDR. Histone variants and modifications
can function to organize and/or stabilize DNA repair machinery, and chromatin can also
help to restrain transcription and signaling at the site of damage. Furthermore, higherorder 3D chromatin architecture likely plays an important role in facilitating repair, at the
very least HR repair, although this has not yet been intensely studied.
The most well-characterized histone variant and modification in the context of the DDR
is phosphorylation of histone H2A variant H2AX at serine 139 (γH2AX) by the PI-3
kinases ATM, ATR, or DNA-PK (Kinner et al., 2008). The FACT (facilitates chromatin
during transcription) complex is responsible for deposition of H2AX (Heo et al., 2008).
Immediately following induction of a DSB, γH2AX can be detected at the site of damage,
which eventually spans at least a megabase of chromatin surrounding the break
(Nakamura et al., 2010; Rogakou et al., 1998) (Figure 1-4). Spreading of γH2AX is a
discontinuous process influenced by both transcription (Iacovoni et al., 2010) and cohesin
binding (Caron et al., 2012). The DNA repair process manifests cytologically as DNA
repair foci that are formed by the recruitment and accumulation of DNA repair factors at
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sites of DNA damage. γH2AX is a major constituent of DNA repair foci, and serves as a
beacon for the assembly of repair factors and to coordinate the DDR with other cellular
functions such as cell cycle arrest (Polo and Jackson, 2011). H2AZ and macroH2A are
other H2A variants with documented roles in the DDR. Replacement of H2AX with
H2AZ is dynamically regulated at damage sites, stimulating DSB end resection and
promoting an open chromatin conformation to help recruit repair machinery to sites of
DSB (Kalocsay et al., 2009; Xu et al., 2012). MacroH2A accumulates at DNA damage
sites in a PARP-dependent manner and is required for HR repair (Khurana et al., 2014).
Histone H3 variant H3.3 has been shown to mediate replication fork restart and
transcriptional recovery after UV-induced DNA damage in a HIRA-dependent manner
(Adam et al., 2013; Frey et al., 2014), however the requirement for H3.3 incorporation at
other damage lesions has not been addressed and may require distinct pathways for
deposition. For instance, in distinct cellular contexts different pathways of histone
deposition may be required, and it has been shown that DAXX mediates H3.3 deposition
at some neuronal activity-dependent genes (Michod et al., 2012). Collectively, these data
underscore the importance of chromatin dynamics in the DDR and reveal that our
understanding of the contributions of histone variants to DNA damage repair and
signaling is only beginning to emerge.
As mentioned in Section 1.3.1, a key feature of the nucleus is its non-random
organization of chromosomes into distinct subdomains (Bickmore and van Steensel,
2013; Cremer and Cremer, 2001; Misteli, 2007). It has been well established that there
are dedicated centers in the nucleus for transcription and replication, termed “factories”,
begging the question of whether “repair factories” exist. Low-dose irradiation in yeast
leads to ~2-4 DNA repair foci, however higher doses induce larger instead of more foci,
suggesting that newly formed lesions are recruited to pre-existing sites for repair (Lisby
et al., 2003a; Lisby et al., 2003b; Lisby and Rothstein, 2004). This may be different in
mammalian cells, where DSBs appear immobile in the nucleus (Soutoglou et al., 2007),
and despite some evidence of repair center formation (Aten et al., 2004) their existence
has been debated extensively (Dion and Gasser, 2013). While the relevance of higherorder chromatin structure has been thoroughly studied in the context of transcriptional
regulation, we know very little of how 3D chromatin architecture influences replication
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and repair. Recent evidence indicates that topologically associating domains (TADs)
function as stable units of replication timing (Pope et al., 2014) (Figure 1-3). It is
unknown whether DNA damage induces TAD reorganization, yet evidence that
demonstrates relocation of damaged heterochromatin suggests changes to 3D structure in
some capacity. Relocation of heterochromatic breaks to outside of heterochromatin
domains by HR factors has been observed in Drosophila and is believed to prevent
recombination between repetitive sequences that are often found in heterochromatin
(Chiolo et al., 2011). This relocation of DSBs to the periphery of chromocentres is
reminiscent of the location of major satellites replication (Guenatri et al., 2004; Quivy et
al., 2004), raising the idea that a common mechanism may underlie the two processes,
especially since similar proteins are implicated. DSBs in heterochromatin are
characterized by slower repair kinetics than those in euchromatic regions (Goodarzi et al.,
2008). Moreover, ES cells with reduced levels of the linker histone H1 display an
enhanced cellular response to DSBs, which has been ascribed to the less compacted
chromatin in the absence of H1 since histone deacetylase (HDAC) inhibitor trichostatin A
(TSA)-induced global chromatin decompaction has a similar effect on repair efficiency
(Murga et al., 2007). Collectively these results demonstrate that chromatin structure
influences the repair process and that chromatin organizing proteins may help fine-tune
the cellular response to DNA damage. Furthermore, the notion of cohesin mediating the
spatial proximity of sister chromatids during HR implies that reorganization of higherorder chromatin structure is necessary. Studying how nuclear positioning is determined
and how it may influence repair and replication will be essential to fully understand
tumourigenesis and human pathology.

1.4.3 Endogenous sources of DNA damage
As mentioned in section 1.4.1, DNA lesions can arise spontaneously as a result of
reactive oxygen species, abortive topoisomerase I/II reactions, or replication errors.
Spontaneous replication-associated DNA damage is particularly relevant to this thesis
and will therefore be the focus of this section.
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Replication of genetic information is a fundamental biological process, and accurate
replication is essential to maintain genome stability and suppress cancer (Allen et al.,
2011). Apart from exogenous sources of damage, DNA can be damaged by replication
errors that often occur at genomic regions prone to slowed replication forks, such as
chromosomal fragile sites, telomeres, unusual secondary structures, DNA-RNA hybrids
and repetitive sequences (Aguilera and Gomez-Gonzalez, 2008; Durkin and Glover,
2007; Mirkin and Mirkin, 2007; Sfeir et al., 2009; Szilard et al., 2010; Tuduri et al.,
2009). There are a number of conserved tumour-suppressive mechanisms in place to
ensure correct replication and repair of replicative errors that cause cell cycle arrest,
death, or senescence. Cells are also quite vulnerable to DNA damage during replication
since virtually all DNA damage blocks the replication fork, causing replication stress.
Damage can therefore be a cause or consequence of replicative stress.
Although replication stress has been widely recognized as a significant hurdle to
overcome in order to maintain cellular homeostasis, there is yet to be a single unifying
description of the phenomenon. This is likely because replicative stress can arise from a
variety of sources, and ultimately cellular indicators of replicative stress are shared with
other DNA damage response/repair pathways. Typically, the persistence of ssDNA bound
by RPA generates a signal to activate ATR and other replication-stress-response proteins,
resulting in intra-S or G2/M phase arrest to allow the cell to repair damaged DNA before
entering mitosis (Abraham, 2001; Branzei and Foiani, 2007; MacDougall et al., 2007;
Marechal and Zou, 2013; Nam and Cortez, 2011; Zou and Elledge, 2003) (Figure 1-4).
ATR-dependent phosphorylation and activation of RPA (pRPAS33) and checkpoint
kinase 1 (pChk1S345) and detection of ssDNA are the best-known indicators of
replicative stress (Zeman and Cimprich, 2014) (Figure 1-4). However, replicative stress
may occur but is not severe enough to induce ATR activation and phosphorylation of its
downstream targets (Koundrioukoff et al., 2013). To date, the best detection method for
replicative stress is the DNA fiber assay, which allows direct measurements of DNA
synthesis through the use of thymidine analogs (Bianco et al., 2012).
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1.4.4 DNA damage response in the developing central nervous
system
Genesis of the central nervous system requires enormous expansion of neuroprogenitor
cells (NPCs) that give rise to a diverse array of cell types. Brain development and
maturation requires the generation of correct cell numbers and their integration into a
complex network of neurons that are metabolically and functionally supported by
astrocytes and oligodendrocytes. Before the onset of neurogenesis, NPCs (also referred to
as neuroepithelial cells at this time) undergo rapid symmetric divisions to expand the
progenitor pool (Figure 1-5a). At ~E11 in the neocortex, some NPCs begin to divide
asymmetrically to generate one progenitor cell and one post-mitotic neuron (Figure 1-5a).
Newborn neurons then migrate from the proliferative zone to their final destination where
they further differentiate and become integrated into functional networks (Greig et al.,
2013).
A functioning DNA damage response (DDR) and repair system are extremely important
in these early developmental stages since unrepaired lesions can greatly influence the
formation of a functional nervous system (McKinnon, 2013). Overall, the nervous system
has a low threshold for DNA damage, which makes sense since integrating dysfunctional
cells into the neuronal network may be more detrimental than eliminating them (Lee and
McKinnon, 2007), and the nervous system already utilizes apoptosis to eliminate overproduced cells during normal brain development (Nijhawan et al., 2000; Yoshida et al.,
1998). Indeed, enhanced sensitivity to DNA damage following TopBP1 deletion was
observed in early-born compared to later-born cortical progenitors, and irradiation of
mouse brain leads to elevated levels of apoptosis in the neocortex at E11.5 compared to
E14.5 (Lee et al., 2012a). These data indicate a propensity for NPCs to undergo apoptosis
in response to DNA damage rather than risk expanding progenitors with abnormal DNA.
The requirements for genome maintenance change substantially during the transition
from neurogenesis to nervous system maturation. During neurogenesis, a primary source
of damage results from replication errors due to the high proliferative index of progenitor
cells (McKinnon, 2009). Differentiated neural cells are incredibly long-lived and must
withstand the genetic damage throughout the entire life of an organism. Byproducts of
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metabolism, such as ROS, are the primary source of damage in post-mitotic neurons due
to the high energy demand of the mature brain (Harris et al., 2012). Despite these
differences, there remains a constant requirement for the maintenance of genomic
stability in the CNS.
DNA integrity is maintained during development by coordinated signaling pathways that
pause cell proliferation to repair damage or, alternatively, activate apoptotic pathways to
eliminate damaged cells and avoid acquisition of mutations. Damage signaling requires
the ATM and ATR kinases, which have largely distinct roles in maintaining genome
stability in the nervous system since they respond to different types of DNA damage
(Herzog et al., 1998; Lee et al., 2012b) (Figure 1-4). The nervous system contains the full
repertoire of DNA repair and signaling pathways that were outlined in Section 1.4.1.
The requirement of genome surveillance for proper brain development is clearly
illustrated by mouse models of DDR-deficiency (Frappart and McKinnon, 2008). Mice
lacking the essential HR factor XRCC2 (X-ray repair complementing defective repair in
Chinese hamster cells 2) exhibit extensive apoptosis in the brain by E10.5, correlating
with the period of neural progenitor proliferation, while mice deficient in the necessary
NHEJ factor DNA ligase IV (LIG4) display apoptosis at E12.5 in differentiating NPCs
(Orii et al., 2006). These findings indicate that the developing brain is vulnerable to
endogenous DSBs and strengthen the idea that HR is the preferred method of DSB repair
in proliferating cells, while post-mitotic cells default to utilizing NHEJ. However, a new
finding that RNA can be used as a template for homology-directed repair demands
reconsideration of this narrow view (Keskin et al., 2014), since it implies HR capabilities
in all stages of the cell cycle. Nevertheless, the benchmark study by Orii et al.
demonstrates that the types of DNA damage encountered in post-mitotic neurons are
different than those observed in cycling neuroprogenitors and that distinct repair
pathways are utilized (Orii et al., 2006). NPCs have a high proliferative index and thus
encounter replication-associated damage, however post-replicative mature neurons
encounter a high degree of metabolic damage, such as oxidative stress. DNA lesions in
differentiated cells typically do not activate apoptosis, but can interfere with transcription
if unrepaired and located in the vicinity of coding sequence (McKinnon, 2013). Along
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these same lines, persistent DNA damage in mature neurons can cause redistribution of
the histone deacetylase SIRT1 on chromatin, causing dysregulation of aging-associated
genes (Oberdoerffer et al., 2008).
Differential susceptibility of progenitors to DNA damage may be linked to cell cycle
dynamics, as cell cycle regulation of NPCs is a key aspect of cortical development and
involves dynamic changes in G1 and S phase duration (Arai et al., 2011; Dehay and
Kennedy, 2007; Gotz and Huttner, 2005) (Figure 1-5b). A key difference between
proliferating and neurogenic progenitors is the length of S phase; a three-fold longer S
phase is associated with expanding neural progenitors compared to committed neural
cells, which are characterized by a prolonged G1 phase (Arai et al., 2011) (Figure 1-5b).
This is likely due to the increased need for genome surveillance in non-committed
progenitors to prevent transmission of genetic errors. Chromatin state is also an important
determinant of neurogenic potential (Kishi et al., 2012), in addition to its defined roles in
DNA damage response and repair (Soria et al., 2012), however our understanding of the
relationship between chromatin structure, cell cycle regulation, and the DDR in the
context of brain development is limited.
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Figure 1-5 Timeline of corticogenesis and cell cycle dynamics in proliferative versus
neurogenic cortical progenitors
(A) Neuroepithelial (NE) cells divide symmetrically to produce two NE cells and expand
the progenitor pool before the onset of neurogenesis. In the neurogenic stage, NE cells
acquire characteristics of radial glia (RG) and are termed apical progenitors (AP). APs
and outer radial glia (oRG) progenitors divide asymmetrically to self-renew and generate
a cell of neurogenic fate such as a postmitotic projection neuron or basal progenitor (BP).
The earliest born neurons form the preplate, which eventually splits to form the subplate
(SP) and marginal zone (also termed cortical layer I). The cortical plate forms in between
these two layers in an inside-out fashion, with later born neurons migrating past earlier
born neurons using the basal process of AP or oRG. The generation of glial cells
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(oligodendrocytes and astrocytes) begins in late gestation at approximately E18. This
schematic was largely reproduced using information derived from (Grieg et al., 2013).
(B) Different subtypes of postmitotic neurons are born in overlapping temporal waves.
Subplate neurons (SPN) are born at approximately E11.5, followed by corticothalamic
projection neurons (CThPN) that are born at approximately E12.5. At the same time,
callosal projection neurons (CPN) are generated throughout E12.5-E16.5. Subcerebral
projection neurons (SCPN) are born at E13.5, followed by the generation of layer IV
granular neurons (GN) at E14.5. (C) Proliferative and neurogenic progenitors exhibit
differential cell cycle parameters, namely proliferative NPCs are characterized by a
lengthened S phase (8 h versus 2.4 h) and neurogenic NPCs are characterized by a
lengthened G1 phase (17.1 h versus 12.7 h) (Arai et al., 2011). VZ: ventricular zone;
SVZ: subventricular zone; CR: Cajal-Retizus.
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1.4.5 Microcephaly is caused by defective cell cycle regulation, DNA
damage response, and centrosome biology
Microcephaly is defined as head circumference two- to three-standard deviations below
the mean, is often equivalent to microencephaly (reduced brain size), and is frequently
associated with intellectual disability, or impaired cognition or adaptive functioning
(Dolk, 1991). Microcephaly is a clinically heterogeneous disease and can present in the
absence (primary microcephaly) of syndromic features or as a characteristic of specific
syndromes, like ATR-X syndrome (Gibbons, 2006). Microcephaly is caused by
abnormalities in cellular production, and as such the study of developmental
microcephalies have taught us an enormous amount about how the brain generates the
correct number of neurons to support brain size (Gilmore and Walsh, 2013). By and
large, microcephaly-associated gene products are components of the centrosome, regulate
cell cycle dynamics, or are involved in the DNA damage response. How these particular
types of proteins are linked to microcephaly is still unresolved. It is possible that
defective cell cycle regulation can lead to cellular proliferation deficiencies and/or
apoptotic induction, which have both been observed in mouse models of microcephaly.
For instance, deletion of Cdk5rap2 causes excessive cell death (Lizarraga et al., 2010)
and ASPM (abnormal spindle-like, microcephaly-associated) influences progenitor
proliferation by controlling WNT signaling (Buchman et al., 2011).
Remarkably, all genes associated with primary microcephaly encode proteins associated
with the centrosome or centrosomal-related activities (Bond et al., 2002; Bond et al.,
2005; Guernsey et al., 2010; Jackson et al., 2002; Kalay et al., 2011; Kumar et al., 2009;
Kumar et al., 2002; Nicholas et al., 2010; Yu et al., 2010b). Centrosomes are organelles
with a critical role during mitosis where they associate with microtubules and are
involved in formation of the mitotic spindle. How centrosomal defects cause
microcephaly is not well understood. There is also crosstalk between centrosomal
components, DNA damage signaling, and cell cycle regulation. For instance, the primary
microcephaly gene product microcephalin (MCPH1) couples the centrosomal cycle with
mitotic entry through phosphorylation of Cdc25/Chk1 (Gruber et al., 2011), and recruits
the SWI/SNF complex to DNA damage sites facilitate local chromatin remodeling and
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proper DDR signaling (Peng et al., 2009). This example highlights the dynamic interplay
between the DNA damage response and cell cycle control, and underscores the
importance of these processes in neurodevelopment since MCPH1 mutations in humans
solely affect the brain.
Microcephaly can also be caused by mutations in DNA repair pathway genes including
NBS1, XLF, DNA ligase IV, and MCPH1 (Ben-Omran et al., 2005; Buck et al., 2006;
Carney et al., 1998; O'Driscoll et al., 2001; O'Driscoll and Jeggo, 2008; Xu et al., 2004).
A question in the field is why defects in the DNA damage response pathway particularly
affect brain development. During neurogenesis, replicative stress is a primary source of
endogenous damage due to the rapid proliferative index of NPCs (McKinnon, 2013).
Since DNA damage can lead to altered cell cycle dynamics, defects in the cellular
response to or repair of damage may perturb the precise balance between NPC
proliferation, differentiation and cell death. Excessive cell death during brain
development would result in decreased neuronal numbers, and is one of the potential
mechanisms underlying the microcephaly phenotype.

1.4.6 The DNA damage theory of aging
It has been well established that DNA damage and mutations accumulate as we age (Vijg,
2000). This fact has led to the DNA damage theory of aging, which postulates that the
accumulation of genetic lesions is the major cause of the accelerated physiological
decline associated with aging (Freitas and de Magalhaes, 2011; Gensler and Bernstein,
1981; Kirkwood and Holliday, 1979; Szilard, 1959). Aging is a natural process that
affects most biological functions and appears to be a consequence of the cumulative
action of various stressors such as telomere attrition, oxidative damage, and the decline of
DNA repair (Kirkwood, 2005; Vijg and Campisi, 2008). Understanding the biological
mechanisms underlying aging is of utmost importance since age is the primary risk factor
for most human diseases, including neurodegeneration and cancer.
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Human progeroid syndromes exhibit clinical manifestations that resemble accelerated
aging, and have been linked to defects in DNA repair or processing. Genetic
manipulation of DNA repair or response factors in mice result in the appearance of aginglike phenotypes, supporting the idea that DNA damage may be directly linked to aging.
However, the best proof of principle would be to decrease physiological levels of DNA
damage to lengthen lifespan in these models, which is difficult, if not impossible, to
accomplish in vivo. The study of progeroid syndromes for the understanding of normal
aging is controversial, since mouse models and even human progeria patients only exhibit
a subset of the symptoms of normal aging and are therefore often referred to as
“segmental progeria” (Miller, 2004). Nevertheless, progeroid and accelerated aging
syndromes clearly demonstrate that disruption of DNA repair pathways can elicit aging
phenotypes.
Hormone signaling plays a key role in the regulation of aging: in particular, the
somatotroph (insulin-like growth factor 1/growth hormone) axis is a critical regulator of
metabolism and longevity (Russell and Kahn, 2007) (Figure 1-6). An intriguing aspect of
these longevity pathways is that they function non-cell autonomously; mutations or
abnormalities in one cell type can alter the entire organism. Specifically, neuronal cells
play a special role in cell non-autonomous lifespan regulation by the IGF-1 pathway in C.
elegans (Wolkow et al., 2000). Chronic activation of the stress response is associated
with human aging, and causes transcriptional changes associated with dampening of the
somatotroph axis (Bartke, 2005; Lombardi et al., 2005). This molecular signature is also
observed in mouse models that exhibit accelerated aging (Niedernhofer et al., 2006; van
der Pluijm et al., 2007). Signaling between the hypothalamus, the pituitary gland, and the
thyroid gland is essential for metabolic regulation (Figure 1-6). The hypothalamus senses
low circulating levels of thyroid hormone and responds by releasing thyrotropin-releasing
hormone (TRH). TRH stimulates the pituitary to produce thyroid-stimulating hormone
(TSH), which in turn stimulates the thyroid to produce thyroid hormone (Dietrich et al.,
2012). Thyroid hormone (thyroxine/T4) levels are also critical for the regulation of IGF-1
during prepubertal development (Xing et al., 2012) (Figure 1-6). Despite extensive
evidence of a link between DNA damage and suppressed IGF-1 responses, there has not
yet been satisfactory mechanistic explanation of the connection with aging.
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Taken together, there is a strong relationship between DNA damage accumulation and
the systemic defects associated with aging. Furthering our understanding of the complex
interplay between DNA damage, metabolic signaling, and physiological decline will be
necessary to solve the biological enigma of aging.
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Figure 1-6 Insulin-like growth factor-1 (IGF-1) signaling controls organismal
metabolism, growth and development, and longevity and can be controlled by
thyroxine (T4) or growth hormone (GH)
Thyrotropin-releasing hormone (TRH)-expressing cells in the hypothalamus release
TRH, which acts on cells in the anterior pituitary (yellow) to produce and release thyroid
stimulating hormone (TSH). TSH acts on the thyroid gland to produce thyroxine (T4),
which is converted to the biologically active T3 form that acts on the liver to induce IGF1 production. This pathway is the major activator of IGF-1 signaling during prepubescent
development (Xing et al., 2012). Alternatively, gonadotropin-releasing hormone (GnRH)expressing neurons in the hypothalamus act on cells in the anterior pituitary to produce
and release growth hormone (GH), which is released into the blood stream and increases
IGF-1 levels.
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1.5 Thesis Overview
The overarching goal of this thesis is to identify the molecular mechanism(s) underlying
neurological disorders associated with defective chromatin structure.

1.5.1 Rationale and Hypothesis
Human mutations in ATRX and CTCF cause intellectual disability associated with
microcephaly as well as various cancer subtypes, however we do not yet fully
comprehend the role of ATRX or CTCF in brain development and suppression of
tumourigenesis. Using mouse models deficient for Atrx and Ctcf in the embryonic brain,
the work herein tests the hypothesis that chromatin regulation is critical for correct
neurodevelopment by suppressing genomic instability and promoting NPC survival.

1.5.2 Chapter Two: Atrx deficiency induces telomere dysfunction,
endocrine defects and reduced lifespan
This chapter describes work demonstrating that ATRX is required for NPC survival by
suppressing DNA double-strand breaks at telomeric and pericentromeric heterochromatin
during replication. Atrx-null NPCs are sensitive to telomestatin, a drug that selectively
stabilizes G4-DNA structures, suggesting that ATRX may resolve G4-DNA to facilitate
progression of the replicative machinery through repetitive sequences, i.e. telomeres,
during late-S phase.

1.5.3 Chapter Three: Dual effect of CTCF loss on neuroprogenitor
differentiation and survival
Chapter three provides evidence that CTCF is required for NPC survival, functioning to
suppress p53/PUMA activation. Despite rescue of cell death in the embryonic brain,
Ctcf/Puma-deficient mice display microcephaly, indicating that PUMA-dependent
apoptosis does not completely explain the reduced brain size of Ctcf-deficient mice.
Instead, Ctcf-deficient NPCs exhibit precocious differentiation, causing a depletion of the
cortical progenitor pool. Together, these data indicate that CTCF functions to promote a
balance between NPC proliferation/differentiation and to suppress p53/PUMA-mediated
cell death for correct neurodevelopment.
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1.5.4 Chapter Four: CTCF is required to prevent replicative stress
and p53/PUMA-dependent apoptosis
Chapter four explores the mechanism underlying NPC death in the Ctcf-deficient brain
and demonstrates CTCF loss results in endogenous DNA breaks that correlate with active
proliferation and Ctcf-null NPCs exhibit characteristics of replicative stress. Moreover,
Ctcf-null NPCs are sensitive to exogenous replicative stress, indicating that CTCF may
function to prevent or repair replication-associated damage. Together, the findings
described in the final chapter of this thesis identify a novel role for CTCF in preventing
replicative stress and uncovers the mechanisms involved.
Overall, this thesis highlights the importance of two chromatin regulators in brain
development and demonstrates that correct chromatin structure is critical to the
differentiation and survival of neuroprogenitor cells. Dysfunctional chromatin induced by
loss of ATRX or CTCF renders NPCs especially vulnerable to replication-associated
damage and p53-dependent apoptosis. Not only do my findings provide some insight into
mechanisms underlying defective brain development stemming from ATRX or CTCF
mutation, it also has broad implications for the pathogenesis of complex neuropsychiatric
diseases such as autism and schizophrenia.
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Chapter 2

2 Atrx deficiency induces telomere dysfunction, endocrine
defects, and reduced lifespan
Prior to the research presented in this chapter, we identified that ATRX is required for
survival of neuroprogenitor cells, and that loss of ATRX results in p53-dependent
apoptosis (Berube et al., 2005; Seah et al., 2008). In this chapter, I sought to investigate
the molecular mechanism underlying p53-dependent apoptosis resulting from Atrxdeficiency.
This chapter was previously published as (Watson et al., 2013). Permissions for
reproduction are found in Appendix A.

2.1 Introduction
Faithful replication of DNA maintains genomic stability, limits the accumulation of
cancer-promoting mutations, and can extend life span. Replication stress can occur
spontaneously from stalling of the replication machinery as it encounters obstacles on the
DNA template, such as DNA lesions, intricate secondary structures, or DNA-bound
proteins (Branzei and Foiani, 2010). Impaired progression of the replication machinery
can also occur when cells are exposed to exogenous damage or drugs that limit the
nucleotide pool, or that cause interstrand crosslinking. The stabilization of paused
replication forks to allow restart involves activation of checkpoint signaling to provide
the cell extra time to respond (Allen et al., 2011). Failure to stabilize stalled forks causes
fork collapse, a process involving dissociation of the polymerases, exposure of extended
single-stranded DNA (ssDNA) regions, improper processing, and DNA breakage. Stalled
replication can have serious consequences, such as genomic instability, chromosomal
rearrangements from illegitimate recombination events, and reduced cell viability
(Branzei and Foiani, 2010). Constitutive heterochromatin, telomeric DNA, and other
DNA structures can pose particular challenges to the replication machinery. To overcome
such hindrances, specialized factors are required to resolve difficult DNA structures or to
promote access of restart pathway proteins to stalled forks (Buonomo, 2010).
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ATRX is a Rad54-like ATP-driven DNA translocase belonging to the Swi/Snf family of
chromatin remodelers (Xue et al., 2003). The biological impact of ATRX mutations in
humans appears to vary according to the extent and timing of disruption. In humans,
ATRX somatic frameshift and nonsense mutations that completely abolish protein
function have been identified in pancreatic neuroendocrine tumours (PanNETs) (Heaphy
et al., 2011a; Jiao et al., 2011; Yachida et al., 2012), pediatric and adult glioblastoma, and
other cancers of the CNS (Cheung et al., 2012; Jiao et al., 2012; Kannan et al., 2012;
Molenaar et al., 2012; Schwartzentruber et al., 2012), underscoring the anti-tumourigenic
roles of ATRX. Tumours with ATRX mutations often harbor long telomeres, which are
characteristic of the telomere maintenance mechanism known as alternative lengthening
of telomeres (ALT) (Heaphy et al., 2011a; Jiao et al., 2011; Kannan et al., 2012; Lovejoy
et al., 2012; Nguyen et al., 2013). Conversely, hypomorphic inherited mutations of the
ATRX gene cause a rare developmental disorder, ATR-X syndrome (OMIM 301040),
with diagnostic features of severe cognitive deficits, microcephaly, seizures, short stature,
developmental delay, and α-thalassemia, without increased neoplasia incidence (Gibbons
and Higgs, 2000; Gibbons et al., 1995a; Gibbons et al., 1995b). Thus, inactivating
mutations of the ATRX gene during development are likely embryonic lethal, while
diminished ATRX activity leads to severe developmental and cognitive abnormalities.
ATRX somatic inactivating mutations that arise later and consequently bypass embryonic
development appear to drive cancer progression, particularly in the CNS.
The cellular functions of ATRX are not completely clear; however, several lines of
evidence point to a role in the maintenance of genomic integrity. Decreasing levels of
ATRX by RNA interference induces spindle defects, as well as chromosomal alignment
and segregation problems during mitosis and meiosis, and complete loss of ATRX in
neuroprogenitor cells (NPCs) can also induce mitotic abnormalities (Baumann et al.,
2010; De La Fuente et al., 2004; Ritchie et al., 2008; Seah et al., 2008). Furthermore,
ATRX-depleted mouse embryonic stem cells have unstable telomeres (Wong et al.,
2010). The ATRX protein can bind to specific genomic sites, including imprinting
control regions and the Rhox5 promoter (Bagheri-Fam et al., 2011; Kernohan et al.,
2010), but is also highly enriched at repetitive regions, including ribosomal DNA repeats,
pericentromeric heterochromatin, and telomeric chromatin, where it was proposed to
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cooperate with DAXX to incorporate the histone variant H3.3 into chromatin (Baumann
et al., 2008; Berube et al., 2000; Eustermann et al., 2011; Lewis et al., 2010; McDowell et
al., 1999; Wong et al., 2010).
In the present report, we demonstrate that ATRX deletion in NPCs causes excessive
replication–related DNA damage, which is exacerbated by loss of p53, replication stress–
inducing drugs, and telomestatin (TMS), a G-quadruplex (G4) ligand. Unexpectedly,
mutant mice lacking ATRX in the forebrain and pituitary had low circulating IGF-1,
thyroxine (T4), and glucose levels and displayed degenerative phenotypes previously
described in mouse models of progeria. Collectively, our data reveal that ATRX protects
cells from replicative stress–induced DNA damage and telomeric fusions and that loss of
ATRX in the embryonic CNS and anterior pituitary elicits systemic endocrine and
metabolic abnormalities.

2.2 Materials and Methods
2.2.1 Mouse husbandry, genotyping, and tissue preparation
Mice were exposed to 12-hour light/12-hour dark cycles and fed tap water and regular
chow ad libitum. The AtrxloxP mice have been described previously (Berube et al., 2005;
Garrick et al., 2006). AtrxloxP mice, when mated to mice expressing Cre recombinase
under the control of the Foxg1 promoter (Foxg1KiCre/+) (Hebert and McConnell, 2000),
produce male progeny (AtrxloxP/YFoxg1KiCre/+) with Atrx deficiency in the forebrain
(AtrxFoxg1Cre). To account for heterozygosity of Foxg1 due to knock-in of the Cre
recombinase gene, Cre+ males were used as controls. Trp53tm1Tyj/J mice were obtained
from The Jackson Laboratory, and the mutant allele was introduced into the AtrxloxP and
Foxg1KiCre/+ mice. Subsequent mating of this progeny yielded mice that are p53-null in all
tissues and Atrx/p53 double-null in the forebrain. For timed matings, midday of discovery
of the vaginal plug was considered to be E0.5. Yolk sac or tail DNA was used for
genotyping. Atrx, Cre, and p53 genotyping was performed by PCR as previously
described (Berube et al., 2005; Seah et al., 2008).
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2.2.2 Immunofluorescence and antibodies
Embryos were fixed overnight in 4% paraformaldehyde, washed 3 times in 1× PBS for 5
minutes each, and dehydrated in 30% sucrose PBS. Postnatal mice were perfused with
4% paraformaldehyde before PBS washes and dehydration. Brains were flash-frozen in
liquid nitrogen using Cryomatrix (Thermo Scientific) cryoprotectant and sectioned as
described previously (Berube et al., 2002). For immunofluorescence staining of
cryosections, antigen retrieval was performed on slides by warming 10 mM sodium
citrate pH 6 solution to approximately 95°C and microwaving slides in solution for 10
minutes on low. After cooling, slides were washed and incubated with primary antibody
overnight at 4°C. For detection of PCNA, primary antibody was incubated in 10 U/ml
DNase I (Sigma-Aldrich) as previously described (Seah et al., 2008). Slides were washed
in PBS and incubated with secondary antibody for 1 hour. Sections were counterstained
with DAPI (Sigma-Aldrich) and mounted with Vectashield (Vector Laboratories) or
SlowFade Gold (Invitrogen). For immunofluorescence staining of primary cortical
culture, cells were incubated in blocking solution (PBS with 0.3% Triton-X and 5%
normal goat serum) for 30 minutes and subsequently incubated with primary antibody
overnight at 4°C. Cells were washed in PBS and incubated with secondary antibody for 1
hour. Cells were counterstained with DAPI and mounted with Vectashield.
The following primary antibodies were used: anti-ATRX, rabbit polyclonal (1:200; Santa
Cruz Biotechnology Inc.); anti–cleaved caspase-3 (Asp175), rabbit monoclonal (1:400;
Cell Signaling Technology); anti-γH2AX (Ser139), rabbit (1:100; Cell Signaling
Technology); anti-γH2AX (Ser139), mouse monoclonal (1:400; Millipore); and antiPCNA, mouse monoclonal (1:100; Santa Cruz Biotechnology Inc.). The secondary
antibodies used were goat anti-rabbit–Alexa Fluor 594 (1:800 dilution; Molecular Probes)
and goat anti-mouse–Alexa Fluor 488 (1:800 dilution; Molecular Probes).

2.2.3 Microscopy
Experiments demonstrating colocalization of γH2AX and PCNA, γH2AX and major
satellite repeats, and γH2AX and telomeres were captured using a laser scanning confocal
microscope (FV1000, Olympus). z-Stacks were obtained at 0.25-µm z intervals generally
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spanning 10–20 µm. Overlapping signal was scored as a colocalization event. For
colocalization of γH2AX and PCNA, only cells in which PCNA staining was
characteristic of late S phase were counted. Each cell (n = 300) was scored for the
number of γH2AX foci that overlapped with PCNA foci divided by the total number of
γH2AX foci per cell, to obtain a measure of the cellular levels of DNA damage (γH2AX)
at late-replicating chromatin. All other images were captured using an inverted
microscope (DMI 6000b, Leica). Digital microscopy images were captured with a digital
camera (ORCA-ER, Hamamatsu). Openlab imaging software was used for manual and
automated image capture, and processing was performed using Volocity software
(PerkinElmer). For quantification of γH2AX foci per area, at least 6 serial cortical
cryosections were assessed for γH2AX foci within the indicated regions. To obtain a
relative measure of DNA damage, the ratio of γH2AX foci to area (mm2) was calculated.
The same method was used to quantify the ratio of cleaved capsase-3+ and γH2AX+ cells,
and for this experiment a Student’s t test was used to compare only the proportion of
caspase-3+γH2AX+ cells between control and Atrx-null mice.

2.2.4 Western blot analysis
Nuclear protein was extracted from E13.5 telencephalon using a standard extraction kit
(Thermo Scientific) and quantified using a Bradford assay. Protein (10 µg) was resolved
on 6% SDS-PAGE and transferred onto nitrocellulose membranes (Bio-Rad). The
membranes were probed with anti-ATM, rabbit monoclonal (1:500, Millipore); anti–
phospho-ATM (S1981), mouse monoclonal (1:250, Rockland); anti-ATR, goat
polyclonal (1:250, Santa Cruz Biotechnology Inc.); anti–phospho-ATR (S428), rabbit
polyclonal (1:250, Santa Cruz Biotechnology Inc.); and anti-INCENP, rabbit polyclonal
(1:10,000, Sigma-Aldrich) antibodies, followed by the appropriate horseradish
peroxidase–conjugated secondary antibodies (1:4,000, GE Healthcare). The membrane
was incubated in ECL before exposure to X-ray film.

2.2.5 Primary NPC cultures and manipulation
Cortical progenitor cultures were prepared as described previously (Gloster et al., 1999;
Slack et al., 1998) using cortices dissected from E13.5 embryos. Cells were seeded on
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polyornithine-coated (Sigma-Aldrich) plastic plates or glass coverslips. Primary cortical
cultures were treated with acute γ-irradiation (0, 1, 5, and 10 Gy) at 2 days after plating
using a Cobalt-60 irradiator (Theratron 60, Atomic Energy of Canada Limited) located in
the London Regional Cancer Center, London, Ontario, Canada. Cells were fixed in 4%
paraformaldehyde for 10 minutes, washed in PBS, and stored in PBS at 4°C at 0, 3, and 6
hours after treatment and processed for immunofluorescence. HU (Sigma-Aldrich),
MMC (Sigma-Aldrich), γ-irradiation, and TMS (synthesized in the Biomedicinal
Information Research Center, National Institute of Advanced Industrial Science and
Technology, Tokyo, Japan) sensitivity assays in cultured NPCs were conducted 48 hours
after plating cells. NPC cultures were treated with appropriate doses of HU, γ-irradiation,
or TMS for the indicated length of time, and cell viability was measured using the trypan
blue dye exclusion method. Cell counts were determined with a hemacytometer.

2.2.6 FISH
For DNA-FISH experiments, primary cortical cultures were permeabilized in CSK buffer
with 0.5% Triton-X (Sigma-Aldrich) prior to fixation. For TelFISH, a fluorophorelabeled DNA oligonucleotide probe, TAACCC7-Alexa 488-3′ (Integrated DNA
Technologies), was dissolved at 1 pmol/µl in hybridization buffer. Hybridization was
performed as previously described (Zhang et al., 2009). For major satellite FISH,
immunofluorescence

was

performed

first,

followed

by

fixation

with

4%

paraformaldehyde for 10 minutes and subsequent hybridization with a major satellite
repeat probe as previously described (Isaac et al., 2006).

2.2.7 MEF cultures and manipulations
E13.5 embryos were minced, digested in trypsin for 45 minutes at 37°C, and resuspended
in DMEM (Sigma-Aldrich) containing 10% FBS, 50 U/ml penicillin, 50 µg/ml
streptomycin, and 2 mM l-glutamine. Primary AtrxloxP/Y and wild-type MEFs were seeded
at 1.5 × 106 cells per 6-well plate and transduced with adenovirus expressing Cre
recombinase and a GFP reporter gene (Ad-CreGFP) or GFP only (Ad-GFP control)
approximately 12 hours later. Three days after transduction, MEFs were counted and
reseeded at 1.5 × 106 cells per 6-well plate (P5/P0). HU sensitivity in MEFs was
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determined by transducing 1.5 × 106 cells with adenovirus, culturing for 72 hours, and
treating cells with appropriate doses of HU for 24 hours, replacing medium, and
measuring viability via trypan blue dye exclusion 2 days later. Sensitivity to γ-irradiation
in MEFs was assessed by transducing 1.5 × 106 cells with adenovirus, waiting 72 hours,
and treating cells with appropriate doses of γ-irradiation and measuring viability via
trypan blue dye exclusion 48 hours later.

2.2.8 qRT-PCR
Total RNA was obtained from control and cKO liver with the RNeasy Mini Kit
(QIAGEN) and reverse transcribed into cDNA as described previously (Kernohan et al.,
2010). Control reactions without reverse transcriptase were prepared in parallel. cDNA
was amplified with gene-specific primers under the following conditions: 25–35 cycles of
95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute. For qRT-PCR, cDNA
was amplified with iQ SYBR Green Master Mix (Bio-Rad) by using the standard curve
Ct method of quantification. Experiments were performed on a Chromo-4 thermocycler
(MJ Research) and analyzed with Opticon Monitor 3 and GeneX (Bio-Rad) software.
Gene expression analysis was repeated in triplicate for each sample. Conditions for
amplification were as follows: 35 cycles of 95°C for 10 seconds, 55°C for 20 seconds,
72°C for 30 seconds, and a final melting curve generated in increments of 0.5°C per plate
read. Standard curves were generated for each primer pair with 3-fold serial dilutions of
control cDNA. Primer efficiency was calculated as: E = (10[–1/slope] – 1) * 100%,
where a desirable slope is –3.32 and r2 > 0.990. All data were corrected against Gapdh as
an internal control. Error bars represent SEM.

2.2.9 Alcian blue and alizarin red staining
Skinned and eviscerated mouse carcasses at P17 were fixed overnight in 95% ethanol and
transferred to acetone. Fixed skeletons were stained in alizarin red and alcian blue, as
described previously (Wang et al., 2007). Images were captured using an Olympus SP57OUZ digital camera. Skeletal elements from at least 4 different littermate pairs were
imaged using a Zeiss Stereo Zoom Microscope Stemi SV6, and measurements of
individual bones were undertaken with a ruler accurate to 0.1 mm.
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2.2.10

microCT

Mice were euthanized on P17, skinned, eviscerated, and stored in formalin. Whole
skeletons were scanned on a GE Locus Ultra scanner at 120 kV and 20 mA, with a 0.154mm3 voxel resolution with a total of 900 slices per scan. To assess bone density, hind
limbs were scanned on a GE Locus scanner at 80 kV and 0.450 mA with a 0.020-mm3
voxel resolution with 900 slices per scan. BMD, cortical thickness, and trabecular
numbers were calculated using MicroView 3D visualization and analysis software
(version 2.1.2, GE Healthcare Biosciences) (Ulici et al., 2008). BMD was determined
from proximal tibias using the bone analysis module within MicroView by defining the
region of interest (ROI) as the area between 0.3 mm and 0.6 mm proximal to the growth
plate to include the trabecular spongiosa. The ROI was a cylinder fitting within the
central region of the trabecular bone, excluding the cortical bone. Cortical bone–
mimicking epoxy (SB3, Gammex RMI) was used for calibration. Trabecular number was
determined using the stereology function within MicroView, using the same ROI as used
for BMD. Cortical thickness was determined at the tibial mid-diaphysis, defined as the
distance halfway between the two ends of the tibia. Thickness of the bone was measured
radially in each quadrant and averaged.

2.2.11

Picosirius red staining of bone sections

Fore- and hind limbs were dissected at P0, P7, P10, and/or P17 upon sacrifice and
processed for histological analyses by 0.1% picrosirius red (Sigma-Aldrich, catalog
P6744-16A) as described previously (Yan et al., 2012). Trabecular area (µm2) within an
area of interest (AOI) was measured by observers blinded to the experimental protocol
using Openlab 4.0.4 software (Improvision), with the AOI set from just below the
hypertrophic chondrocytes to 200 µm below the growth plate in the trabecular bone area
of the mineralized zone. The AOI measurements were adapted from (O'Connor et al.,
2009; Sawyer et al., 2003). Trabecular area was normalized to total AOI and expressed as
a percentage. All images were taken with a Retiga EX camera (Leeds Precision
Instruments Inc.) connected to a DMRA2 microscope (Leica).
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2.2.12

Ex vivo tibia cultures

Tibiae were isolated from P0 mutant and control mice using a Zeiss Stereo Zoom
Microscope Stemi SV6 and dissection tools, as described previously (Agoston et al.,
2007). Isolated tibiae were plated in 12-well culture dishes and cultured with 1 ml per
well of sterile organ culture α-MEM medium (Gibco, Life Technologies, catalog
1257063) containing ascorbic acid (0.005%, Sigma-Aldrich, A4034), β-glycerophosphate
(0.02%, Sigma-Aldrich, 819830), BSA (0.2%, Fisher Scientific, 9048486), 200 nM
glutamine (0.25 ml, Gibco, Life Technologies, 25030081), and penicillin streptomycin
(0.4 ml, Gibco, Life Technologies, 15140122) for 7 days at 37°C, 5% CO2. Organ culture
medium was refreshed on days 2, 4, and 6. Tibia samples were fixed in 70% ethanol
overnight at 4°C on day 7. Samples were processed, embedded in paraffin, and sectioned
at the Molecular Pathology Core Facility, Robarts Research Institute, London, Ontario,
Canada. Tibia lengths were measured on days 0 and 7 using the Zeiss Stereo Zoom
Microscope Stemi SV6 with a ruler accurate to 0.1 mm.

2.2.13

Measurements of IGF-1, GH, T4, and glucose

Plasma and liver samples were collected from P17 mice. Blood was collected from the
inferior vena cava. EDTA pH 7.0 was added to the blood sample and centrifuged at
21,000 g for 10 minutes at 4°C. Plasma supernatant was collected and kept frozen at –
80°C. Liver samples were collected and homogenized by 2 freeze-thaw cycles. Liver
homogenate supernatant was collected and assayed immediately. Plasma and liver IGF-1
content were measured using a mouse IGF-1 ELISA kit (R&D Systems, catalog MG100).
Plasma GH and T4 were assayed using Millipore (EZRMGH-45K) and Calbiotech
(T4044T) ELISA kits, respectively, according to the manufacturers’ instructions. Blood
glucose levels were measured immediately prior to sacrifice using the OneTouch
FastTake Meter according to the manufacturer’s instructions.

2.2.14

Cell cycle profiling

Primary NPCs were cultured for two days and pulse-labeled with cell proliferation
labeling reagent [10 mM bromodeoxyuridine (BrdU) and 1 mM fluorodeoxyuridine
(FdU) in H2O] at 5 µl/ml media (GE Healthcare Life Sciences), fixed, and stained with
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propidium iodide (PI). The proportion of cells in each phase of the cell cycle was
determined by flow cytometry on a Beckman-Coulter Epics XL-MCL instrument, as
described (Isaac et al., 2006).

2.2.15

Statistics

Statistical analysis was performed using GraphPad Prism software (4.02; GraphPad
Software Inc.), and all results are expressed as the mean ± SEM unless indicated
otherwise. Two independent data sets were compared with the Student’s t test (unpaired,
2-tailed). Statistical analyses of Kaplan-Meier survival curves were performed using the
log-rank test and the Gehan-Breslow-Wilcoxon test. P values of 0.05 or less were
considered to indicate significance.

2.2.16

Study approval

All procedures involving animals were conducted in accordance with the regulations of
the Animals for Research Act of the Province of Ontario and approved by the University
of Western Ontario Animal Care and Use Committee.

2.3 Results
2.3.1 Endogenous DNA damage accumulates in the Atrx-null NPCs
AtrxLoxP female mice (Berube et al., 2005) were mated to Foxg1Cre male mice (Hebert
and McConnell, 2000) to generate male progeny lacking ATRX in the embryonic
forebrain starting at E8.5 (referred to as cKO mice). Since ATRX depletion can induce
telomeric instability in embryonic stem cells (Wong et al., 2010), we stained brain
cryosections from E13.5 embryos with antibodies for the phosphorylated histone variant
H2AX (γH2AX), a canonical marker for double-stranded breaks (DSBs) (Rogakou et al.,
1998). This analysis showed a high level of DNA damage throughout the cortex,
hippocampal hem (future hippocampus), and basal ganglia in the cKO embryonic
forebrain that was significantly increased compared with that in controls (Figure 2-1a).
The level of DNA damage was appreciably lower in the neonatal brain; nevertheless,
comparatively higher levels of γH2AX were observed in the neonatal hippocampus, a
region that is still proliferative at this stage of development, as well as in the cortex of
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mutants (Figure 2-1b). Thus, the pattern of DNA damage was generally confined to
proliferative areas of the developing brain. To determine whether DNA damage incurred
during the embryonic period persists in postmitotic cells, we examined γH2AX and
ATRX staining patterns in P7 control and cKO forebrain cryosections. This analysis
demonstrated that ATRX is indeed not expressed at the protein level and revealed that no
damage was present or remained unrepaired in the absence of ATRX in the postnatal
juvenile brain (Supplemental Figure 2-8a,b). Given the post-replicative state of the brain
at this time, these data suggest that endogenous DNA damage due to loss of ATRX
occurs primarily in proliferating cells in the embryonic and perinatal period.

2.3.2 Accumulation of DNA damage in Atrx-null NPCs induces ATM
activation and is exacerbated by p53 deletion
Persistent DNA damage can result in the phosphorylation and upregulation of p53 by the
ATR/Chk1 or ATM/Chk2 pathways, leading to cell cycle arrest or apoptosis (Roos and
Kaina, 2006; Shiloh, 2001). We previously demonstrated that loss of ATRX results in a
p53-dependent apoptotic response in cultured primary mouse NPCs and in vivo in the
forebrain at E13.5 (Seah et al., 2008). To determine whether accumulated DNA damage
could be the underlying cause of apoptosis, we performed double immunofluorescence of
γH2AX and cleaved caspase-3, a marker of apoptotic cells. The majority of cells
undergoing apoptosis (i.e., cleaved caspase-3+ cells) in the cKO telencephalon also
stained positive for γH2AX, indicating that cell death is likely a downstream
consequence of DNA damage (Figure 2-1c). To substantiate this conclusion and examine
the role of p53, we generated ATRX/p53 compound mutant mice and assessed levels of
DNA DSBs in the brain. γH2AX signal in cKO;p53–/– embryos was increased compared
with that in cKO mice, suggesting that the accumulation of DNA damage in the ATRXdeficient forebrain directly triggers a p53-dependent apoptotic response and that the
absence of p53 prevents the removal of these cells by apoptosis (Figure 2-1a,b; right
panels and graphs). We next explored the possible involvement of ATR and ATM
signaling in the response to increased DNA damage. Western blot analysis of control and
cKO E13.5 telencephalon protein extracts demonstrated similar activation of ATR in
control and cKO samples. On the other hand, a clear increase in ATM activation was
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observed in the cKO embryonic telencephalon (Figure 2-1d). Taken together, these
findings show that loss of ATRX in the embryonic brain results in the accumulation of
DNA damage, which triggers activation of ATM and p53, culminating in neuroprogenitor
cell death.
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Figure 2-1 Increased DNA damage leads to ATM activation and p53-dependent
apoptosis in the Atrx-null embryonic brain
(A) Immunostaining for γH2AX in E13.5 control (Ctrl), cKO, and cKO;p53–/–
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compound mutant cortical cryosections. Scale bar: 100 µm. DAPI staining of E13.5
forebrain highlights in green the hippocampal hem (H), cortex (Ctx), and basal ganglia
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(BG) regions where γH2AX foci per unit area were scored. Control, cKO, and cKO;p53-/(n = 3); p53-/- (n = 2). (B) γH2AX staining in P0.5 control, cKO, and cKO;p53-/- cortical
cryosections. Scale bar: 200 µm. DAPI staining of P0.5 forebrain highlights in green the
hippocampus (H) and cortex (Ctx) regions where γH2AX foci per unit area were scored.
Control and cKO (n = 3); cKO;p53-/- and p53-/- (n = 2). (C) Co-immunofluorescence
detection of γH2AX (red) and activated caspase-3 (AC3; green) in E13.5 cortical
cryosections. Scale bar: 30 µm. AC3+ cells were scored for the presence (AC3 + γH2AX)
or absence (AC3 – γH2AX) of DNA damage (n = 3). (D) Western blot analysis of
nuclear protein extracts obtained from E13.5 telencephalon (n = 3). While levels of ATR
and phospho-ATR were not increased (left panels), phospho-ATM was noticeably
increased in the cKO extracts compared with controls (indicated by an asterisk). Original
magnification, ×100 (A and B); ×200 (C). *P < 0.05.
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2.3.3 DNA damage response at telomeres and telomeric DNA end
fusions
To determine the specific genomic sites of DNA damage response incurred by loss of
ATRX, we examined telomeres, since ATRX enrichment has been previously reported at
these genomic regions. However, since it has been proposed that ATRX associates with
telomeres only in pluripotent embryonic stem cells (Wong et al., 2010), we first assessed
whether ATRX protein is present at telomeres in NPCs. ATRX immunofluorescence
performed in conjunction with telomere FISH (Tel-FISH) in control NPCs demonstrated
colocalization of ATRX and a subset of telomeres (Figure 2-2a). Next, we used Tel-FISH
in combination with γH2AX immunostaining to determine whether the DNA repair
machinery is activated at telomeric chromatin in cultured cKO NPCs. Confocal imaging
showed that the number of telomere dysfunction–induced foci (TIFs) per nucleus was
increased in the cKO compared with control NPCs (Figure 2-2b). In fact, 66.1% of all
γH2AX foci were observed at telomeres in the cKO cells (Supplemental Figure 2-9b).
ATRX protein also binds pericentromeric heterochromatin, and we repeated this
experiment using major satellite-specific labeled DNA probes (MSat-FISH). Again, we
found that γH2AX+/mSAT+ foci were more frequent in cKO NPCs and that a large
proportion of DNA damage foci (69.51% ± 1.27%) corresponded to pericentromeric
heterochromatin in cKO NPCs (Supplemental Figure 2-9a,b). These numbers reflect the
acrocentric nature of mouse chromosomes, with some γH2AX foci overlapping with the
p arm telomere and the adjacent pericentromeric region. Our results demonstrate that
heterochromatic regions of the genome are prone to DNA damage in the absence of
ATRX. To further explore the function of ATRX in genome stability, we examined
metaphase spreads from control and cKO NPC cultures. ATRX immunostaining of
control metaphase spreads revealed strong enrichment of the protein at pericentromeric
heterochromatin and at some telomeres (Supplemental Figure 2-9c). Analysis of DAPIstained spreads revealed an increased frequency of chromosome fusions in cKO
metaphase spreads compared with controls, as evidenced by overlapping chromosomes
(Figure 2-2c). Centromere-to-centromere, centromere–to–q arm, and q arm–to–q arm
fusions were observed. The number of chromosomes per metaphase spread was not
affected in cKO NPCs (Supplemental Figure 2-9d). To further explore the nature of the
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fusions, we performed TelFISH on control and cKO metaphase spreads and detected an
increased incidence of telomeric DNA end fusions (Figure 2-2d). Other common defects
included telomere deletions or duplications, as well as merged or bridged telomeres
(Figure 2-2e). Overall, the frequency of all telomere defects was more than doubled in the
cKO NPCs compared with controls, and defects involved the p and q arm telomeres at an
equal frequency (Supplemental Figure 2-9e).

2.3.4 ATRX is not required for the repair of DSBs
Accumulation of DNA DSBs could occur if ATRX plays a direct role in DSB repair
mechanisms. Two non–mutually exclusive pathways carry out repair of DNA DSBs:
homologous recombination (HR) in proliferative cells; and non-homologous end joining
(NHEJ) in postmitotic cells (Shrivastav et al., 2008). Since γH2AX foci were primarily
concentrated in proliferative zones of the developing brain, we reasoned that ATRX may
be specifically involved in the repair of DSBs via HR. To address this possibility, we
cultured primary NPCs for 2 days in N2 neurobasal medium and exposed proliferative
NPCs to γ-irradiation to induce DSBs and activate the HR pathway. The DNA damage
response (i.e., γH2AX signal accumulation) was measured between 0 and 6 hours after
irradiation, when damage induced by low doses of γ-irradiation should be actively
resolved in control cells (Supplemental Figure 2-10). Both control and cKO NPC
colonies showed a dose-dependent increase in γH2AX signal 3 hours after irradiation,
which was subsequently resolved (i.e., decreased γH2AX staining) by 6 hours after
treatment (Supplemental Figure 2-10). Therefore, we concluded that ATRX is not
required for repair of exogenous irradiation–induced DSBs.
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Figure 2
Increased DNA damage and telomere defects in cKO NPCs. (A) Confocal immuno-FISH images of ATRX (red) and telomeres (Tel-FISH; green) in
NPCs demonstrates colocalization of the ATRX protein with a subset of telomeres. Scale bar: 5 μm. (B) Confocal immuno-FISH images of γH2AX
(red) and telomeres (Tel-FISH; green) shows increased incidence of TIF (γH2AX/Tel-FISH colocalization) in cKO compared with control NPCs
(300 nuclei counted, n = 3 control/cKO littermate-matched pairs). Scale bar: 10 μm. (C) DAPI staining of control and cKO metaphase spreads
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Figure 2-2 Increased DNA damage and telomere defects in cKO NPCs
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3). (D) Tel-FISH (green) demonstrates increased telomeric fusions in cKO metaphase
chromosomes compared with control (1,475 chromosomes counted; n = 3). (E) Telomere defects
(deletion, merge, bridge, and duplication) were scored in control and cKO metaphase
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chromosomes. Representative images of defects appear to the right of quantification. In all cases,
cKO chromosomes showed an increase in telomeric defects compared with control (1,475
chromosomes counted; n = 3). Original magnification, x1,000 (A and B); x630 (C–E). *P < 0.05.
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2.3.5 ATRX protects cells from replication stress
Since ATRX does not appear to function in the repair of DSBs, we reasoned that it might
help prevent DNA damage to preserve genomic integrity. Given that damage is restricted
to proliferating regions of the cKO embryonic brain, we tested the possibility that cKO
NPCs are particularly sensitive to DNA damage during S phase. We inactivated ATRX in
AtrxloxP mouse embryonic fibroblasts (MEFs) with adenoviral delivery of Cre
recombinase and treated them with hydroxyurea (HU), a drug that depletes
deoxyribonucleotide pools, inhibits DNA synthesis, and causes replication fork stalling
(Koc et al., 2004). MEFs were treated with increasing doses of HU for 24 hours, and cell
viability was assessed 2 days later. MEFs lacking ATRX (Ad-CreGFP) were more
sensitive to HU than untreated cells or cells treated with Ad-GFP. Ad-CreGFP treated
MEFs were not more sensitive to γ-irradiation than Ad-GFP–transduced or untransduced
cells (Figure 2-3a). We also treated control and cKO NPCs with HU and mitomycin C
(MMC), a DNA crosslinker that also causes replication fork stalling. Both HU and MMC
treatment caused decreased viability of cKO NPCs compared with control cells. As in
MEFs, exposure to various doses of γ-irradiation did not alter cKO NPC viability
compared with control NPCs, demonstrating a specific sensitivity to drugs that induce
replication fork stalling (Figure 2-3b).
Blocked replication forks could be a source of genomic instability in the cKO cells, since
they can lead to collapse of the replisome and the formation of DSBs (Cahill et al., 2006).
Replicating cortical NPCs lacking ATRX protein were assessed for DNA damage
(γH2AX) at replication foci using an anti-PCNA antibody and imaged using confocal
microscopy (Figure 2-3c). PCNA is a component of the replication machinery and
exhibits a distinct staining pattern during S phase. In late S phase, the replication foci are
observed in regions of the nucleus containing heterochromatin and as such colocalize
with DAPI-bright heterochromatin bundles (Takanari et al., 1994). Atrx-null NPCs
accumulated more DNA damage at these late replication foci compared with control
cells, confirming an increase in DSBs during the replication process (Figure 2-3c). We
also performed FACs analysis to determine whether S phase is extended in these cells.
We detected a small but significant decrease in the G1 population and a modest increase
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in S phase population in the cKO NPCs at 4 days in vitro. This suggests that difficulties
in replicating heterochromatin result in a slight delay in S phase progression of cKO cells
(Supplemental Figure 2-10b). We conclude from these findings that loss of ATRX results
in an accumulation of endogenous replicative damage in cultured NPCs, specifically at
late-replicating chromatin.

2.3.6 G4-DNA stabilization exacerbates DNA damage and decreases
viability of Atrx-null NPCs
A potential function of ATRX is to stabilize stalled forks or facilitate the replication of
complex secondary DNA structures, such as G4-DNA, which are found at telomeres,
among other genomic sites (Wang and Patel, 1992). To test whether ATRX facilitates the
replication of G4-DNA, we treated control and Atrx-null NPCs with TMS, a natural
product isolated from Streptomyces anulatus that binds with high affinity to G4 structures
(Shin-ya et al., 2001). Neuroprogenitors dissected from control and cKO embryonic
forebrain were cultured and treated with 20 µM TMS for 24 hours. γH2AX staining was
increased (Figure 2-3d), and cell viability was decreased (Figure 2-3e) in the TMStreated cKO NPCs compared with TMS-treated control cells. These findings suggest that
ATRX deficiency in NPCs synergizes with G4-DNA stabilization to cause DNA damage
and cell death.
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(A) AtrxloxP/Y MEFs were untransduced or transduced with adenovirus expressing Cre
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recombinase fused to GFP (Ad-CreGFP) or Ad-GFP and subsequently treated with HU
for 24 hours or γ-irradiated at the indicated doses. Cell viability was measured at 24 hours
after HU treatment (n = 4) and at 6 hours after irradiation (n = 3) via trypan blue dye
exclusion. (B) Control and cKO NPCs were treated with HU or MMC for 24 hours or γirradiated at the indicated doses. Cell viability was measured at 24 hours after HU and
MMC treatment and at 6 hours after irradiation (n = 3). (C) Co-immunofluorescence
detection of PCNA, a marker of replication foci, and γH2AX in control and cKO E13.5
cortical cryosections. Results were quantified by measuring the ratio of γH2AX staining
that localized to late-replicating PCNA foci to total γH2AX staining per cell, to account
for overall lower levels of γH2AX signal in control cells (300 nuclei counted, n = 3).
Scale bar: 12 µm. (D) Control and cKO NPCs were treated with 20 µm TMS for 2 hours,
and γH2AX signal was imaged 6 hours after treatment. Scale bar: 70 µm. (E) Control and
cKO NPCs were treated with TMS for 24 hours, and cell viability was measured 24 hours
after treatment (n = 3). Original magnification, ×600 (C); ×100 (D). *P < 0.05.
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2.3.7 Loss of ATRX shortens life span and induces progeroid-like
phenotypes
While a portion of mutant pups die in the neonatal period (Berube et al., 2005), many
cKO male mice survived, but rarely longer than 30 days after birth (P30), with an average
life span of 22.7 ± 1.7 days (Figure 2-4a). Moistening of food pellets to help with intake
of solids did not improve life span, nor did the removal of siblings from the litter to
reduce competition for breast milk (Figure 2-4a). Mutant mice at P20 had milk in the
stomach, suggesting that starvation was not the cause of death or growth retardation. P17
cKO mice had severely stunted growth compared with control littermates, as determined
by measurements of body weight and length, as well as length of various skeletal
elements (Figure 2-4b-e). Reduced body size was apparent at birth (Berube et al., 2005),
but a more dramatic effect was seen from P5 onward. The tibia, femur, humerus, radius,
ulna, and foot were significantly shorter in the cKO mice at P17 (Figure 2-4e). We
confirmed specific deletion of ATRX in the forebrain of cKO mice at several postnatal
time points, while ATRX remained expressed in other tissues, such as the liver, heart,
thymus, spleen, testes, and skeletal growth plate of cKO mice (Supplemental Figure 211a-d).
Microcomputed tomography (microCT) analyses showed that cKO mutant mice
displayed kyphosis, an abnormal curvature of the spinal column (Figure 2-5a), as well as
decreased bone mineral density (BMD), lower trabecular number, and reduced bone
cortical thickness (Figure 2-5a-d). Loss of trabecular bone was confirmed by picrosirius
red staining of tibia, femur, and humerus of control and cKO mice at P17 (Figure 2-5e).
To determine whether this effect stemmed from a developmental problem or was due to
tissue degeneration, we also assessed trabecular bone at earlier ages. We found no
difference in neonatal and P7 mice and detected an intermediate phenotype at P10,
suggesting that bone development occurs initially normally, with evidence of
deterioration from P10 onward (Supplemental Figure 2-11a).
Extensive loss of subcutaneous fat (<25% of controls) was a constant characteristic of the
mutant mice, while thickness of the dermis was not significantly affected (Figure 2-5f).
Again, by measuring subcutaneous fat at various time points, we observed that this
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phenotype was exacerbated at P20 compared with P10 (Supplemental Figure 2-12b,c).
Mutant mice rarely opened their eyes, and analysis of the lens showed the formation of
cataracts (Figure 2-5g). Accounting for decreased total body weight of the cKO mice, the
spleen and liver were consistently smaller and the heart was significantly enlarged at P20
(Figure 2-5h and Supplemental Figure 2-12d). These effects were also seen at P10 but
were not as dramatic, as evidenced by a lack of significant difference between control
and cKO organ size (Supplemental Figure 2-12d). The phenotypes described above
strongly resemble those reported in several mutant mice displaying accelerated aging, but
as the deterioration and death of the mice occurred rather quickly, it is difficult to
completely distinguish between developmental and progeria-like phenotypes.
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Figure 4
Reduced growth and life span in mice lacking ATRX in the forebrain. (A) Kaplan-Meier survival curve of Cre+ control (n = 12) and cKO mice
raised with (+sibs, n = 13) or without (–sibs, n = 11) siblings. Survival of cKO mice was significantly decreased compared with that of control mice
(P = 0.0001). The survival of cKO mice was not significantly different whether they were raised with or without siblings (P = 0.4974). (B) Representative
pictures of P17 control and cKO littermates, illustrating size difference of+the mice. (C) Body weight (g) and length (cm) measurements of control (Cre–,
n = 25; Cre+, n = 8) and cKO (n = 24) mice. No significant difference was observed between Cre– and Cre+ control mice. (D) Skeletal elements of control
and cKO mice were stained with alizarin red and alcian blue. (E) Length measurements of P17 control and cKO skeletal elements. (n = 5). *P < 0.05.

Figure 2-4 Reduced growth and life span in mice lacking ATRX in the forebrain
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Figure 5
Postnatal phenotypes in Atrx-cKO mice. (A) Whole skeletal isosurface images of P17 control and cKO mice were generated using microCT. Arrow
points to kyphosis. Scale bar: 10 mm. (B) Horizontal view of the cKO skull illustrates decreased bone mineralization. Scale bar: 5 mm. (C) Tibial
cross section shows decreased cortical thickness. Scale bar: 1 mm. (D) Decreased BMD (*P = 0.002), trabecular number (**P = 0.002), and cortical thickness (†P = 0.0001) in the cKO mice compared with controls. Data were obtained from hind legs using MicroView 3D software (n = 3). (E)
Picrosirius red staining of P17 control and cKO tibia (representative image), femur, and humerus reveals a drastic loss of trabecular bone area in
cKO compared with control mice (n = 4; *P < 0.05). Scale bar: 200 μm. (F) H&E staining of P20 skin cryosections shows loss of subcutaneous fat
in cKO compared with control mice (n = 3; *P = 0.0002). Dermal thickness was not significantly different (n = 3; *P = 0.3545). Scale bar: 300 mm.
sf, subcutaneous fat; d, dermis. (G) Dark field image of P20 control and cKO ocular lenses demonstrates appearance of cataracts (loss of lens
transparency) in cKO compared with control. (H) Dark field image of P20 control and cKO spleen demonstrates the disproportionally smaller size
of cKO spleen. Original magnification, ×50 (E and F). See also Supplemental Figure 5.

Figure 2-5 Postnatal phenotypes in Atrx-cKO mice

(A) Whole skeletal isosurface images of P17 control and cKO mice were generated using
microCT. Arrow points to kyphosis. Scale bar: 10 mm. (B) Horizontal view of the cKO
skull illustrates decreased bone mineralization. Scale bar: 5 mm. (C) Tibial cross section
shows decreased cortical thickness. Scale bar: 1 mm. (D) Decreased BMD (*P = 0.002),
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compared with control mice (n = 4; *P < 0.05). Scale bar: 200 µm. (F) H&E staining of
P20 skin cryosections shows loss of subcutaneous fat in cKO compared with control mice
(n = 3; *P = 0.0002). Dermal thickness was not significantly different (n = 3; *P =
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0.3545). Scale bar: 300 mm. sf, subcutaneous fat; d, dermis. (G) Dark field image of P20
control and cKO ocular lenses demonstrates appearance of cataracts (loss of lens
transparency) in cKO compared with control. (H) Dark field image of P20 control and
cKO spleen demonstrates the disproportionally smaller size of cKO spleen. Original
magnification, ×50 (E and F). See also Supplemental Figure 2-12.
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2.3.8 Endocrine defects in Atrx-cKO mice
To investigate the mechanism(s) by which ATRX disruption in the CNS could cause such
drastic postnatal phenotypes, we first wanted to confirm that the skeletal growth
phenotype was caused by non-cell-autonomous mechanisms. Indeed, tibiae from cKO
and control mice grew at similar rates in ex vivo organ cultures and had similar growth
plate length or organization (Figure 2-6a), substantiating that bone growth defects are
caused by systemic alterations.
Given the small size of the cKO mice, we suspected that the endocrine system might be
defective. The insulin-like growth factor 1/growth hormone (IGF-1/GH) somatotroph
axis has previously been linked to growth, aging, and life span (Niedernhofer et al.,
2006). We observed impairment in IGF-1 levels and signaling in the cKO mice. ELISA
assays at P17 showed a dramatic reduction of serum and liver IGF-1 levels compared
with those in control samples (Figure 2-6b). In addition, quantitative RT-PCR (qRTPCR) analyses revealed marked transcriptional alterations of key genes for somatotroph
signaling in the liver (Figure 2-6c).
Thyroid hormone is an important regulator of Igf1 expression and skeletal growth during
the prepubertal growth period, while GH effects are limited at that time (Xing et al.,
2012). We observed that circulating thyroxine (T4) levels were dramatically decreased in
the cKO mice, while the GH level was only slightly diminished, and the difference did
not reach statistical significance (Figure 2-6d). In addition, expression of several thyroid
hormone–responsive genes such as Thrsp, Nrp1, Ghr, Prlr was decreased in the liver
(Figure 2-6e). It is important to note that Atrx transcript and protein levels were normal in
livers of cKO mice (Supplemental Figure 2-11c and Figure 2-6e), indicating that these
transcriptional effects are not due to spurious deletion of Atrx in the liver itself. Given
that hypoglycemia is a feature of several mutant mice displaying segmental progeria
(Mostoslavsky et al., 2006; van de Ven et al., 2006; van der Pluijm et al., 2007) and that
thyroid hormone is essential for the maintenance of glucose homeostasis, we measured
blood glucose and found that it was significantly lower in P20 cKO compared with
control mice (Figure 2-6f).
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Figure 6
Figure
2-6 Endocrine defects and hypoglycemia in Atrx-cKO mice
Endocrine defects and hypoglycemia in Atrx-cKO mice. (A) Longitudinal growth of control and cKO tibia was measured after 7 days (d7) of ex
vivo culture. Results are expressed as the ratio of length at d7 to that at d0. No difference in growth was detected between control and cKO mice
(n = 3). Scale bar: 100 μm. (B) Serum and liver IGF-1 levels are decreased in cKO mice (n = 3). (C) Expression of several IGF-1 pathway genes is
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2.3.9 ATRX is deleted and causes DNA damage in the embryonic
anterior pituitary
The control of thyroid hormone levels and actions is complex and relies on the
production of thyroid-releasing hormone (TRH) by the hypothalamus, leading to thyroidsecreting hormone (TSH) production by the pituitary, which in turn induces T3 and T4
synthesis by the thyroid gland (Gaitonde et al., 2012). To determine the cause of low
circulating T4 levels, we first investigated Atrx and Tsh expression levels in the pituitary
of control and cKO mice. Atrx expression was decreased, as were the levels of Tsh
transcripts (Figure 2-7a). In addition, several genes responsible for T4 production (Tshr,
Tpo, Tg, and Slc5a5) were expressed at lower levels in the thyroid of cKO mice
compared with control mice (Figure 2-7a). These findings suggest that Atrx deletion in
the pituitary impairs TSH production, leading to decreased signaling to the thyroid and
low T4 production. ATRX immunofluorescence of P20 pituitary cryosections confirmed
ATRX expression in the pituitary of control mice and that it was absent in the anterior
and intermediate pituitary of cKO mice (Figure 2-7b,c). We also observed deletion of
ATRX in the embryonic anterior pituitary at E13.5 (Figure 2-7d), which corresponded to
a dramatic increase in γH2AX staining (Figure 2-7e). These results suggest that ATRX is
deleted early during embryonic development of the anterior pituitary of cKO mice, where
it causes increased DNA damage and results in abnormal function of the thyrotrophs in
postnatal cKO mice.
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pituitary. (D) Immunofluorescence detection of ATRX in E13.5 control and cKO sagittal
embryonic pituitary cryosections shows loss of ATRX expression. Scale bar: 100 µm. Pit,
pituitary. (E) Immunofluorescence detection of γH2AX in E13.5 sagittal embryonic
pituitary cryosections shows increased DNA damage in cKO embryonic pituitary
compared with control. Scale bar: 100 µm. Original magnification, ×25 (C, left panels);
×100 (C, right panels, and E); ×50 (D). *P < 0.05.
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2.4 Discussion
We have shown that ATRX deficiency causes replicative DNA damage at telomeres and
pericentromeric heterochromatin and increases the incidence of telomeric fusions.
Moreover, deletion of the Atrx gene in the embryonic nervous system and anterior
pituitary attenuates postnatal endocrine and metabolic signaling with concurrent growth
reduction and progressive progeria-like tissue deterioration. Control experiments
confirmed that loss of ATRX is restricted to the forebrain and anterior pituitary.
Furthermore, our previous studies have shown that specific and efficient inactivation of
the Atrx gene in cartilage does not cause any of the skeletal and growth phenotypes
described here (Solomon et al., 2009), providing further evidence that these defects are
non-cell-autonomous.
We do not yet fully comprehend the mechanisms responsible for the accumulation of
DNA damage observed in the Atrx-null embryonic forebrain and pituitary. We
established that loss of ATRX does not prevent DNA repair, since γH2AX foci did no
persist in the postnatal brain at P7 and Atrx-null cultured NPCs could resolve DSBs
induced by γ-irradiation. However, we provide evidence that the accumulation of damage
is partly due to replication stress linked to G4-DNA stability. Telomeres are
nucleoprotein complexes that protect chromosome ends from degradation and end
fusions. They consist of repetitive DNA high in guanine and cytosine nucleotide residues
and have the ability to form G4s when in the single-stranded form (Wang and Patel,
1992). The presence of these bulky DNA adducts can potentially impede DNA
replication. We demonstrate that Atrx-null NPCs are hypersensitive to the potent G4
ligand TMS, suggesting that in the absence of ATRX, cells have difficulty in resolving
G4-DNA. This conclusion is supported by the demonstration that the ATRX protein can
bind G4-DNA structures in vitro (Law et al., 2010). Since G4-DNA structures form at
telomeres, the γH2AX signals we observed at telomeres in Atrx-null NPCs may result
from a failure to properly resolve G4 structures, leading to telomere uncapping and
initiation of the DNA damage response. This in turn may explain the increase in telomere
fusions observed in Atrx-null NPCs due to repeating break-fusion-break cycles. In
contrast, heterochromatic regions flanking centromeres are AT rich, and a role for ATRX
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in facilitating replication of G4-DNA structures cannot explain the increased genetic
damage at these sites. ATRX potentially plays a more general role in heterochromatin
remodeling/replication during late S phase or may be required to facilitate replication of
other secondary structures. ATRX is associated with the DAXX histone chaperone and
was proposed to participate in the incorporation of histone variant H3.3 at highly
repetitive regions, including pericentric heterochromatin and telomeric chromatin (Drane
et al., 2010; Lewis et al., 2010). There is evidence that promyelocytic nuclear bodies
(PML-NBs) are involved in facilitating heterochromatin remodeling/replication in late
S/G2 phase (Luciani et al., 2006). ATR-X syndrome patient mutations have been shown
to alter ATRX targeting to PML-NBs, suggesting an important requirement for ATRX at
these subnuclear domains (Berube et al., 2008). ATRX and DAXX localize to PML-NBs
during S phase and may be required for remodeling of heterochromatin during
replication, a process likely to involve nucleosome remodeling and histone variant
deposition or ejection (Ishov et al., 2004).
An important and unexpected finding from our studies is that specific loss of ATRX early
during embryonic brain and pituitary development can influence postnatal health and life
span. Systemic loss or mutation of several factors required for telomeric stability,
response to replication stress, or nucleotide excision repair (NER) cause phenotypes that
resemble premature aging in mice (de Boer et al., 2002; Harada et al., 1999; Jaarsma et
al., 2011; Murga et al., 2009; Niedernhofer, 2008a, b; O'Driscoll, 2009; van de Ven et al.,
2006; Weeda et al., 1997) and segmental progeria syndromes in humans, including
XPF/ERCC1 in xeroderma pigmentosum, ERCC6/8 in Cockayne syndrome, and ATR in
Seckel syndrome (Neveling et al., 2007).
The link between excessive DNA damage and a suppressed IGF-1 response, although
reported in many progeria models, has not yet been satisfactorily explained. Here, we
provide evidence that DNA damage in the embryonic pituitary leads to decreased
expression of Tsh, with the predictable outcome of low thyroxine production by the
thyroid. Recent reports have demonstrated that thyroid hormone is more critical than
growth hormone in the regulation of IGF-1 levels at prepubertal stages of development
(Wang et al., 2010). Genetically modified mice that are deficient in thyroid hormone
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show greater than 50% reduction in Igf1 expression in liver and bone, and T4 treatment
can reverse this effect (Wang et al., 2010). In addition, thyroid hormone and its receptor
can bind intron 1 of the Igf1 gene and stimulate its expression (Wang et al., 2010). In line
with this model, circulating thyroid hormone levels were decreased in the Atrx-cKO
mice, and several thyroid hormone–responsive genes were decreased in the liver. We also
detected altered expression of several genes involved in IGF-1 signaling in the liver,
including reduced Igfals and increased Igfbp1 expression. Notably, Ercc1-/- mice exhibit a
quite rapid postnatal degeneration phenotype similar to that of the Atrx-cKO mice, and
Thrsp is the most downregulated gene in the Ercc1-null liver, exhibiting a 15-fold
decrease (Kamileri et al., 2012b). This suggests that diminished thyroid hormone action
might be implicated in both models, and it will be important in the future to examine
thyroxine levels in other models of progeria. Taken together, our findings suggest that
DNA damage incurred in the embryonic anterior pituitary leads to defective expression of
Tsh postnatally, causing hypothyroidism, decreased IGF-1 signaling, and hypoglycemia.
Decreased IGF-1 in the serum can negatively impact skeletal growth development,
trabecular content, and subsequent mineralization, as seen in our cKO mice (Mohan and
Kesavan, 2012). It should be noted that thyroid hormone can also act directly on target
tissues such as growth plate chondrocytes, independent of liver-derived IGF-1. Reduced
bone growth, and possibly other phenotypes observed in our mutant mice, might
therefore be caused by a combination of reduced circulating IGF-1 and reduced thyroid
hormone receptor activation in the target tissue (Wit and Camacho-Hubner, 2011;
Wojcicka et al., 2013).
Hyperactivity of the p53 tumour suppressor gene shortens life span and accelerates aging
in mice (Tyner et al., 2002). We had previously reported that p53 is activated in the
absence of ATRX in the embryonic brain and that loss of p53 rescued cell death in the
ATRX-deficient mouse brain (Seah et al., 2008). Thus, p53 is required for the removal of
cells with excessive DNA damage in the Atrx-null brain, which explains the enhanced
accumulation of DNA damage we observed upon simultaneous loss of ATRX and p53.
Decreased telomere stability and length are also key determinants of life span and have
been reported in cancer as well as several types of segmental progeria syndromes, such as
Werner syndrome, Cockayne syndrome, dyskeratosis congenita, and Hutchinson-Gilford
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progeria (Batenburg et al., 2012; Benson et al., 2010; Chang et al., 2004; Crabbe et al.,
2007; Damerla et al., 2012; Mitchell et al., 1999; Opresko et al., 2004; Shay and Wright,
1999). If telomeric damage is the key driver of life span, our findings would then suggest
that telomeric abnormalities confined to specific brain and/or pituitary cells are in
themselves sufficient to induce several aging-like phenotypes prematurely, a provocative
idea that would have to be confirmed or dismissed in future work.
Problems in replication have been shown to lead to chromosome segregation failures in
ensuing mitoses (Chan et al., 2009). Similarly, several G4-DNA ligands have been
demonstrated to cause telomeric fusions and telomere aggregate formation that eventually
lead to chromosomal instability, anaphase bridges, and mitotic catastrophe (Gauthier et
al., 2012; Hampel et al., 2013; Incles et al., 2004; Kim et al., 2003; Tahara et al., 2006). It
is conceivable that replicative damage is the underlying cause of mitotic defects that we
previously

reported

in

ATRX-deficient

human

cells,

such

as

chromosome

missegregation, anaphase bridges, and micronucleus formation (Ritchie et al., 2008).
Functions for ATRX in restricting replicative stress, telomere fusions, and mitotic defects
may also help explain the tumour-suppressive roles recently ascribed to the ATRX
protein. Mutations in the ATRX gene were identified in several types of cancers,
including pediatric brain tumours (Cheung et al., 2012; Heaphy et al., 2011a; Jiao et al.,
2011; Schwartzentruber et al., 2012; Yachida et al., 2012; Yuan et al., 2014). A common
denominator in the majority of Atrx-null tumours was the frequent appearance of large
telomeric foci, a hallmark of alternative lengthening of telomeres (ALT), providing
further evidence that ATRX function is intimately linked to telomere biology, possibly as
a suppressor of illegitimate recombination events. The hypersensitivity of Atrx-null
neuroprogenitors to TMS is an important finding in that regard, as it indicates that Atrxnull tumours may be susceptible to treatment with G4-DNA binding ligands.
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2.5 Supplementary Figures
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Figure 2-9 DNA damage occurs at major satellite repeats and telomeric repeats in
ATRX-null NPCs, however there is no difference in chromosome number and
telomere defects are not restricted to the p or q arms of cKO chromosomes
(A) Confocal immunoFISH images of γH2AX (red) and major satellite repeats (MajSatFISH; green) shows that DNA damage occurs at PCH more frequently in cKO compared
to control NPCs (γH2AX/MSat-FISH colocalization; 300 nuclei counted, n = 3). (B)
Since endogenous γH2AX levels are higher in cKO NPCs compared to control, the ratio
of γH2AX and Tel-FISH or MajSat-FISH colocalization vs. total γH2AX foci per cell
was calculated to obtain a relative measure of the percentage of γH2AX foci per nucleus
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that occurred at either telomeres or major satellite repeats (300 nuclei counted, n = 3).
Scale bar: 10 µm. (C) ImmunoFISH staining of ATRX (red) and telomeres (Tel-FISH;
green) in control and cKO NPCs demonstrates loss of ATRX staining in cKO NPCs.
Scale bar: 10 µm. (D) Chromosome number per metaphase spread did not differ between
control and cKO NPCs (control: 88 metaphases and cKO 108 metaphases, n = 3). (E)
Telomeric defects quantified in Figure 2-2e were scored for occurring on the P or Q arm
of chromosomes. Frequency of defects on either arm did not differ in control and cKO
NPCs (1475 chromosomes counted, n = 3). Original magnification, x1000 (A); x630 (C).
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induced by γ-irradiation were largely repaired by 6h post-treatment in both control and
cKO NPCs, as evidenced by the resolution of γH2AX foci. Scale bars: 100 µm. (B)
Actively proliferating control and cKO NPCs were pulse-labeled with BrdU at 2 and 4
D.I.V., processed for flow cytometry, and analyzed for propidium iodide (PI) and BrdU
staining. The proportion of cells in each phase of the cell cycle is indicated (n = 3).
Original magnification, x200 and x100 (A).
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Figure 2-11 ATRX is specifically deleted in the forebrain
(A) Western blot analysis of ATRX expression using nuclear protein extracts obtained
from P0.5, P10, and P20 control and cKO telencephalon (n = 3). (B) Quantitative RTPCR analysis of Atrx expression in P20 control and cKO organs. Forebrain and liver (n =
3); heart, thymus, spleen, and testes (n = 1). Real-time data is normalized to Gapdh
expression. (C) Western blot analysis of ATRX expression using nuclear protein extracts
obtained from P20 control and cKO liver. (D) Immunohistochemistry detection of ATRX
in P20 control and cKO tibia paraffin-embedded sections. Scale bar: 100 µm. Original
magnification, x50 (D).
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tibia, femur and humerus reveals trabecular bone area is not significantly different between control and
cKO until approximately P10 (n = 3 at both time points). (B) H&E staining of skin cryosections from P10
and P14 shows decreased subcutaneous fat thickness as early as P10 in cKO mice compared to
controls (P10, n = 3; P14 n = 1). Scale bar: 200μm. (C) Subcutaneous fat thickness in the Atrx cKO
at different developmental time points shows cKO mice develop subcutaneous fat (P10), which is
gradually reduced in thickness by P20 (n = 3 at P10 and P20; *P = 0.0409). (D) Organ weight (g) relative
to total body weight at P10 and P20. Representative dark field images of organs from control and cKO
mice at the indicated time points.
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(A) Quantification of Picrosirius Red staining in tibia, femur and humerus reveals
trabecular bone area is not significantly different between control and cKO until
approximately P10 (n = 3 at both time points). (B) H&E staining of skin cryosections
from P10 and P14 shows decreased subcutaneous fat thickness as early as P10 in cKO
mice compared to controls (P10, n = 3; P14, n = 1). Scale bar: 200 µm. (C) Subcutaneous
fat thickness in the Atrx cKO at different developmental time points shows cKO mice
develop subcutaneous fat (P10), which is gradually reduced in thickness by P20 (n = 3 at
P10 and P20; *P = 0.0409). (D) Organ weight (g) relative to total body weight at P10 and
P20. Representative dark field images of organs from control and cKO mice at the
indicated time points. Original magnification, x50 (B).
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Chapter 3

3 Dual effect of CTCF
differentiation and survival

loss

on

neuroprogenitor

This study was the first to investigate the functions of CTCF in brain development. Prior
to this study virtually nothing was known regarding CTCF activities in the brain, or in a
general physiological context. This chapter investigates the consequences of CTCF lossof-function to embryonic brain development by primarily focusing on neocortical
neurogenesis, which is particularly relevant to understanding the significance of human
CTCF mutations that cause intellectual disability.
This chapter was previously published as (Watson et al., 2014). The Journal of
Neuroscience does not require permissions for reproduction.

3.1 Introduction
CTCF is a multifunctional DNA binding protein that regulates higher-order chromatin
structure to influence transcriptional regulation, genomic imprinting, X chromosome
inactivation, and chromatin insulation (Holwerda and de Laat, 2013). It binds to a variety
of highly divergent target sequences throughout the genome using a combination of its 11
zinc finger motifs (Nakahashi et al., 2013). CTCF partners with a number of chromatinrelated proteins such as the cohesin complex (Parelho et al., 2008; Wendt and Peters,
2009), nucleophosmin, and CTCF itself (Yusufzai and Felsenfeld, 2004; Yusufzai et al.,
2004). These interactions may allow CTCF sites to contact one another and/or to be
tethered to subnuclear domains. CTCF-mediated chromatin interactions detected by
Chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) correlate with
approximately 10% of all CTCF binding sites (CBSs), however, indicating that CTCF
likely plays additional roles within the cell (Handoko et al., 2011).
De novo mutations in CTCF have been identified previously in patients with varying
degrees of intellectual disability and microcephaly (Gregor et al., 2013), highlighting the
importance of chromatin organization for the normal development and function of the
CNS. Whereas CTCF function has been studied extensively in cell culture systems, its
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function in an in vivo context remains to be completely resolved (Ohlsson et al., 2010a).
Ubiquitous deletion of CTCF in the mouse leads to lethality before embryonic day 3.5
(E3.5), suggesting that it is essential for early developmental processes (Fedoriw et al.,
2004; Heath et al., 2008; Moore et al., 2012). Conditional deletion of Ctcf in specific
tissues causes either reduced proliferation or apoptotic cell death, depending on the tissue
targeted for Cre recombination. For example, deletion of Ctcf in thymocytes resulted in
increased p21 and p27 expression and cell cycle arrest, whereas reduced CTCF in mouse
oocytes induced meiotic and mitotic defects and apoptotic cell death before the blastocyst
stage (Fedoriw et al., 2004; Heath et al., 2008; Wan et al., 2008). Deletion of Ctcf in the
developing limb bud resulted in massive apoptosis and near-complete loss of limb
structures, accompanied by increased p53 upregulated modulator of apoptosis (PUMA), a
known activator of caspase-mediated apoptosis (Nakano and Vousden, 2001; Soshnikova
et al., 2010; Yu et al., 2001). In human cancer cells, CTCF binds to the Puma gene, and
its depletion results in increased Puma transcript and rapid apoptosis, indicating that
Puma transcription can be directly influenced by the presence or absence of CTCF
(Gomes and Espinosa, 2010a, b).
Given the deleterious effects of CTCF mutations in the human CNS, we specifically
inactivated Ctcf in the developing mouse brain. CTCF loss of function using two different
Cre driver lines in mice triggered apoptosis in dividing neuroprogenitor cells (NPCs) of
the forebrain. Despite prevention of apoptosis by Puma deletion, rescued Ctcf/Puma
double-null apical and outer radial glia (oRG) progenitors exhibited decreased
proliferative capacity. Furthermore, loss of CTCF caused premature neurogenesis,
resulting in depletion of the progenitor pool and a microcephaly phenotype at birth. These
findings highlight the complexity of CTCF activities during neurogenesis.

3.2 Materials and Methods
3.2.1 Mouse husbandry and genotyping
Mice were exposed to 12 h light/dark cycles and fed tap water and regular chow ad
libitum. The CtcfloxP mice, in which loxP sites flank exons 3–12, have been described
previously (Heath et al., 2008). Mice conditionally deficient in CTCF were generated by
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crossing CtcfloxP/+ females (C57BL/6 background) with heterozygous Foxg1Cre knock-in
male mice (129/sv background) or with NestinCre heterozygous male mice (C57BL/6
background; (Berube et al., 2005; Hebert and McConnell, 2000). To account for
decreased Foxg1 expression due to knock-in of the Cre recombinase gene, Cre+ males
were used as controls (Ctcf+/+Foxg1-cre+/−) unless stated otherwise. Using the NestinCre
driver line, CtcfloxP/loxP mice were crossed with CtcfloxP/+;Nestin+ mice to generate Ctcflox/P/loxP
or CtcfloxP/+ (controls) and CtcfloxP/loxP;Nestin+ (CtcfNes-cre). Puma−/− (Bbc3tm1Ast) mice were
obtained from The Jackson Laboratory (stock #011067; (Villunger et al., 2003). DNA
from tail biopsies of newborn pups or yolk sac from embryos was genotyped by PCR.
Primer sequences are provided in Table 1.

3.2.2 Immunostaining and histology
For immunofluorescence staining, cryosections were incubated with the primary antibody
overnight at 4°C, washed in PBS/0.3% Triton-X 100, and incubated with the secondary
antibody for 1 h. Sections were counterstained with DAPI (Sigma-Aldrich) and mounted
in SlowFade Gold (Invitrogen). Primary antibodies used were as follows: rabbit antiCTCF (1:400; Cell Signaling Technology), rabbit anti-cleaved caspase 3 (AC3; Asp175;
1:400; Cell Signaling Technology), mouse anti-BrdU (1:50; BD Biosciences), rabbit antiPUMA (1:200; Cell Signaling Technology), rabbit anti-TBR2 (1:200; Abcam), goat antiSOX2 (1:400; Santa Cruz Biotechnology), goat anti-PAX6 (1:200; Santa Cruz
Biotechnology), rabbit anti-SOX2 (1:100; Millipore Bioscience Research Reagents),
rabbit anti-Ki67 (1:200; Abcam), rabbit anti-TBR1 (1:200; Abcam), mouse anti-SATB2
(1:200; Abcam), and rabbit anti-CTIP2 (1:200; Abcam). Secondary antibodies used were
as follows: goat-anti-rabbit Alexa 594 (1:800; Invitrogen), goat-anti-mouse Alexa 488
(1:800; Invitrogen), donkey-anti-sheep Alexa 594 (1:800; Invitrogen), and donkey-antimouse Alexa 488 (1:800; Invitrogen). Sections were subjected to antigen retrieval
(incubated in 0.1 mM sodium citrate, pH 6.0, heated to ∼95°C and microwaved on low
for 10 min) before overnight incubation (for BrdU, SOX2, PAX6, TBR2, STAB2, TBR1,
and CTIP2). Terminal deoxynucleotidyl nick end labeling (TUNEL) was performed
according to the manufacturer's instructions (Roche). For histological studies, slides were
stained with hematoxylin and eosin (H&E).

140

3.2.3 BrdU labeling
Pregnant mice were injected intraperitoneally with cell proliferation labeling reagent [10
mM bromodeoxyuridine (BrdU) and 1 mM fluorodeoxyuridine (FdU) in H2O] at 1
ml/100 g body weight, or 0.3 mg/g body weight (GE Healthcare Life Sciences). Animals
were killed after 1 h by CO2 asphyxiation, and the embryos were recovered in ice-cold
PBS, pH 7.4, and were fixed in 4% paraformaldehyde. Tissue was equilibrated in 30%
sucrose/PBS and frozen in OCT (Tissue Tek). For cell cycle exit analysis, pregnant
female mice (E13) were injected with cell proliferation labeling reagent at 1 ml/100 g
body weight (GE Healthcare Life Sciences), and embryos were collected and processed
for immunofluorescence analysis 24 h later. Before immunofluorescence analysis,
cryosections (8 µm) were treated with 2N HCl to denature the DNA, and neutralized with
0.1 M Na2B4O7, pH 8.5.

3.2.4 Primary NPC cultures and manipulation
Cortical progenitor cultures were prepared as described previously (Gloster et al., 1999;
Slack et al., 1998; Watson et al., 2013) using cortices dissected from E12.5 embryos.
Cells were seeded on polyornithine-coated (Sigma-Aldrich) plastic plates or glass
coverslips. Cells were fixed in 4% paraformaldehyde for 10 min, washed in PBS, and
processed for immunofluorescence. Cell viability was measured using the trypan blue dye
exclusion method. Cell counts were determined with a hemacytometer.

3.2.5 Western blot analysis
Nuclear protein was extracted from the E16.5 telencephalon using a standard extraction
kit (Thermo Scientific) and quantified using the Bradford assay. Protein (20 µg) was
resolved on a 6% SDS-polyacrylamide gel and transferred onto a nitrocellulose
membrane (Bio-Rad). The membrane was probed with rabbit anti-p53 (1:500; Santa Cruz
Biotechnology) and rabbit anti-inner centromere protein (INCENP) (1:10000; Sigma
Aldrich) antibodies followed by the appropriate horseradish peroxidase-conjugated
secondary antibodies (1:4000; GE Healthcare Life Sciences). The membrane was
incubated in ECL before exposure to x-ray film. Densitometry analysis was performed
using ImageJ software (version 1.47).
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3.2.6 Real-time PCR
Total RNA was isolated using the RNeasy Mini kit (Qiagen). First-strand cDNA was
synthesized from 1 µg of total RNA using the SuperScriptTM II Reverse Transcriptase
kit (Invitrogen) with deoxyribonucleotide triphosphates (dNTPs) (1 mM final
concentration; GE Healthcare), porcine RNAguard (GE Healthcare), and 0.3 µg random
primers (GE Healthcare). Amplification was performed using a Chromo-4 Continuous
Fluorescence Detector (Bio-Rad) in the presence of iQ SYBR Green supermix (Bio-Rad)
and recorded using Opticon Monitor 3 software (Bio-Rad). Results were normalized to βactin expression, and relative gene expression levels were calculated using GeneX
software (Bio-Rad). Samples were amplified as follows: 95°C for 10 s, annealed for 20 s,
72°C for 30 s. After amplification, a melting curve was generated, and samples were
resolved on a 1.5% agarose gel (75 V for 1 h) to verify amplicon purity. Primer oligomers
were designed using Primer3 software (http://bioinfo.ut.ee/primer3-0.4.0/primer3/) and
were obtained from Integrated DNA Technologies. Sequences are provided in Table 1.

3.2.7 Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) experiments were performed as described
previously (Kernohan et al., 2010). Briefly, mouse forebrain tissue was dissected and
processed to single-cell suspension. Cells were cross-linked in 1% formaldehyde, lysed in
SDS buffer and sonicated. Immunoprecipitation was performed with a rabbit anti-CTCF
antibody (Cell Signaling Technology) and a rabbit anti-p53 antibody (Santa Cruz
Biotechnology). Input samples represent 1/25 of total chromatin input. ChIP products
were amplified in duplicate with iQ SYBR Green Master Mix (Bio-Rad) on a Chromo-4
thermocycler under the following conditions: 95°C for 5 min, followed by 35 cycles of
95°C for 10 s, 55°C for 20 s, 72°C for 30 s, and a final melting curve generated from
55°C to 95°C in increments of 1°C per plate read. Fold change and percent input
formulas were adapted from (Mukhopadhyay et al., 2004) as follows: percent input = 100
* [2(ΔCtInput − ΔCtInput) − (ΔCtInput − ΔCtAb)]/25. Error bars represent the SEM.
Primer sequences are provided in Table 1.
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3.2.8 Microscopy
Images were captured with a digital camera (ORCA-ER; Hamamatsu) using an inverted
microscope (DMI 6000b; Leica). Openlab imaging software (PerkinElmer) was used for
manual image capture, and processing was performed using Volocity software
(PerkinElmer). For quantification of AC3+ cells per area, AC3+ cells were counted in a
defined area in at least six serial cortical cryosections, and the ratio of AC3+ cells to area
(square millimeters) was calculated. For BrdU, SOX2, TBR2, BrdU/Ki67, TBR1,
SATB2, and CTIP2 quantification, at least two serial cortical cryosections were assessed
for positive cells within the indicated regions per embryo. DAPI morphology was used to
bin cortex into the ventricular/subventricular zone (VZ/SVZ), intermediate zone (IZ), and
cortical plate (CP).

3.2.9 Statistical analyses
Statistical analysis was performed using GraphPad Prism software (GraphPad Software;
version 4.02), and all results are expressed as the mean ± SEM. Unless indicated
otherwise, p values were generated using Student's t test (unpaired, two-tailed) to
compare between two independent data sets. Genotype ratios (Figure 3-1a, 3-2a) were
compared using a χ2 test. To compare cell viability data (see Figure 3-4e), a one-way
ANOVA was used with Dunnett's multiple comparison post-test to compare the cell
viability of each genotype (CtcfNes-cre, CtcfNes-cre;Puma−/−, and Puma−/−) to control.

3.2.10

Study approval

All procedures involving animals were conducted in accordance with the regulations of
the Animals for Research Act of the Province of Ontario and approved by the University
of Western Ontario Animal Care and Use Committee.
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3.3 Results
3.3.1 CtcfFoxg1-cre mice exhibit widespread apoptosis and profound
loss of telencephalic and anterior retinal tissue
To study the function of CTCF in the embryonic brain, Ctcf floxed mice were
intercrossed with the previously characterized Foxg1Cre mice (Berube et al., 2005; Heath
et al., 2008; Hebert and McConnell, 2000). Foxg1 expression is first detected between E8
and E9 in the telencephalic neuroepithelium, the basal ganglia, the olfactory bulbs, and
the anterior retina (Dou et al., 1999). Foxg1-cre+ CtcfloxP/loxP progeny resulting from this
cross are Ctcf null in the anterior retina and forebrain, and will be referred to as CtcfFoxg1cre

throughout this text.

We failed to recover live CtcfFoxg1-cre pups at birth (Figure 3-1a). At E13.5, the size of
telencephalic and retinal structures was greatly diminished in mutant embryos (Figure 31b,c). At E11.5, the telencephalon of mutant embryos was already noticeably smaller
compared to littermate-matched controls (Figure 3-1d, hatched circle). CTCF
immunostaining demonstrated nuclear expression of the protein throughout the forebrain
in control tissue and its absence in mutant embryos (Figure 3-1e). To determine the
underlying cause of cell loss, we measured levels of proliferation and cell death in E11.5
CtcfFoxg1-cre and control embryos. Acute (1 h) BrdU labeling of control and CtcfFoxg1-cre
embryos revealed that the percentage of cells in S phase does not vary significantly
between mutant and control forebrain tissue (Figure 3-1f,g). To measure apoptosis, we
stained sections with an antibody against activated caspase-3 as a marker of cell death
(Figure 3-1h). Quantification of the results revealed a large increase in the proportion of
cells undergoing apoptotic cell death in CtcfFoxg1-cre embryos compared to littermatematched controls (Figure 3-1i). TUNEL also showed increased apoptosis in CtcfFoxg1-cre
embryos compared to control (Figure 3-1j). Since we already observed profound cell loss
by E11.5, we wanted to analyze whether a similar mechanism was occurring earlier in
this system. We observed increased AC3 immunostaining in CtcfFoxg1-cre forebrain
cryosections at E10.5, confirming that cell death occurs at this earlier time point (data not
shown). We conclude that deletion of Ctcf in the mouse forebrain at approximately E8.5
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causes extensive apoptosis resulting in profound loss of telencephalic and anterior retinal
tissue by E13.5.
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Figure 1. Foxg1Cre-mediated deletion of Ctcf results in a massive increase in apoptosis. A, Table of genotypes obtained during the embryonic and postnatal periods. Ratios at each time point were

analyzed using a !3-1
test. Het,
Ctcf
;Foxg1-cre . B, Dark-field imagesdeletion
of control and Ctcf of Ctcf
embryos at E13.5.
(Please notein
limbs a
were massive
taken for genotyping).
C, H&E staining of E13.5
Figure
Foxg1Cre-mediated
results
increase
in
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apoptosis

(A) Table of genotypes obtained during the embryonic and postnatal periods. Ratios at

each time point were analyzed using a χ2 test. Het, Ctcfflox/WT;Foxg1-cre+/-. (B) Dark-field
melting curve generated from 55°C to 95°C in increments of 1°C per plate

tween two independent data sets. Genotype ratios (Figs. 1A, 2A) were

hopadhyay et al., 2008) as follows: percent input ! 100 * [2("CtInput #
"CtInput) # ("CtInput # "CtAb)]/25. Error bars represent the SEM.
Primer sequences are provided in Table 1.
Microscopy. Images were captured with a digital camera (ORCA-ER;
Hamamatsu) using an inverted microscope (DMI 6000b; Leica). Openlab imaging software (PerkinElmer) was used for manual image capture,
and processing was performed using Volocity software (PerkinElmer).
For quantification of AC3 $ cells per area, AC3 $ cells were counted in a
defined area in at least six Foxg1-cre
serial cortical cryosections, and the ratio of
AC3 $ cells to area (square millimeters) was calculated. For BrdU, SOX2,
TBR2, BrdU/Ki67, TBR1, SATB2, and CTIP2 quantification, at least two
serial cortical cryosections were assessed for positive cells within the indicated regions per embryo. DAPI morphology was used to bin cortex
into the ventricular/subventricular zone (VZ/SVZ), intermediate zone
(IZ), and cortical plate (CP).
Statistical analyses. Statistical analysis was performed using GraphPad
Prism software (GraphPad Software; version 4.02), and all results are
expressed as the mean % SEM. Unless indicated otherwise, p values were
generated using Student’s t test (unpaired, two-tailed) to compare be-

one-way ANOVA was used with Dunnett’s multiple comparison posttest to compare the cell viability of each genotype (Ctcf Nes-cre, Ctcf Nes-cre;
Puma#/#, and Puma#/#) to control.
Study approval. All procedures involving animals were conducted in
accordance with the regulations of the Animals for Research Act of the
Province of Ontario and approved by the University of Western Ontario
Foxg1-cre
Animal
Care and Use Committee.
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of DAPI+ cells (n = 3). (H) Immunodetection of activated caspase-3 (red) in control and
CtcfFoxg1-cre cortical neuroepithelium at E11.5. (I) AC3+ cells were counted and expressed
as a percentage of the total number of DAPI+ cells (n = 3). (J) TUNEL (green) detection
in E11.5 control and CtcfFoxg1-cre cortical neuroepithelium. Error bars represent the SEM.
Original magnification: (C) x25; (E) x50; (F, H, J) x200. Scale bars: (C) top, 1 mm;
bottom, 400 µm; (E) 200 µm; (F, H) 50 µm; (J) 100 µm.
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3.3.2 NestinCre-driven inactivation of Ctcf decreases cell survival
To determine the outcome of Ctcf deletion at a later embryonic time point in the
telencephalon, we mated Ctcfflox/flox mice to the previously characterized NestinCre
transgenic mice (Berube et al., 2005; Heath et al., 2008). The resulting mutant is hereafter
referred to as CtcfNes-cre for simplicity. Cre is expressed after preplate formation in this
system, resulting in specific deletion of Ctcf in neural progenitor cells at approximately
E11 (Bérubé et al., 2005). We obtained the expected ratio of CtcfNes-cre mice at birth;
however, almost all mutant pups were already dead and blue in color (Figure 3-2a). One
live CtcfNes-cre pup was found struggling to breathe, appeared weak, and was killed. We
conclude that neonatal lethality of CtcfNes-cre mice is likely due to asphyxiation at birth.
We first established that the CTCF protein was lost in the basal ganglia and many cells of
the cortex at E12.5 (Figure 3-2b), and expression was undetectable in the E14 CtcfNes-cre
cortex, basal ganglia, and hippocampal hem (Figure 3-2c). To determine whether
NestinCre-mediated deletion of Ctcf also induces apoptosis, we analyzed CtcfNes-cre
forebrain cryosections at E12.5–E15.5 for evidence of AC3. At E12.5, we observed no
increase in apoptotic cells in the mutant telencephalon (Figure 3-2d). However, at E14,
we detected an increase in AC3+ cells in the CtcfNes-cre cortex, basal ganglia, and
hippocampal hem compared to controls (Figure 3-2d). The increase in caspase activation
was also observed at E15.5 in all three forebrain regions, with the highest level of AC3+
cells in the basal ganglia (Figure 3-2d,e). Increased apoptotic cell death was also
observed in vitro in primary cortical progenitor cultures established from E12.5 control
and Ctcf-null telencephalon. Levels of AC3 staining were low in both control and Ctcfnull NPCs after 2 d in vitro (DIV), and we only observed a detectable increase in staining
at 4 DIV (Figure 3-2f). Together, the data suggest that when using the NestinCre driver
line of mice, Ctcf deficiency does trigger the activation of caspase-mediated apoptosis in
NPCs, but the effect is delayed and less severe than that observed in the CtcfFoxg1-cre
embryos, suggesting that early neuroepithelial cells are more sensitive to CTCF loss than
the neuroprogenitors present slightly later in development.
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Figure 2. NestinCre-mediated deletion of CTCF results in activation of caspase-mediated
apoptosis. A, Table of genotype ratios obtained during the embryonic period. Ratios at each
time point were analyzed by a ! 2 test. B, Immunodetection of CTCF in E12.5 control and
Ctcf Nes-cre coronal forebrain sections. C, Immunodetection of CTCF in E14 control and Ctcf Nes-cre
coronal forebrain sections. D, Quantification of AC3 immunostaining in E12.5, E14, and E15.5
forebrain tissue (n " 3). AC3 ! cells were counted and expressed per unit area (square millimeter). E, Immunodetection of AC3 in E15.5 control and Ctcf Nes-cre basal ganglia. F, ImmunoNes-cre
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Figure 3-2 NestinCre-mediated deletion of CTCF results in activation of caspasemediated apoptosis
(A) Table of genotype ratios obtained during the embryonic period. Ratios at each time
point were analyzed by a χ2 test. (B) Immunodetection of CTCF in E12.5 control and
CtcfNes-cre coronal forebrain sections. Scale bar: 220 µm. (C) Immunodetection of CTCF
in E14 control and CtcfNes-cre coronal forebrain sections. Scale bar: 300 µm. (D)
Quantification of AC3 immunostaining in E12.5, E14, and E15.5 forebrain tissue (n = 3).
AC3+ cells were counted and expressed per unit area (square millimeter). (E)
Immunodetection of AC3 in E15.5 control and CtcfNes-cre basal ganglia. Scale bar: 100 µm
(F) Immunodetection of AC3 in control and CtcfNes-cre at 4 DIV. Scale bar: 25 µm. Het,
Ctcfflox/WT; Nestin-cre+; Ctx, cortex; BG, basal ganglia; H, hippocampal hem. Error bars
represent the SEM. Original magnification: (B, C) x50; (D) x100; (E) x200.
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3.3.3 Increased p53 and PUMA levels in the Ctcf-null telencephalon
Both the Foxg1Cre and NestinCre models of CTCF loss exhibit increased levels of
apoptosis, although the timing of onset differs between the two mutants. To investigate
the molecular mechanism responsible for neuronal cell death due to CTCF loss, we
assessed activation of the p53/PUMA pathway. Using Western blot analysis, we found
that neuronal cell death correlated with an increase in p53 protein levels in the CtcfNes-cre
forebrain compared to control, suggesting activation and stabilization of the protein (Fig.
3A). We next investigated the levels of PUMA, which has been demonstrated previously
to mediate NPC death downstream of p53 (Jeffers et al., 2003). Moreover, Puma is one
of the most upregulated genes in response to CTCF loss in the limb bud (Soshnikova et
al., 2010). CTCF binding sites in the Puma gene demarcate an intragenic chromatin
boundary that is abolished upon CTCF knockdown in human cells, resulting in increased
PUMA expression (Gomes and Espinosa, 2010b). To determine whether PUMA is
involved caspase-mediated cell death in the Ctcf mutant embryos, we examined PUMA
protein levels in the CtcfFoxg1-cre and CtcfNes-cre mice. In the E11.5 CtcfFoxg1-cre forebrain,
we observed an increase in PUMA immunostaining compared to littermate controls,
corresponding to the high levels of AC3 staining in these embryos (Figure 3-3b). In the
CtcfNes-cre embryos, PUMA was increased in the E15.5 basal ganglia, again correlating
with the highest levels of cell death (Figure 3-3c). In primary cultures, Ctcf-null NPCs
exhibited increased PUMA immunostaining at 4 DIV when compared to control NPCs
obtained from littermate embryos (Figure 3-3d). We also quantified Puma transcript
levels by quantitative reverse-transcriptase PCR and observed a significant increase in the
E16.5 CtcfNes-cre forebrain compared to controls (Figure 3-3e). These observations
demonstrate that increased PUMA transcript and proteins levels occur as a consequence
of CTCF loss in NPCs and correlate with p53 activation and the onset of caspasemediated cell death.
PUMA upregulation in the Ctcf-deficient embryonic brain could result from decreased
CTCF occupancy within the Puma gene body, or because of p53-dependent activation of
the gene. To investigate these possibilities further, we performed quantitative CTCF and
p53 ChIP using E16.5 telencephalon isolated from control and CtcfNes-cre embryos (Figure
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3-3f-h). ChIP analysis confirmed CTCF binding sites found downstream of Puma exon 1
(CBS1) and exon 3 (CBS2) at the Puma gene in control tissue, similar to the binding
profile of CTCF in human cancer cells (Figure 3-3g; (Gomes and Espinosa, 2010a). As
expected, CTCF binding was diminished in the CtcfNes-cre tissue (Figure 3-3g). ChIP for
p53 demonstrated specific enrichment of the protein at the Puma promoter in CtcfNes-cre
forebrain compared to control in E16.5 tissue (Figure 3-3h). Together, loss of CTCF in
NPCs causes increased Puma transcription and protein levels due to increased p53dependent transcriptional activation, likely combined with the loss of CTCF-dependent
repression.
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Figure 3. Loss of CTCF causes p53-dependent transcriptional activation of Puma. A, Western blot analysis of nuclear protein extracts obtained from E16.5 control and Ctcf Nes-cre telencephalon.
Densitometry analysis of blots revealed a 2.3-fold increase in Ctcf Nes-cre p53 levels compared to control. B, C, INCENP was used as a loading control. Immunodetection of PUMA in E11.5 control and
Ctcf Foxg1-cre cortical neuroepithelium (B), E15.5 control and Ctcf Nes-cre forebrain (C), and control and Ctcf-null NPCs (D) at 4 DIV. E, Quantitative real-time PCR analysis of Ctcf and Puma expression in
control and Ctcf Nes-cre E16.5 forebrain using primers spanning Puma exons 3– 4 (n " 3). !-actin was used as an internal control. F, Schematic representation of the mouse Puma gene. PCR products
used to detect sites of CTCF binding (CBS1 and CBS2) and p53 binding (p53BS) are shown. G, Quantitative chromatin immunoprecipitation of CTCF at the Puma gene in E16.5 control and Ctcf Nes-cre
telencephalon tissue (n " 3). Primer pairs 5 kb upstream and downstream of binding sites were used as negative controls. H, Quantitative chromatin immunoprecipitation of p53 at the Puma gene
in E16.5 control
and Ctcf Nes-cre telencephalon tissue shows increased p53 occupancy at the Puma promoter in the Ctcf Nes-cre telencephalon (n " 3). Primer pairs 1 kb upstream and downstream of
Nes-cre
the binding site were used as negative controls. Error bars represent SEM. Original magnification: A, C, 200#; B, 100#. Scale bars: B, C, 50 "m; D, 25 "m.
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3.3.4 Deletion of Puma in a Ctcf-null context rescues cell death, but
does not improve hypocellularity at birth
To investigate whether increased PUMA levels cause cell death in the Ctcf-deficient
embryonic brain, we introduced a mutant Puma allele (Bbc3tm1Ast) in the CtcfloxP and
NestinCre mice to generate mice that lack both Ctcf and Puma expression in the brain
(hereafter referred to as CtcfNes-cre;Puma−/−). Histological analysis of E16.5 CtcfNes-cre
cryosections showed thinning of the VZ/SVZ, hypocellularity of the intermediate zone,
and a dramatic reduction in the size of the hippocampal hem (Figure 3-4a). CtcfNescre

;Puma−/− embryos at E16.5 showed rescue in the VZ/SVZ thickness, as well as

hippocampal size (Figure 3-4a). We confirmed these observations by partitioning the
E16.5 cortex into the CP, IZ, and VZ/SVZ based on cytoarchitecture and quantifying the
number of DAPI+ cells per region (Figure 3-4b,c). We observed a restoration in the
number of IZ cells and partial restoration in the number of VZ/SVZ cells in the CtcfNes-cre;
Puma−/− compared to CtcfNes-cre cortex (Figure 3-4c). There was no significant difference
in the number of CP cells between genotypes at E16.5 (Figure 3-4c).
We performed AC3 immunostaining in E16.5 brain sections to investigate whether
apoptotic cell death was rescued in the double mutant brain. AC3+ cells were elevated in
the CtcfNes-cre cortex, basal ganglia, and hippocampal hem compared to control (Figure 34b,d). AC3+ cells were largely localized to the ventricular zone of the neocortex,
indicating that Ctcf-null proliferating cells are more susceptible to caspase-dependent cell
death than differentiated cells of the cortical plate. Deletion of Puma in the CtcfNes-cre
mouse was sufficient to abolish apoptotic cell death, indicating that PUMA mediates
increased caspase-dependent cell death in Ctcf-null neuroprogenitor cells (Figure 3-4b,d).
Together, these data indicate a specific decrease in intermediate zone cellularity in the
E16.5 CtcfNes-cre cortex that is fully restored upon inhibition of cell death. The number of
cells in the ventricular/subventricular zone is only partially restored, suggesting that loss
of cells cannot completely be explained by increased cell death.
To further confirm that cell viability is rescued by deletion of Puma in a Ctcf-null
context, we established primary cortical progenitor cultures from E12.5 control, CtcfNescre

, CtcfNes-cre;Puma−/−, and Puma−/− telencephalon and measured viability via trypan blue
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dye exclusion at 2–5 DIV. Each time point was analyzed by a one-way ANOVA
followed by Dunnett's multiple comparisons post-test to determine which genotypes had
a mean percentage of viability that was significantly different from control. No difference
in viability was observed at 2 and 3 DIV; however, at 4 and 5 DIV, CtcfNes-cre NPCs
exhibited a marked reduction in viability, correlating with increased levels of AC3
(Figure 3-4e). NPCs obtained from CtcfNes-cre;Puma−/− embryos did not show a significant
decrease in viability at any of the time points analyzed (Figure 3-4e).
Since we observed a rescue in caspase-mediated cell death in the embryonic CtcfNescre

;Puma−/− brain, we predicted that the brain size at birth would also be recovered and

that the mice would survive into the postnatal period, allowing for more extended
analyses. Surprisingly, we failed to recover live CtcfNes-cre;Puma−/− mice at birth.
Histological staining of postnatal day 0.5 (P0.5) CtcfNes-cre;Puma−/− sections demonstrated
severe hypocellularity and disorganization of the cortical plate and hippocampus, and an
overall similarity to the CtcfNes-cre neonatal brain (Figure 3-5a). Histological cell counts
confirmed that there are fewer cells in CtcfNes-cre and CtcfNes-cre;Puma−/− cortical plate
compared to controls; however, no significant difference in cell number was detected
between CtcfNes-cre and CtcfNes-cre;Puma−/− (Figure 3-5b). These findings indicate that
although deletion of Puma prevents Ctcf-null cells from undergoing apoptosis, other
factors come into play to prevent cortical size expansion in the double mutant brain.
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respectively); however, viability was significantly different between CtcfNes-cre and control
at 3 and 4 DIV (P = 0.01), but not between CtcfNes-cre;Puma-/- and control or Puma-/- and
control (P > 0.05). Error bars represent SEM. Original magnification: (A) x100; (C) x50.
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3.3.5 Ctcf-null apical and oRG progenitors rescued from death by
Puma deletion fail to proliferate
Given that cell death at E16.5 was rescued in the double mutant embryos but the brain
hypocellularity at birth was not, we speculated that the cells rescued from apoptosis
might become arrested in the cell cycle, resulting in decreased proliferation. To test this
hypothesis, we performed acute BrdU labeling at E16.5 and quantified the proportion of
cells in S phase by BrdU immunostaining. To compare the cortical distribution and
number of NPCs in S phase, the E16.5 cortex was partitioned into the CP, IZ, and
VZ/SVZ based on cytoarchitecture (Figure 3-6a). The number of BrdU+ cells was
significantly reduced in the CtcfNes-cre and CtcfNes-cre;Puma−/− intermediate zones and
ventricular zone/subventricular zones compared to control (Figure 3-6a,b). Despite
substantial rescue in cellularity of the CtcfNes-cre;Puma−/− cortex compared to CtcfNes-cre at
E16.5, the proliferative capacity of progenitors was not significantly different (Figure 36a,b). Our results demonstrate that Puma deletion rescues cell death in the Ctcf-null
brain, but that the rescued cells display reduced proliferative capacity.
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Figure 6. Ctcf-deficient cells that are rescued from apoptotic death display reduced proliferative capacity. Pregnant females were subjected to a 1 h BrdU pulse before being killed. A, BrdU (green)
immunostaining of E16.5 control, Ctcf Nes-cre, and Ctcf Nes-cre;Puma"/" cortical cryosections. The inset demonstrates fewer BrdU ! cells in the Ctcf Nes-cre and Ctcf Nes-cre;Puma"/" IZ compared with
control. Scale bar, 50 !m. Original magnification, 100#. B, The number of cells in S phase was quantified by counting BrdU ! cells in 200-!m-wide cortical images (n $ 3). Error bars represent
SEM.

Figure 3-6 Ctcf deficient cells that are rescued from apoptotic death display reduced
proliferative capacity

Pregnant females were subjected to a 1 h BrdU pulse before being killed. (A) BrdU
(green) immunostaining of E16.5 control, CtcfNes-cre, and CtcfNes-cre;Puma-/- cortical
cryosections. The inset demonstrates fewer BrdU+ cells in the CtcfNes-cre and CtcfNescre

;Puma-/- IZ compared with control. Scale bar, 50 µm. Original magnification, x100. (B)

The number of cells in S phase was quantified by counting BrdU+ cells in 200-µm-wide
cortical images (n = 3). Error bars represent SEM. Original magnification, (A) x100.
Figure 7. Ctcf-deficiency results in PUMA-dependent apoptosis of basal progenitor cells. Pregnant females were subjected to a 1 h BrdU pulse before being killed. A, TBR2 (red) and BrdU (green)
coimmunostaining of E16.5 cortical cryosections. Arrowheads indicate TBR2 !/BrdU ! cells in the IZ and VZ/SVZ. Scale bar, 50 !m. Original magnification, 100#. B, TBR2 ! cells were quantified
in 200-!m-wide cortical images (n $ 3). C, TBR2 !/BrdU ! cells were quantified in 200-!m-wide cortical images (n $ 3). Error bars represent SEM.

fected (Fig. 9 A, B), suggesting that differentiation of apical progenitors into basal progenitors is increased. Next, we measured
the proportion of cells exiting the cell cycle by labeling embryos
with BrdU for 24 h and analyzing Ki67 ! and BrdU ! cells in E14
control and Ctcf Nes-cre cortex. Cell cycle exit (BrdU !Ki67 " cells/
total BrdU ! cells) was significantly higher in Ctcf Nes-cre cortex
compared to controls (Fig. 9C,D).
The cortical plate is established by projection neurons that
organize themselves in an “inside-out” manner, such that earlyborn neurons populate deeper cortical layers (layer VI, then layer
V), and late-born neurons migrate past the early-born neurons to
populate the more superficial layers of the cortex (layer IV, then
layer II/III; Greig et al., 2013). Increased cell cycle exit and differentiation at E13–E14 is predicted to result in an increased number of layer VI corticothalamic projection neurons (TBR1 !),
layer V subcerebral projection neurons (CTIP2 !), and callosal
projection neurons (SATB2 !). We found that the relative generation of these neuronal subtypes was increased in the Ctcf Nes-cre
cortex compared to control (Fig. 8E--G), confirming premature
differentiation of Ctcf-null apical progenitors, which is predicted
to result in a reduced number of this progenitor pool by late
neurogenesis.

Discussion
This study provides evidence that CTCF is required at very early
stages of telencephalon development for the maintenance and

survival of neuroprogenitor cells. We found that ablation of
CTCF leads to Puma-dependent apoptosis of NPCs using two
different conditional deletion strategies. Increased apoptosis correlated with p53-dependent Puma transcription, suggesting that
CTCF loss results in p53 stabilization and transcriptional activation of its downstream targets. CTCF loss might also result in a
more open chromatin environment at the Puma gene, facilitating
p53-dependent activation of transcription and elongation of
RNA polymerase II (Gomes and Espinosa, 2010a,b). Ctcf inactivation in postmitotic cortical and hippocampal neurons does not
induce apoptosis (Hirayama et al., 2012), pointing to a specific
survival role for CTCF in proliferating cells. However, CTCF loss
of function may not induce apoptosis in all types of proliferating
cells in vivo, as Ctcf deletion in thymocytes was shown previously
to induce cell cycle arrest without induction of apoptosis (Heath
et al., 2008). It is possible that the outcome of CTCF deficiency
leads to either p53-dependent cell cycle arrest or apoptosis, depending on varying cell-specific or temporal cues. This could be
similar to the outcomes described upon Nbs1 (Nijmegen breakage
syndrome 1/Nibrin) deletion in the CNS, which leads to p53dependent apoptosis in the cerebellum, but causes p53dependent cell cycle arrest in the neocortex (Li et al., 2012).
In the present report, we demonstrate that deletion of Puma
effectively rescues apoptotic cell death observed at E16.5 in the
Ctcf Nes-cre brain (Fig. 4). Despite this apparent recovery at E16.5,
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Three NPC subtypes exist in the embryonic cortex: apical radial glia (apical progenitors),
basal progenitors, and outer radial glia. Apical progenitors can be identified by their
expression of SOX2 and PAX6 transcription factors (Bani-Yaghoub et al., 2006; Gotz et
al., 1998; Shitamukai and Matsuzaki, 2012; Tarabykin et al., 2001). They undergo
interkinetic nuclear migration and divide at the ventricular surface to either self-renew or
differentiate into basal progenitors, outer radial glia, or cortical neurons (Shitamukai et
al., 2011; Shitamukai and Matsuzaki, 2012). Basal progenitors reside in the
subventricular zone and uniquely express the T-box transcription factor TBR2 (Englund
et al., 2005). They are reported to have the potential to self-renew; however, the majority
of their divisions are neurogenic (Haubensak et al., 2004; Miyata et al., 2004; Noctor et
al., 2004). Outer radial glia are similar to radial glia in that they have a basal process and
express SOX2 and PAX6; however, oRG cells are located outside of the VZ in the outer
SVZ. They are able to divide asymmetrically, producing one oRG and one neuroncommitted cell with each division (Reillo et al., 2011; Shitamukai et al., 2011;
Shitamukai and Matsuzaki, 2012; Wang et al., 2011a; Wang et al., 2011b). We performed
acute BrdU-labeling for 1 h and coimmunostained E16.5 cortical sections with antibodies
against BrdU and TBR2 or SOX2 to examine the behavior of different progenitor
subtypes after loss of CTCF (Figure 3-7,8).
The total number of TBR2+ basal progenitor cells was reduced in the CtcfNes-cre cortex
compared to control (Figure 3-7a,b). The number of basal progenitors was restored to
control levels in the CtcfNes-cre;Puma−/− cortex, and most rescued cells were still able to
enter S phase (Figure 3-7a,c). Despite the correct overall number of TBR2+ cells in the
CtcfNes-cre;Puma−/− cortex, the localization of basal progenitors appeared to be shifted
apically compared to control (Figure 3-7a,b). This is perhaps due to an inability of the
rescued basal progenitors to correctly delaminate from the ventricular surface.

Figure 6. Ctcf-deficient cells that are rescued from apoptotic death display reduced proliferative capacity. Pregnant females were subjected to a 1 h BrdU pulse before being killed. A, BrdU (green)
immunostaining of E16.5 control, Ctcf Nes-cre, and Ctcf Nes-cre;Puma"/" cortical cryosections. The inset demonstrates fewer BrdU ! cells in the Ctcf Nes-cre and Ctcf Nes-cre;Puma"/" IZ compared with
control. Scale bar, 50 !m. Original magnification, 100#. B, The number of cells in S phase was quantified by counting BrdU ! cells in 200-!m-wide cortical images (n $ 3). Error bars represent
SEM.
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Figure 7.

Ctcf-deficiency results in PUMA-dependent apoptosis of basal progenitor cells. Pregnant females were subjected to a 1 h BrdU pulse before being killed. A, TBR2 (red) and BrdU (green)
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Quantification of SOX2+ cells indicated a dramatic reduction in the number of apical
progenitors and oRGs in the CtcfNes-cre cortex (Figure 3-8a,b). The number of SOX2+
apical progenitors was only partially rescued in the CtcfNes-cre;Puma−/− cortex, indicating
that CTCF may control the size of the apical progenitor pool independently of apoptosis
(Figure 3-8a,b). Conversely, oRG (SOX2+ cells in the intermediate zone) numbers were
restored to control levels in the CtcfNes-cre;Puma−/− cortex, indicating that these cells are
lost via Puma-mediated apoptotic cell death upon deletion of Ctcf (Figure 3-8a,b). The
proliferative capacity of apical progenitors (SOX2+/BrdU+ cells in the VZ/SVZ) was
severely diminished in the CtcfNes-cre cortex compared to control, and was not restored in
the CtcfNes-cre;Puma−/− cortex (Figure 3-8a,c). Similarly, BrdU incorporation in the
rescued CtcfNes-cre;Puma−/− oRG cells was extremely low, indicating that they are likely
arrested in the cell cycle and fail to correctly enter S phase (Figure 3-8a,c). To confirm
that these cells are oRG progenitors, we performed SOX2 and PAX6 coimmunostaining
and indeed observed a decreased number of SOX2+PAX6+ cells in the intermediate zone
of CtcfNes-cre embryos compared to control and CtcfNes-cre;Puma−/− at E16.5 (Figure 3-8d).
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Apical and outer radial glia progenitors that are rescued from apoptotic death fail to
proliferate. Pregnant females were subjected to a 1 h BrdU pulse before being killed. A,
SOX2 (red) and BrdU (green) coimmunostaining of E16.5 cortical cryosections. The
inset demonstrates fewer SOX2+ cells in the CtcfNes-cre IZ than control or CtcfNes-cre;Puma/-

. Scale bar: 50 µm. (B) SOX2+ cells were quantified in 200-µm-wide cortical images (n

= 3). (C) SOX2+/BrdU+ cells were quantified in 200-µm-wide cortical images (n = 3). (D)
Immunodetection of SOX2 (green) and PAX6 (red) in the E16.5 cortical IZ demonstrates
restoration of oRG progenitors in CtcfNes-cre;Puma-/- cortex compared to CtcfNes-cre. Scale
bar: 10 µm. Arrowheads indicate SOX2+/PAX6+ oRG cells. Error bars represent SEM.
Original magnification: (A, D) x100.
Figure 9. Ctcf-deficiency causes premature neurogenesis. A, Immunodetection of SOX2 (red) and TBR2 (green) in E14 control and Ctcf Nes-cre cortex. B, SOX2 ", TBR2 ", and SOX2 "/TBR2 " cells
were quantified in 150-!m-wide cortical images and expressed as a percentage of total DAPI " cells (n # 3). C, Pregnant female mice were subjected to a 24 h BrdU pulse before being killed. Ki67
(red) and BrdU (green) immunostaining was used to determine the percentage of cells exiting the cell cycle in control and Ctcf Nes-cre E14 cortex. Arrowheads indicate BrdU "Ki67 ! cells that have
exited the cell cycle. D, Cell cycle exit indices were calculated by measuring the ratio of BrdU "Ki67 ! cells to total BrdU " cells in control and Ctcf Nes-cre cortex at E14 (n # 3). E, Immunodetection
of TBR1 (red) and SATB2 (green) in E14 control and Ctcf Nes-cre cortex. F, Immunodetection of CTIP2 (green) in E14 control and Ctcf Nes-cre cortex. G, SATB2 ", TBR1 ", and CTIP2 " cells were quantified
and expressed as a percentage of DAPI " cells (n # 3). Error bars represent SEM. Original magnification: A, C, E, F, 100$. Scale bars: A, C, 50 !m; E, F, 50 !m.

the double mutant brain at birth appeared hypocellular and was
nearly undistinguishable histologically from the Ctcf Nes-cre brain
(Fig. 5). We showed that Ctcf Nes-cre;Puma!/! apical and oRG
progenitors that cannot activate the apoptotic pathway fail to
incorporate BrdU, which might be explained by a p53-mediated
cell cycle arrest. Further investigations into the mechanism underlying increased p53 levels in the Ctcf-null brain will be important to fully elucidate the role of CTCF in progenitor cell survival.

Given that oRG cells are implicated in neocortical expansion in
humans, their reduced ability to proliferate in the double mutant
cortex might partly explain the failure to recover cortical size at
birth, and may be relevant to microcephaly caused by CTCF mutations in humans (Hansen et al., 2010; Lui et al., 2011; Reillo et
al., 2011).
A key observation is that deletion of Puma did not completely
restore the number of apical cells in the Ctcf Nes-cre;Puma!/! cor-
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3.3.6 Ctcf loss causes premature differentiation of apical progenitors
Incomplete restoration of the apical progenitor population in the CtcfNes-cre;Puma−/−
cortex suggests that loss of CTCF leads to an apoptosis-independent reduction of these
cells (Figure 3-8a,b). To identify the cause of reduced apical cell numbers, we analyzed
the progenitor pool composition, cell cycle exit indices, and postmitotic projection
neuron subtypes in control and CtcfNes-cre cortex at E14.
Apical progenitors begin to produce projection neurons at approximately E11.5 (Figure
1-5a). At the same time, they generate neuron-committed basal progenitors and oRG
progenitors (Figure 1-5a). Since the majority of basal progenitor divisions are terminal
and result in the production of two neurons, this would result in increased generation of
neurons at the expense of the progenitor pool (Haubensak et al., 2004; Miyata et al.,
2004; Noctor et al., 2004; Watson et al., 2014). The relative abundance of TBR2+ basal
progenitors was significantly increased in the E14 CtcfNes-cre cortex compared to control,
whereas the number of SOX2+ apical progenitors was not affected (Figure 3-9a,b),
suggesting that differentiation of apical progenitors into basal progenitors is increased.
Next, we measured the proportion of cells exiting the cell cycle by labeling embryos with
BrdU for 24 h and analyzing Ki67+ and BrdU+ cells in E14 control and CtcfNes-cre cortex.
Cell cycle exit (BrdU+Ki67− cells/total BrdU+ cells) was significantly higher in CtcfNes-cre
cortex compared to controls (Figure 3-9c,d).
The cortical plate is established by projection neurons that organize themselves in an
“inside-out” manner, such that early-born neurons populate deeper cortical layers (layer
VI, then layer V), and late-born neurons migrate past the early-born neurons to populate
the more superficial layers of the cortex (layer IV, then layer II/III; (Greig et al., 2013)
(Figure 1-5a). Increased cell cycle exit and differentiation at E13–E14 is predicted to
result in an increased number of layer VI corticothalamic projection neurons (TBR1+),
layer V subcerebral projection neurons (CTIP2+), and callosal projection neurons
(SATB2+) (Figure 1-5a). We found that the relative generation of these neuronal subtypes
was increased in the CtcfNes-cre cortex compared to control (Figure 3-9e-g), confirming
premature differentiation of Ctcf-null apical progenitors, which is predicted to result in a
reduced number of this progenitor pool by late neurogenesis.

Figure 8. Ctcf-deficiency results in PUMA-dependent apoptosis of apical and outer radial glia progenitors. Apical and outer radial glia progenitors that are rescued from apoptotic death fail to
proliferate. Pregnant females were subjected to a 1 h BrdU pulse before being killed. A, SOX2 (red) and BrdU (green) coimmunostaining of E16.5 cortical cryosections. The inset demonstrates fewer
SOX2 " cells in the Ctcf Nes-cre IZ than control or Ctcf Nes-cre;Puma!/!. B, SOX2 " cells were quantified in 200-!m-wide cortical images (n # 3). C, SOX2 "/BrdU " cells were quantified in
200-!m-wide cortical images (n # 3). D, Immunodetection of SOX2 (green) and PAX6 (red) in the E16.5 cortical IZ demonstrates restoration of oRG progenitors in Ctcf Nes-cre;Puma!/! cortex
compared to Ctcf Nes-cre. Arrowheads indicate SOX2 "/PAX6 " oRG cells. Error bars represent SEM. Original magnification: A, D, 100$. Scale bars: A, 50 !m; D, 10 !m.

166

Figure 9. Ctcf-deficiency causes premature neurogenesis. A, Immunodetection of SOX2 (red) and TBR2 (green) in E14 control and Ctcf Nes-cre cortex. B, SOX2 ", TBR2 ", and SOX2 "/TBR2 " cells
were quantified in 150-!m-wide cortical images and expressed as a percentage of total DAPI " cells (n # 3). C, Pregnant female mice were subjected to a 24 h BrdU pulse before being killed. Ki67
(red) and BrdU (green) immunostaining was used to determine the percentage of cells exiting the cell cycle in control and Ctcf Nes-cre E14 cortex. Arrowheads indicate BrdU "Ki67 ! cells that have
exited the cell cycle. D, Cell cycle exit indices were calculated by measuring the ratio of BrdU "Ki67 ! cells to total BrdU " cells in control and Ctcf Nes-cre cortex at E14 (n # 3). E, Immunodetection
of TBR1 (red) and SATB2 (green) in E14 control and Ctcf Nes-cre cortex. F, Immunodetection of CTIP2 (green) in E14 control and Ctcf Nes-cre cortex. G, SATB2 ", TBR1 ", and CTIP2 " cells wereNes-cre
quantified
and expressed as a percentage of DAPI " cells (n # 3). Error bars represent SEM. Original magnification: A, C, E, F, 100$. Scale bars: A, C, 50 !m; E, F, 50 !m.

Figure 3-9 Ctcf-deficiency causes premature neurogenesis
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3.4 Discussion
This study provides evidence that CTCF is required at very early stages of telencephalon
development for the maintenance and survival of neuroprogenitor cells. We found that
ablation of CTCF leads to Puma-dependent apoptosis of NPCs using two different
conditional deletion strategies. Increased apoptosis correlated with p53-dependent Puma
transcription, suggesting that CTCF loss results in p53 stabilization and transcriptional
activation of its downstream targets. CTCF loss might also result in a more open
chromatin environment at the Puma gene, facilitating p53-dependent activation of
transcription and elongation of RNA polymerase II (Gomes and Espinosa, 2010a, b). Ctcf
inactivation in postmitotic cortical and hippocampal neurons does not induce apoptosis
(Hirayama et al., 2012), pointing to a specific survival role for CTCF in proliferating
cells. However, CTCF loss of function may not induce apoptosis in all types of
proliferating cells in vivo, as Ctcf deletion in thymocytes was shown previously to induce
cell cycle arrest without induction of apoptosis (Heath et al., 2008). It is possible that the
outcome of CTCF deficiency leads to either p53-dependent cell cycle arrest or apoptosis,
depending on varying cell-specific or temporal cues. This could be similar to the
outcomes described upon Nbs1 (Nijmegen breakage syndrome 1/Nibrin) deletion in the
CNS, which leads to p53-dependent apoptosis in the cerebellum, but causes p53dependent cell cycle arrest in the neocortex (Li et al., 2012).
In the present report, we demonstrate that deletion of Puma effectively rescues apoptotic
cell death observed at E16.5 in the CtcfNes-cre brain (Figure 3-4). Despite this apparent
recovery at E16.5, the double mutant brain at birth appeared hypocellular and was nearly
undistinguishable histologically from the CtcfNes-cre brain (Figure 3-5). We showed that
CtcfNes-cre;Puma−/− apical and oRG progenitors that cannot activate the apoptotic pathway
fail to incorporate BrdU, which might be explained by a p53-mediated cell cycle arrest.
Further investigations into the mechanism underlying increased p53 levels in the Ctcfnull brain will be important to fully elucidate the role of CTCF in progenitor cell survival.
Given that oRG cells are implicated in neocortical expansion in humans, their reduced
ability to proliferate in the double mutant cortex might partly explain the failure to
recover cortical size at birth, and may be relevant to microcephaly caused by CTCF
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mutations in humans (Hansen et al., 2011; Lui et al., 2011; Reillo et al., 2011).
A key observation is that deletion of Puma did not completely restore the number of
apical cells in the CtcfNes-cre;Puma−/− cortex, suggesting that while a proportion of this
progenitor population undergoes Puma-dependent death in the absence of CTCF, apical
cells exhibit an independent defect. We found that Ctcf-null apical progenitors
differentiate prematurely, causing an initial increase in the production of basal
progenitors and early-born postmitotic neurons (Figure 3-9). However, the increased
number of basal progenitors is later counteracted by a reduction of the progenitor pool
from which they are derived, and exacerbated by increased levels of apoptosis. Given that
CTCF colocalizes with the cohesin complex and is required for cohesin localization to
specific genomic sites to influence gene expression (Parelho et al., 2008; Wendt and
Peters, 2009), it is conceivable that premature neurogenesis in the CtcfNes-cre cortex results
from dysregulation of CTCF target genes.
The number of basal progenitor cells marked by TBR2 expression was completely
restored in the double mutant brain, indicating that PUMA activation causes basal
progenitor cell death in the absence of CTCF. Simultaneous labeling of brain sections
with TBR2 and BrdU showed that rescued basal progenitors are still able to proliferate,
unlike rescued apical and oRG cells. Despite the overall equivalent number of TBR2+
cells in the control and double mutant cortex, several rescued basal progenitors did not
move basally out of the ventricular zone, perhaps due to a defect in apical radial glia or
an inability to correctly delaminate from the apical surface of the Ctcf-deficient cortex.
In summary, we demonstrated that CTCF is required in the early developing mouse brain
for neuroprogenitor cell survival and that its deletion induces p53- and PUMA-dependent
apoptosis. Independent from its role in promoting cell survival, CTCF is required for the
correct balance of proliferative versus differentiative divisions and maintenance of the
apical progenitor pool. Together, these functions of CTCF contribute to the normal
development of the mammalian neocortex.
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Chapter 4

4 CTCF is required to prevent replication-associated DNA
damage in neuroprogenitor cells
This chapter aims to address the molecular mechanism underlying p53/PUMA-dependent
apoptosis downstream of CTCF loss by investigating a role for CTCF in genomic
stability. Several reports have identified that CTCF is and important regulator of
replication (Bergstrom et al., 2007; Cleary et al., 2010), and one study reported telomere
dysfunction as a consequence of CTCF depletion (Deng et al., 2012a), however the exact
roles for CTCF in replication are not well understood. This is the first study to identify
that CTCF loss causes replication-associated damage.

4.1 Introduction
The CCCTC-binding factor (CTCF) is implicated in higher-order genome organization
through its ability to mediate intra- and inter-chromosomal contacts, bringing disparate
regions of the genome into close proximity (Kurukuti et al., 2006; Ling et al., 2006;
Splinter et al., 2006). This function of CTCF has been primarily studied in the context of
transcriptional regulation, whereby CTCF controls enhancer-promoter interactions.
Additionally, transcription-independent roles for CTCF have been described in the
literature: CTCF regulates stability of trinucleotide repeats implicated in expansion
disorders such as spinocerebellar ataxia type 7 (SCA7) and myotonic dystrophy type I
(DM1) (Filippova et al., 2001; Libby et al., 2008; Sopher et al., 2011). At the DM1 locus,
CTCF binding upstream of the repeat is required to slow DNA polymerase before
replication of the repetitive tract, and mutations in the CTCF binding site results in repeat
expansion likely due to strand slippage (Cleary et al., 2010). Intriguingly, DM1 is
asymmetrically replicated (Rajcan-Separovic 1998) and CTCF regulates asymmetric
replication of the H19/Igf2 imprinted domain (Bergstrom et al., 2007). CTCF is thus an
important factor for DNA replication, although its actions may be limited to certain loci
as direct roles for the protein have only been described at asymmetrically replicated
regions. CTCF has also been implicated in replication origin firing. Overexpression of the
oncogenic replication licensing factor Cdc6 causes CTCF dissociation from the
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promoters of the tumour-suppressor genes CDH1 and INK4/ARF, resulting in reduced
expression and activation of adjacent replication origins (Sideridou et al., 2011). It was
suggested that because replication origins are defined by structural chromatin context
rather than DNA sequence CTCF might facilitate higher-order organization of replication
origins (Antequera, 2004; Cvetic and Walter, 2005).
Whereas the CTCF partner cohesin is implicated in organizing replication factories and
controlling S phase progression, CTCF depletion had little effect on cell cycle dynamics
or the overall size of replicon units identified by the DNA halo assay (Guillou et al.,
2010). A more global role for CTCF in DNA replication have not yet been thoroughly
investigated, but is of interest given the importance of CTCF for replication timing,
progression, and origin firing at individual loci. Furthermore, the finding that TADs
regulate replication timing suggests that CTCF may participate in this process if indeed
CTCF is involved in orchestrating TAD organization (Dixon et al., 2012; Pope et al.,
2014).
Human mutations in CTCF cause intellectual disability associated with microcephaly and
autistic features (Gregor et al., 2013) and single nucleotide polymorphisms (SNPs) at the
CTCF locus are associated with schizophrenia (Juraeva et al., 2014). Deletion at 16q22.1,
the genomic locus of CTCF, is one of the most frequent genetic events in breast cancer
and is well documented in several other cancers (Filippova et al., 1998; Rakha et al.,
2006). Together, this suggests that CTCF is important for correct brain development and
to suppress tumourigenesis, however the molecular underpinnings of these associations
are unknown.
CTCF is an essential factor for cellular survival (Fedoriw et al., 2004; Heath et al., 2008;
Moore et al., 2012; Soshnikova et al., 2010; Wan et al., 2008; Watson et al., 2014).
However, the mechanisms responsible have not been characterized. We previously
reported that CTCF loss in neuroprogenitor cells (NPCs) causes p53 stabilization, Puma
upregulation, and PUMA-dependent apoptosis (Watson et al., 2014). Here, we provide
novel evidence that CTCF is required to safeguard the genome through S phase during
early stages of fate restriction in NPCs. CTCF localizes to damage sites under conditions
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of replicative stress but it does not appear to be required for repair of exogenous
replication-associated damage, perhaps reflecting a more general role for CTCF in
organizing chromatin domains during replication to facilitate replication and prevent
genetic instability.

4.2 Materials and Methods
4.2.1 Mouse husbandry and genotyping
Mice were exposed to 12 h light/dark cycles and fed tap water and regular chow ad
libitum. The CtcfloxP mice, in which loxP sites flank exons 3–12, have been described
previously (Heath et al., 2008). Mice conditionally deficient in CTCF were generated by
crossing CtcfloxP/+ females (C57BL/6 background) with heterozygous Foxg1Cre knock-in
male mice (129/sv background) or with NestinCre heterozygous male mice (C57BL/6
background; (Berube et al., 2005; Hebert and McConnell, 2000). To account for
decreased Foxg1 expression due to knock-in of the Cre recombinase gene, Cre+ males
were used as controls (Ctcf+/+Foxg1-cre+/−) unless stated otherwise. Using the NestinCre
driver line, CtcfloxP/loxP mice were crossed with CtcfloxP/+;Nestin+ mice to generate
Ctcflox/P/loxP or CtcfloxP/+ (controls) and CtcfloxP/loxP;Nestin+ (CtcfNes-cre). DNA from tail
biopsies of newborn pups or yolk sac from embryos was genotyped by PCR, as
previously described (Watson et al., 2014).

4.2.2 Immunostaining, histology, and antibodies
For immunofluorescence staining, cryosections and cells were incubated with the primary
antibody overnight at 4°C, washed in PBS/0.3% Triton-X 100, and incubated with the
secondary antibody for 1 h at room temperature. Sections and cells were counterstained
with DAPI (Sigma-Aldrich) and mounted in SlowFade Gold (Invitrogen). Primary
antibodies used were as follows: rabbit anti-CTCF (1:400; Cell Signaling Technology),
rabbit anti-γH2AX (S139; 1:100; Cell Signaling Technology), mouse anti-PCNA (1:400;
Santa Cruz Biotechnology), mouse anti-BrdU (1:50; BD Biosciences), rabbit antiphosphorylated H3 (S10; 1:500; Millipore). Secondary antibodies used were as follows:
goat-anti-rabbit Alexa 594 (1:800; Invitrogen), goat-anti-mouse Alexa 488 (1:800;
Invitrogen), donkey-anti-sheep Alexa 594 (1:800; Invitrogen), and donkey-anti-mouse
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Alexa 488 (1:800; Invitrogen). Sections were subjected to antigen retrieval (incubated in
0.1 mM sodium citrate, pH 6.0, heated to ∼95°C and microwaved on low for 10 min)
before overnight incubation. For histological studies, slides were stained with
hematoxylin and eosin (H&E).

4.2.3 BrdU labeling
Pregnant mice were injected intraperitoneally with cell proliferation labeling reagent [10
mM bromodeoxyuridine (BrdU) and 1 mM fluorodeoxyuridine (FdU) in H2O] at 1
ml/100 g body weight, or 0.3 mg/g body weight (GE Healthcare Life Sciences). Animals
were killed after 1 h by CO2 asphyxiation, and the embryos were recovered in ice-cold
PBS, pH 7.4, and were fixed in 4% paraformaldehyde. Tissue was equilibrated in 30%
sucrose/PBS and frozen in OCT (Tissue Tek). Before immunofluorescence analysis,
cryosections (8 µm) were treated with 2N HCl to denature the DNA, and neutralized with
0.1 M Na2B4O7, pH 8.5.

4.2.4 Primary NPC cultures and manipulation
Cortical progenitor cultures were prepared as described previously (Gloster et al., 1999;
Slack et al., 1998; Watson et al., 2013) using cortices dissected from E12.5 embryos.
Cells were seeded on polyornithine-coated (Sigma-Aldrich) plastic plates or glass
coverslips. Cells were fixed in 4% paraformaldehyde for 10 min, washed in PBS, and
processed for immunofluorescence. Cell viability was measured using the trypan blue dye
exclusion method. Cell counts were determined with a hemacytometer.

4.2.5 Western blot analysis
Total protein was extracted using RIPA buffer and quantified using the Bradford assay.
Protein (20 µg) was resolved on a 6% SDS-polyacrylamide gel and transferred onto a
nitrocellulose membrane (Bio-Rad). The membrane was probed with primary antibodies
followed by the appropriate horseradish peroxidase-conjugated secondary antibodies
(1:4000; GE Healthcare Life Sciences). The membrane was incubated in ECL before
exposure to x-ray film or on a ChemiDoc™ MP (BioRad). Densitometry analysis was
performed using ImageJ software (version 1.47).
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4.2.6 Cell cycle profiling
Primary NPCs were cultured for two days and pulse-labeled with cell proliferation
labeling reagent [10 mM bromodeoxyuridine (BrdU) and 1 mM fluorodeoxyuridine
(FdU) in H2O] at 5 µl/ml media (GE Healthcare Life Sciences), fixed, and stained with
propidium iodide (PI). The proportion of cells in each phase of the cell cycle was
determined by flow cytometry on a Beckman-Coulter Epics XL-MCL instrument, as
described (Isaac et al., 2006).

4.2.7 Immunoprecipitation
Total cell lysates were obtained from primary NPC cultures using RIPA buffer for 30
minutes on ice. 500 µg of protein was treated with 100U/ml DNase I (Sigma) for 10
minutes at 37oC, followed by incubation with 1 µg mouse anti-PCNA antibody (Santa
Cruz Biotechnologies) while rotating overnight at 4oC. Normal mouse IgG (Santa Cruz
Biotechnologies) was used as a negative control. Samples were then incubated with
Dynabeads protein G (Invitrogen) for 2 h at 4oC. Immunoprecipitates were washed three
times with 1XPBS/0.2% Tween-20, eluted at 70oC for 10 minutes, and resolved on 812% SDS-PAGE. Western blot analysis was carried out with a rabbit anti-CTCF
(1:1,000; Cell Signaling) and mouse anti-PCNA (1:500; Santa Cruz Biotechnology).

4.2.8 Molecular Combing
Primary NPCs were cultured for two days and pulse-labeled with CldU (25µM) for 30
minutes, followed by washing with 1XPBS, and IdU (125µM) labeling for 30 minutes.
Cells were trypsinized and embedded into 1% low melt-grade agarose plugs (Bioshop) to
a final concentration of 1x106 cells/ml. The plugs were incubated in 1% N-lauryl sarcosyl
plus 1mg/ml proteinase K until processing. Plugs were washed, immunostained, and
analyzed as previously described (Yang et al., 2012).

4.2.9 Microscopy
Experiments demonstrating co-localization of γH2AX/PCNA and repair capacity
(resolution of γH2AX foci) were captured using a laser scanning confocal microscope
(FV1000, Olympus). Stacks were obtained at 0.25-µm z intervals generally spanning 10–
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20 µm. Overlapping signal was scored as a co-localization event. All other images were
captured with a digital camera (ORCA-ER; Hamamatsu) using an inverted microscope
(DMI 6000b; Leica). Openlab imaging software (PerkinElmer) was used for manual
image capture, and processing was performed using Volocity software (PerkinElmer).
For quantification of γH2AX foci, nuclei were counted in a defined area in at least three
serial cortical cryosections, and the ratio of γH2AX foci to area (mm2) was calculated.
For BrdU and phosphorylated histone H3 (S10) quantification, at least three serial
cortical cryosections were quantified in 150µm-wide sections per embryo.

4.2.10

Statistical analyses

Statistical analysis was performed using GraphPad Prism software (GraphPad Software;
version 4.02), and all results are expressed as the mean ± SEM. Unless indicated
otherwise, p values were generated using Student's t test (unpaired, two-tailed) to
compare between two independent data sets. For replication fork rates, P values were
determined using the Mann-Whitney U-test for non-parametric data.

4.3 Results
4.3.1 CTCF loss causes an accumulation of endogenous DNA
damage in the embryonic brain
CTCF loss in NPCs causes p53 stabilization, Puma upregulation, and PUMA-dependent
apoptosis (Watson et al., 2014). Given the essential nature of CTCF for cellular survival
(Fedoriw et al., 2004; Heath et al., 2008; Moore et al., 2012; Soshnikova et al., 2010;
Watson et al., 2014) and aspects of chromatin organization (Zuin et al., 2014) we
hypothesized that CTCF may be required to prevent genomic instability, an upstream
activator of p53/PUMA signaling in NPCs (Jeffers et al., 2003).
To test this hypothesis we evaluated the nuclear pattern and levels of γH2AX, a marker of
DNA double-strand breaks (DSBs) in two models of embryonic brain-specific Ctcf
deficiency (CtcfFoxg1-cre and CtcfNes-cre). We observed that in both models of Ctcf
deficiency, the number of γH2AX foci were elevated, indicating that endogenous DNA
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damage accumulation is likely responsible for activation of p53/PUMA-dependent
apoptosis in the two systems (Figure 4-1a-c). We observed that γH2AX-positive cells
were primarily localized to the ventricular/subventricular zone (VZ/SVZ) of the
embryonic CtcfNes-cre neocortex. Moreover, γH2AX foci were rarely present in postmitotic cells of the cortical plate (CP) (Figure 4-1b). These observations indicate that
damage accumulation in Ctcf-deficient embryonic brain might be linked to proliferative
state.
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4.3.2 CTCF protects against endogenous replicative stress
To investigate the relationship between damage accumulation and proliferative state, we
assessed PCNA and γH2AX immunoreactivity in control and CtcfNes-cre neocortex (Figure
4-2). PCNA is a cell cycle marker present at high levels during late-G1, appears in a
punctate pattern during mid/late-S phase, and is downregulated in G2 before the onset of
mitosis (Arai et al., 2011; Bravo and Macdonald-Bravo, 1987). PCNA-positive Ctcfdeficient NPCs exhibited an elevated number of γH2AX foci per cell than PCNAnegative cells, and both populations had a significant increase in the number of γH2AX
foci over control cells (Figure 4-2b). Additionally, the percentage of γH2AX foci that colocalize with punctate PCNA foci was increased in CtcfNes-cre cells (Figure 4-2c), despite
the finding that CTCF loss was associated with a reduced number of PCNA foci (Figure
4-2b,d). Since punctate PCNA staining is typically observed in mid/late-S phase, when
heterochromatin is replicated, Ctcf-null cells may have difficulties in replicating
heterochromatin. Together, these data point to a link between damage accumulation and
DNA replication sites during S phase in Ctcf-deficient NPCs.
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To gain more insight into the type of DNA damage incurred in the absence of CTCF,
NPCs were subjected to a variety of exogenous damaging agents. Ctcf-null NPCs were
hypersensitive to the DNA polymerase inhibitor aphidicolin (Berger et al., 1979), the
ribonucleotide reductase inhibitor hydroxyurea (Young and Hodas, 1964) and the
interstrand crosslinking agent mitomycin C (Nakata et al., 1961), but not γ-irradiation or
the topoisomerase II inhibitor etoposide (Minocha and Long, 1984) (Figure 4-3a-e).
Collectively, these findings implicate CTCF in either the response to, or repair of, DNA
replication-related damage.
Replicative stress has been broadly defined as any event that alters fulfillment of the
DNA replication program (Magdalou et al., 2014; Zeman and Cimprich, 2014).
Replication fork stalling results in a build-up of single stranded DNA (ssDNA),
accumulation and phosphorylation of replication associated protein A (pRPAS33),
recruitment of the PI-3 kinase ataxia telangiectasia and Rad3 related (ATR), and
activation of the checkpoint kinase Chk1 (pChk1S345) (Zeman and Cimprich, 2014).
Replication stress can also occur if the replication fork encounters barriers to its
progression i.e. transcriptional complexes, unresolved DNA secondary structures, or
double-stranded breaks (DSBs) (Allen et al., 2011; Mirkin and Mirkin, 2007).
Replication stress can itself result in DSB formation, as prolonged replication fork
stalling can result in collapse of the fork (Zeman and Cimprich, 2014). Western blot
analysis of control and CtcfNes-cre NPCs established from E12.5 telencephalon and
cultured for two days in vitro demonstrated modest increases in pRPAS33, pChk1S345
and γH2AX levels under basal conditions, suggesting that CTCF loss induces a
replicative stress response (Figure 4-3f,g). Induction of exogenous replicative stress by
the addition of aphidicolin resulted in a similar increases in pRPAS33, pChk1S345 and
γH2AX levels in CtcfNes-cre compared to control NPCs (Figure 4-3f,g). These results
indicate that CTCF is not required for signaling downstream of replicative stress through
these molecules (Figure 4-3f,g). A more detailed analysis of replication fork dynamics by
molecular combing revealed decreased replication fork speed in CtcfNes-cre NPCs relative
to control, suggesting that CTCF is required for normal replication fork progression
(Figure 4-3h). Together, these experiments demonstrate that CTCF is required to prevent
replication-associated damage and a replicative stress response in NPCs.
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Figure 4-3 Ctcf-null NPCs exhibit evidence of replicative stress
(A-E) Cells were treated with a variety of DNA damaging agents for 24h (except for
acute γ-irradiation) and viability was measured 24h later, n = 4; *P < 0.05. (F) Control
and CtcfNes-cre NPCs were cultured in the presence or absence of aphidicolin (Aph; 10µM,
6h) and lysates were probed for pRPAS33, total RPA, γH2AX, and pChk1S345. H3 was
used as a loading control. Densitometry analysis of γH2AX, pRPAS33, and pChk1S345
relative to H3 is depicted in (G), n = 2. Graphical data is represented as mean ± standard
error of the mean. (H) The distribution of replication fork progression rates in control
and CtcfNes-cre (KO) NPCs are represented in a box plot. Track lengths were converted
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into kilobase pairs using a conversion factor for λ DNA and the median fork rate for each
biological replicate is shown. P values were determined using the Mann-Whitney U-test
for non-parametric data to compare the distributions of fork rates (kb/min) between two
samples.
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Activation of the replicative stress response can result in intra-S or G2/M arrest (Feijoo et
al., 2001; Walworth et al., 1993). Flow cytometry was performed to determine the effect
of CTCF loss on cell cycle progression of NPCs established from E12.5 telencephalon
and cultured for two days in vitro (Figure 4-4a). Analysis of BrdU/propidium iodide
incorporation indicated a modest increase in the proportion of Ctcf-null NPCs in S phase,
with a concomitant decrease in G0/G1 cells (Figure 4-4a). This trend was not statistically
significant, likely owing to variability between biological replicates. In vivo
immunofluorescence analysis of E14 cryosections using a G2/M marker (pH3S10) in
conjunction BrdU (1h injection of pregnant dam prior to sacrifice) indicated no
significant differences between the proportion of cells in S phase (BrdU+/pH3-) or G2
phase (BrdU+/pH3+) in control and CtcfNes-cre neocortex (Figure 4-4b-d). There was a
slight increase in the number of mitoses (pH3+/BrdU-) in the basal SVZ, while there was
no difference in the number of apical mitoses along the VZ (Figure 4-4e). This data fits
with our previous results showing an increase in the population of TBR2+ basal
progenitor cells, which undergo mitosis in the SVZ (Haubensak et al., 2004; Miyata et
al., 2004; Noctor et al., 2004; Watson et al., 2014). In summary, despite evidence that
supports activation of a replicative stress response as measured by phosphorylation of
RPA (pRPAS33) and Chk1 (pChk1S345), cell cycle profiles are similar between control
and Ctcf-null NPCs (Figure 4-4).
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4.3.3 An interaction between CTCF and PCNA is DNA-mediated
An important role for CTCF in DNA replication has been supported by the finding that
CTCF is important for asynchronous replication of the H19/Igf2 imprinted domain, and
that CTCF binding upstream of the DM1 repetitive tract in the myotonic dystrophy gene
is required to slow the replication fork before encountering repetitive DNA to ensure
replicative fidelity (Bergstrom et al., 2007; Cleary et al., 2010; Libby et al., 2008).
Additionally, mass spectrometry analysis of CTCF binding partners in embryonic stem
cells revealed numerous binding partners that participate in DNA replication such as
PCNA, RCF1, RCF2, RCF4, Orc1, and DNA polymerase delta (van de Nobelen, 2008).
We validated the interaction between CTCF and PCNA by immunoprecipitation of
PCNA in control NPCs, followed by immunoblotting for CTCF (Figure 4-5a).
Pretreatment of the protein lysates with DNAse I prior to immunoprecipitation
demonstrated a diminished interaction between CTCF and PCNA, indicating an indirect
interaction mediated by DNA but supporting a close association between the two proteins
(Figure 4-5a).

4.3.4 CTCF is not required for timely repair of exogenous replicationassociated damage
We next considered that the increased endogenous replication-associated damage
observed in Ctcf-deficient cells might result from a requirement for CTCF in DNA repair.
Indeed, NPCs encounter a high degree of replicative stress due to their high proliferative
index (McKinnon, 2013), and CTCF localizes to replicative stress-induced damage foci
in NPCs (Figure 4-5b). Given the close relationship between CTCF and the cohesin
complex (Parelho et al., 2008; Rubio et al., 2008; Wendt et al., 2008), and the fact that
cohesin is required for post-replicative repair by homologous recombination (Sjogren and
Nasmyth, 2001), this became an intriguing hypothesis. To test this, we subjected control
and Ctcf-null NPCs to aphidicolin treatment and measured repair kinetics by assessing
γH2AX levels over time (Figure 4-5b,c). Control NPCs exhibited a 6-fold increase in
γH2AX foci 6 h after aphidicolin treatment that was reduced by 24 h post treatment
(Figure 4-5b,c). The number of γH2AX foci in Ctcf-null NPCs followed a similar trend,
despite the basal level of γH2AX foci (Figure 4-5c,d). This experiment provides evidence
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that CTCF is not required for resolution of γH2AX foci after the induction of exogenous
replicative stress. Interestingly, the DNA-mediated interaction between CTCF and PCNA
was enhanced under conditions of replicative stress (10µM aphidicolin, 6h; Figure 4-5a),
however the functional significance of this relationship is not yet understood.
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Figure 4-5 An indirect interaction between CTCF and PCNA is enhanced under
conditions of replicative stress, however CTCF is not required for repair of
replication-associated damage
(A) Control NPCs were cultured in the presence or absence of 10µM aphidicolin for 6h
and subjected to PCNA immunoprecipitation (IP) followed by immunoblotting for
CTCF. Lysates were pretreated with Dnase I prior to IP where indicated. (B) Confocal
images of γH2AX immunostaining in control and Ctcf-null NPCs post 10 µM aphidicolin
for the length of time indicated. Scale bar: 5 µm. (C) The number of γH2AX foci per
DAPI+ nucleus was quantified at 0, 6, and 24 hours post 10 µM aphidicolin treatment, n =
4; 50-100 nuclei counted per treatment. Graphical data is represented as mean ± standard
error of the mean.
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4.4 Discussion
We, and others, have previously demonstrated that CTCF is an essential factor for
cellular survival (Fedoriw et al., 2004; Heath et al., 2008; Moore et al., 2012; Soshnikova
et al., 2010; Wan et al., 2008; Watson et al., 2014). Despite this important role in the cell,
the mechanism underlying apoptosis of Ctcf-deficient cells is largely unknown. Here, we
provide evidence that CTCF is required to prevent replication-associated DNA damage in
NPCs.
Mice in which Ctcf was deleted from early forebrain progenitors using Foxg1-cre
exhibited massive apoptosis resulting in near-complete ablation of telencephalic
structures (Watson et al., 2014). Remarkably, when Ctcf was deleted a few days later
using Nestin-cre, cortical progenitor loss was reduced (Watson et al., 2014). Both models
of CTCF loss exhibited elevated DNA damage concurrent with apoptosis. This is
reminiscent of models of Topbp1 deletion, where levels of apoptosis were higher upon
deletion of Topbp1 in early progenitors (using Emx1-cre) compared to later progenitors
(using Nestin-cre) despite similar levels of DNA strand breaks in the two models (Lee et
al., 2012a). The results presented here support the idea that earlier NPCs have a lower
threshold for DNA damage-induced apoptosis compared with progenitors generated at a
later developmental stage.
In response to DNA damage, p53 activates cell cycle arrest and/or apoptosis (Amundson
et al., 1998). Ctcf-deficient NPCs have increased levels of γH2AX, exhibit replicative
stress, and are sensitive to exogenous agents that perturb replication. However, the
increased replication-associated DNA damage was not sufficient to dramatically alter cell
cycle progression, perhaps indicating that DNA damage levels only exceeded a threshold
sufficient to activate cell cycle arrest in a proportion of mutant cells. This idea is
supported by the modest increases observed in activation of the effector proteins involved
in replicative stress-associated cell cycle arrest, and a subtle trend towards increased Ctcfdeficient S phase cells in vitro and in vivo (Figures 4-3f, 4-4a,c). Since neurogenic
progenitors have a lengthened G1 phase, and postmitotic neurons behave like cells in G1
in their DNA content and failure to incorporate BrdU, then the increased basal progenitor
population and increased generation of postmitotic neurons observed in the Ctcf-null
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neocortex would result in an artificially high G1 population by flow cytometry. Since
flow cytometry is a population-based measure, the proportion of cells in other phases
would be compromised. Analysis of strictly proliferative progenitors by analyzing Tis21negative cells (Calegari and Huttner, 2003) would more accurately identify S phase
populations.
Our experiments provide evidence that CTCF is not required for repair of exogenous
replication-associated DNA damage since Ctcf-null NPCs exhibited similar capacity to
resolve γH2AX foci relative to control cells after aphidicolin treatment (Figure 4-5a,b).
This result must be interpreted with caution, however, since different types of stress elicit
different cellular responses. More sensitive assays to measure repair kinetics such as the
comet assay to directly measure single- and double-stranded breaks without relying on a
cellular marker like γH2AX will provide more insight into the ability of Ctcf-null cells to
repair DNA damage. The finding that CTCF is not required for repair of aphidicolininduced damage but that Ctcf-null cells are sensitive to the drug indicates that additional
replicative stress in the absence of CTCF likely exceeds the threshold for apoptosis.
Interestingly, CTCF is enriched at aphidicolin-induced damage foci and indirectly
interacts with PCNA and γH2AX under conditions of replicative stress. While CTCF
may not be required for repair of aphidicolin-induced damage per se, it may play a role in
organizing higher-order chromatin structure surrounding DNA breaks to help facilitate
timely repair.
Genome-wide maps of chromatin interaction revealed that the genome is organized into
specific domains within the nucleus, termed topologically associating domains (TADs),
whose borders are enriched for CTCF binding sites, suggesting a role for CTCF in
establishment of this type of genome organization (Dixon et al., 2012). Recently, it was
demonstrated that chromatin loops bound by CTCF demarcate TAD borders (Rao et al.,
2014) and that TADs show a striking correlation with replication timing domains (Pope
et al., 2014). Thus, if CTCF is important for TAD organization, it may also be important
for the organization of replication timing. Indeed, RNAi-mediated CTCF knockdown
results in the loss of some TAD boundary activity (Zuin et al., 2014). Furthermore, large
changes to the replication-timing program can result in replicative stress, and thus CTCF
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may function to organize TADs and by extension replication timing domains to suppress
this type of damage (Buonomo et al., 2009; Cornacchia et al., 2012). In light of our
findings, it will be important to test this hypothesis by assessing genome-wide replication
timing profiles of control and Ctcf-null NPCs in the future.
Collectively, our findings provide insight into the mechanism underlying CTCF function
in cellular survival. CTCF is required to prevent replication-associated damage, p53
activation, and apoptotic induction. It remains unclear whether CTCF is required directly
for repair of endogenously occurring replicative stress, or rather if increased DNA
damage resulting from CTCF loss are a secondary consequence of its functions in
chromatin organization. Future studies addressing the contributions of CTCF function to
DNA replication and repair will be critical to further our understanding of the
requirements for CTCF in cellular survival.

194

4.5 References
Allen, C., Ashley, A.K., Hromas, R., and Nickoloff, J.A. (2011). More forks on the road
to replication stress recovery. Journal of molecular cell biology 3, 4-12.
Amundson, S.A., Myers, T.G., and Fornace, A.J., Jr. (1998). Roles for p53 in growth
arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17, 32873299.
Antequera, F. (2004). Genomic specification and epigenetic regulation of eukaryotic
DNA replication origins. The EMBO journal 23, 4365-4370.
Arai, Y., Pulvers, J.N., Haffner, C., Schilling, B., Nusslein, I., Calegari, F., and Huttner,
W.B. (2011). Neural stem and progenitor cells shorten S-phase on commitment to neuron
production. Nature communications 2, 154.
Berger, N.A., Kurohara, K.K., Petzold, S.J., and Sikorski, G.W. (1979). Aphidicolin
inhibits eukaryotic DNA replication and repair --- implications for involvement of DNA
polymerase alpha in both processes. Biochemical and biophysical research
communications 89, 218-225.
Bergstrom, R., Whitehead, J., Kurukuti, S., and Ohlsson, R. (2007). CTCF regulates
asynchronous replication of the imprinted H19/Igf2 domain. Cell cycle 6, 450-454.
Berube, N.G., Mangelsdorf, M., Jagla, M., Vanderluit, J., Garrick, D., Gibbons, R.J.,
Higgs, D.R., Slack, R.S., and Picketts, D.J. (2005). The chromatin-remodeling protein
ATRX is critical for neuronal survival during corticogenesis. The Journal of clinical
investigation 115, 258-267.
Bravo, R., and Macdonald-Bravo, H. (1987). Existence of two populations of
cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA
replication sites. The Journal of cell biology 105, 1549-1554.
Buonomo, S.B., Wu, Y., Ferguson, D., and de Lange, T. (2009). Mammalian Rif1
contributes to replication stress survival and homology-directed repair. The Journal of
cell biology 187, 385-398.
Cleary, J.D., Tome, S., Lopez Castel, A., Panigrahi, G.B., Foiry, L., Hagerman, K.A.,
Sroka, H., Chitayat, D., Gourdon, G., and Pearson, C.E. (2010). Tissue- and age-specific
DNA replication patterns at the CTG/CAG-expanded human myotonic dystrophy type 1
locus. Nature structural & molecular biology 17, 1079-1087.
Cornacchia, D., Dileep, V., Quivy, J.P., Foti, R., Tili, F., Santarella-Mellwig, R., Antony,
C., Almouzni, G., Gilbert, D.M., and Buonomo, S.B. (2012). Mouse Rif1 is a key
regulator of the replication-timing programme in mammalian cells. The EMBO journal
31, 3678-3690.

195
Cvetic, C., and Walter, J.C. (2005). Eukaryotic origins of DNA replication: could you
please be more specific? Seminars in cell & developmental biology 16, 343-353.
Dixon, J.R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J.S., and Ren,
B. (2012). Topological domains in mammalian genomes identified by analysis of
chromatin interactions. Nature 485, 376-380.
Fedoriw, A.M., Stein, P., Svoboda, P., Schultz, R.M., and Bartolomei, M.S. (2004).
Transgenic RNAi reveals essential function for CTCF in H19 gene imprinting. Science
303, 238-240.
Feijoo, C., Hall-Jackson, C., Wu, R., Jenkins, D., Leitch, J., Gilbert, D.M., and Smythe,
C. (2001). Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1
in the intra-S phase checkpoint monitoring replication origin firing. The Journal of cell
biology 154, 913-923.
Filippova, G.N., Lindblom, A., Meincke, L.J., Klenova, E.M., Neiman, P.E., Collins, S.J.,
Doggett, N.A., and Lobanenkov, V.V. (1998). A widely expressed transcription factor
with multiple DNA sequence specificity, CTCF, is localized at chromosome segment
16q22.1 within one of the smallest regions of overlap for common deletions in breast and
prostate cancers. Genes, chromosomes & cancer 22, 26-36.
Filippova, G.N., Thienes, C.P., Penn, B.H., Cho, D.H., Hu, Y.J., Moore, J.M., Klesert,
T.R., Lobanenkov, V.V., and Tapscott, S.J. (2001). CTCF-binding sites flank CTG/CAG
repeats and form a methylation-sensitive insulator at the DM1 locus. Nature genetics 28,
335-343.
Gloster, A., El-Bizri, H., Bamji, S.X., Rogers, D., and Miller, F.D. (1999). Early
induction of Talpha1 alpha-tubulin transcription in neurons of the developing nervous
system. The Journal of comparative neurology 405, 45-60.
Gregor, A., Oti, M., Kouwenhoven, E.N., Hoyer, J., Sticht, H., Ekici, A.B., Kjaergaard,
S., Rauch, A., Stunnenberg, H.G., Uebe, S., et al. (2013). De novo mutations in the
genome organizer CTCF cause intellectual disability. American journal of human
genetics 93, 124-131.
Guillou, E., Ibarra, A., Coulon, V., Casado-Vela, J., Rico, D., Casal, I., Schwob, E.,
Losada, A., and Mendez, J. (2010). Cohesin organizes chromatin loops at DNA
replication factories. Genes & development 24, 2812-2822.
Haubensak, W., Attardo, A., Denk, W., and Huttner, W.B. (2004). Neurons arise in the
basal neuroepithelium of the early mammalian telencephalon: a major site of
neurogenesis. Proceedings of the National Academy of Sciences of the United States of
America 101, 3196-3201.
Heath, H., Ribeiro de Almeida, C., Sleutels, F., Dingjan, G., van de Nobelen, S., Jonkers,
I., Ling, K.W., Gribnau, J., Renkawitz, R., Grosveld, F., et al. (2008). CTCF regulates

196
cell cycle progression of alphabeta T cells in the thymus. The EMBO journal 27, 28392850.
Hebert, J.M., and McConnell, S.K. (2000). Targeting of cre to the Foxg1 (BF-1) locus
mediates loxP recombination in the telencephalon and other developing head structures.
Developmental biology 222, 296-306.
Isaac, C.E., Francis, S.M., Martens, A.L., Julian, L.M., Seifried, L.A., Erdmann, N.,
Binne, U.K., Harrington, L., Sicinski, P., Berube, N.G., et al. (2006). The retinoblastoma
protein regulates pericentric heterochromatin. Molecular and cellular biology 26, 36593671.
Jeffers, J.R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., MacLean, K.H., Han,
J., Chittenden, T., Ihle, J.N., et al. (2003). Puma is an essential mediator of p53dependent and -independent apoptotic pathways. Cancer cell 4, 321-328.
Juraeva, D., Haenisch, B., Zapatka, M., Frank, J., Investigators, G., Group, P.-G.S.W.,
Witt, S.H., Muhleisen, T.W., Treutlein, J., Strohmaier, J., et al. (2014). Integrated
pathway-based approach identifies association between genomic regions at CTCF and
CACNB2 and schizophrenia. PLoS genetics 10, e1004345.
Kurukuti, S., Tiwari, V.K., Tavoosidana, G., Pugacheva, E., Murrell, A., Zhao, Z.,
Lobanenkov, V., Reik, W., and Ohlsson, R. (2006). CTCF binding at the H19 imprinting
control region mediates maternally inherited higher-order chromatin conformation to
restrict enhancer access to Igf2. Proceedings of the National Academy of Sciences of the
United States of America 103, 10684-10689.
Lee, Y., Katyal, S., Downing, S.M., Zhao, J., Russell, H.R., and McKinnon, P.J. (2012).
Neurogenesis requires TopBP1 to prevent catastrophic replicative DNA damage in early
progenitors. Nature neuroscience 15, 819-826.
Libby, R.T., Hagerman, K.A., Pineda, V.V., Lau, R., Cho, D.H., Baccam, S.L., Axford,
M.M., Cleary, J.D., Moore, J.M., Sopher, B.L., et al. (2008). CTCF cis-regulates
trinucleotide repeat instability in an epigenetic manner: a novel basis for mutational hot
spot determination. PLoS genetics 4, e1000257.
Ling, J.Q., Li, T., Hu, J.F., Vu, T.H., Chen, H.L., Qiu, X.W., Cherry, A.M., and
Hoffman, A.R. (2006). CTCF mediates interchromosomal colocalization between
Igf2/H19 and Wsb1/Nf1. Science 312, 269-272.
Magdalou, I., Lopez, B.S., Pasero, P., and Lambert, S.A. (2014). The causes of
replication stress and their consequences on genome stability and cell fate. Seminars in
cell & developmental biology 30, 154-164.
McKinnon, P.J. (2013). Maintaining genome stability in the nervous system. Nature
neuroscience 16, 1523-1529.

197
Minocha, A., and Long, B.H. (1984). Inhibition of the DNA catenation activity of type II
topoisomerase by VP16-213 and VM26. Biochemical and biophysical research
communications 122, 165-170.
Mirkin, E.V., and Mirkin, S.M. (2007). Replication fork stalling at natural impediments.
Microbiology and molecular biology reviews : MMBR 71, 13-35.
Miyata, T., Kawaguchi, A., Saito, K., Kawano, M., Muto, T., and Ogawa, M. (2004).
Asymmetric production of surface-dividing and non-surface-dividing cortical progenitor
cells. Development 131, 3133-3145.
Moore, J.M., Rabaia, N.A., Smith, L.E., Fagerlie, S., Gurley, K., Loukinov, D., Disteche,
C.M., Collins, S.J., Kemp, C.J., Lobanenkov, V.V., et al. (2012). Loss of maternal CTCF
is associated with peri-implantation lethality of Ctcf null embryos. PloS one 7, e34915.
Nakata, Y., Nakata, K., and Sakamoto, Y. (1961). On the action mechanism of
mitomycin C. Biochemical and biophysical research communications 6, 339-343.
Noctor, S.C., Martinez-Cerdeno, V., Ivic, L., and Kriegstein, A.R. (2004). Cortical
neurons arise in symmetric and asymmetric division zones and migrate through specific
phases. Nature neuroscience 7, 136-144.
Parelho, V., Hadjur, S., Spivakov, M., Leleu, M., Sauer, S., Gregson, H.C., Jarmuz, A.,
Canzonetta, C., Webster, Z., Nesterova, T., et al. (2008). Cohesins functionally associate
with CTCF on mammalian chromosome arms. Cell 132, 422-433.
Pope, B.D., Ryba, T., Dileep, V., Yue, F., Wu, W., Denas, O., Vera, D.L., Wang, Y.,
Hansen, R.S., Canfield, T.K., et al. (2014). Topologically associating domains are stable
units of replication-timing regulation. Nature 515, 402-405.
Rakha, E.A., Green, A.R., Powe, D.G., Roylance, R., and Ellis, I.O. (2006). Chromosome
16 tumor-suppressor genes in breast cancer. Genes, chromosomes & cancer 45, 527-535.
Rao, S.S., Huntley, M.H., Durand, N.C., Stamenova, E.K., Bochkov, I.D., Robinson, J.T.,
Sanborn, A.L., Machol, I., Omer, A.D., Lander, E.S., et al. (2014). A 3D Map of the
Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping. Cell
159, 1665-1680.
Rubio, E.D., Reiss, D.J., Welcsh, P.L., Disteche, C.M., Filippova, G.N., Baliga, N.S.,
Aebersold, R., Ranish, J.A., and Krumm, A. (2008). CTCF physically links cohesin to
chromatin. Proceedings of the National Academy of Sciences of the United States of
America 105, 8309-8314.
Sideridou, M., Zakopoulou, R., Evangelou, K., Liontos, M., Kotsinas, A., Rampakakis,
E., Gagos, S., Kahata, K., Grabusic, K., Gkouskou, K., et al. (2011). Cdc6 expression
represses E-cadherin transcription and activates adjacent replication origins. The Journal
of cell biology 195, 1123-1140.

198
Sjogren, C., and Nasmyth, K. (2001). Sister chromatid cohesion is required for
postreplicative double-strand break repair in Saccharomyces cerevisiae. Current biology :
CB 11, 991-995.
Slack, R.S., El-Bizri, H., Wong, J., Belliveau, D.J., and Miller, F.D. (1998). A critical
temporal requirement for the retinoblastoma protein family during neuronal
determination. The Journal of cell biology 140, 1497-1509.
Sopher, B.L., Ladd, P.D., Pineda, V.V., Libby, R.T., Sunkin, S.M., Hurley, J.B., Thienes,
C.P., Gaasterland, T., Filippova, G.N., and La Spada, A.R. (2011). CTCF regulates
ataxin-7 expression through promotion of a convergently transcribed, antisense
noncoding RNA. Neuron 70, 1071-1084.
Soshnikova, N., Montavon, T., Leleu, M., Galjart, N., and Duboule, D. (2010).
Functional analysis of CTCF during mammalian limb development. Developmental cell
19, 819-830.
Splinter, E., Heath, H., Kooren, J., Palstra, R.J., Klous, P., Grosveld, F., Galjart, N., and
de Laat, W. (2006). CTCF mediates long-range chromatin looping and local histone
modification in the beta-globin locus. Genes & development 20, 2349-2354.
van de Nobelen, S. (2008). Touched by CTCF: Analysis of a Multi-Functional Zinc
Finger Protein. In Cell Biology (Erasmus MC in Rotterdam), pp. 175.
Walworth, N., Davey, S., and Beach, D. (1993). Fission yeast chk1 protein kinase links
the rad checkpoint pathway to cdc2. Nature 363, 368-371.
Wan, L.B., Pan, H., Hannenhalli, S., Cheng, Y., Ma, J., Fedoriw, A., Lobanenkov, V.,
Latham, K.E., Schultz, R.M., and Bartolomei, M.S. (2008). Maternal depletion of CTCF
reveals multiple functions during oocyte and preimplantation embryo development.
Development 135, 2729-2738.
Watson, L.A., Solomon, L.A., Li, J.R., Jiang, Y., Edwards, M., Shin-ya, K., Beier, F., and
Berube, N.G. (2013). Atrx deficiency induces telomere dysfunction, endocrine defects,
and reduced life span. The Journal of clinical investigation 123, 2049-2063.
Watson, L.A., Wang, X., Elbert, A., Kernohan, K.D., Galjart, N., and Berube, N.G.
(2014). Dual effect of CTCF loss on neuroprogenitor differentiation and survival. The
Journal of neuroscience : the official journal of the Society for Neuroscience 34, 28602870.
Wendt, K.S., Yoshida, K., Itoh, T., Bando, M., Koch, B., Schirghuber, E., Tsutsumi, S.,
Nagae, G., Ishihara, K., Mishiro, T., et al. (2008). Cohesin mediates transcriptional
insulation by CCCTC-binding factor. Nature 451, 796-801.
Yang, J., O'Donnell, L., Durocher, D., and Brown, G.W. (2012). RMI1 promotes DNA
replication fork progression and recovery from replication fork stress. Molecular and
cellular biology 32, 3054-3064.

199
Young, C.W., and Hodas, S. (1964). Hydroxyurea: Inhibitory Effect on DNA
Metabolism. Science 146, 1172-1174.
Zeman, M.K., and Cimprich, K.A. (2014). Causes and consequences of replication stress.
Nature cell biology 16, 2-9.
Zuin, J., Dixon, J.R., van der Reijden, M.I., Ye, Z., Kolovos, P., Brouwer, R.W., van de
Corput, M.P., van de Werken, H.J., Knoch, T.A., van, I.W.F., et al. (2014). Cohesin and
CTCF differentially affect chromatin architecture and gene expression in human cells.
Proceedings of the National Academy of Sciences of the United States of America 111,
996-1001.

200

Chapter 5
5 Discussion and Future Directions
The body of work presented in this thesis provides molecular evidence that epigenetic
regulators, such as those involved in organizing higher-order chromatin structure, are
necessary for NPC survival and growth by promoting genomic stability to support correct
brain development. This data aligns with the finding that intellectual disability,
microcephaly, and/or neuropsychiatric disorders are enriched for mutations in epigenetic
regulators (De Rubeis et al., 2014; Gibbons et al., 1995a; Gregor et al., 2013; Iossifov et
al., 2014; Pinto et al., 2014; Ronemus et al., 2014), and that human cancers are enriched
for alterations in epigenetic pathways (Elsasser et al., 2011; Filippova et al., 1996;
Huether et al., 2014; Jiao et al., 2011; Schwartzentruber et al., 2012).
In chapter two, I demonstrate that ATRX is required for stability of repetitive elements,
such as telomeres and pericentromeric heterochromatin, particularly during DNA
replication. I began exploring a mechanism underlying genomic instability in the absence
of ATRX and found that Atrx-null NPCs are sensitive to G4-DNA stabilization,
suggesting that ATRX may resolve G4-DNA structures that have the propensity to form
at telomeric sequences. More globally, ATRX may aid in the replication of repetitive
sequences through incorporation of H3.3, explaining the instability observed at
pericentromeric heterochromatin, which is AT- rather than GC-rich. Systemically, loss of
ATRX in the forebrain and anterior pituitary resulted in aging-associated phenotypes,
endocrine dysregulation, and reduced lifespan. Together, these findings implicate ATRX
in suppressing genome instability, which when restricted to the forebrain and anterior
pituitary can cause systemic defects that resemble accelerated aging.
Chapter three and four focus on characterizing the role of CTCF in embryonic brain
development. I found that CTCF is required for NPC survival by suppressing replicationassociated DNA damage and p53/PUMA-dependent apoptotic signaling. Additionally,
CTCF controls the balance between NPC proliferation and differentiation to support
correct brain growth and size. Taken together, these studies identify CTCF as an
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important regulator of brain development through controlling cell cycle dynamics and
cellular survival.
Collectively, the work presented in this thesis highlights the dynamic interplay between
chromatin structure, genomic stability, and brain development by revealing that ATRX
and CTCF are essential genomic stability factors in NPCs. The findings also begin to
dissect the mechanism underlying neurodevelopmental abnormalities stemming from loss
of ATRX or CTCF by identifying that loss of either factor causes replication-associated
DNA damage, highlighting the requirement of safeguarding the genome for correct
development of the central nervous system.

5.1 ATRX is a critical regulator of genomic stability
At the outset of this study, ATRX had not been implicated in promoting genomic
stability. In fact, it was believed that although ATRX is a homolog of the DNA repair
protein Rad54, it was unlikely to play a role in maintaining stability of the genome since
ATR-X patient cells do not display UV sensitivity (Gibbons et al., 1995b). My work
clearly demonstrates a requirement for ATRX in promoting genomic stability, providing
an explanation for p53-dependent apoptosis of Atrx-null NPCs (Seah et al., 2008). Other
studies have since shown that ATRX is required to prevent DNA damage during DNA
replication in myoblasts, HCT116 human colon cancer cells, limb bud cells, and ES cells
(Clynes et al., 2014; Conte et al., 2012; Huh et al., 2012; Leung et al., 2013; Solomon et
al., 2013).
ATRX-mediated genomic stability is critical for cellular survival, however it is not yet
known whether accumulation of DNA damage in Atrx-null cells is primary or secondary
to defects in replication. This remains difficult to distinguish since replication defects can
cause DNA damage and vice versa. For instance, DNA DSBs can impede the replication
fork to cause replication stalling and S phase lengthening. At the same time it is equally
possible that problems during replication, like fork slowing or failure to resolve complex
secondary structures, could cause stalling and collapse of the replication fork into DSBs.
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Several studies have demonstrated a role for ATRX in correct cell division (Baumann et
al., 2010; De La Fuente et al., 2004; Ritchie et al., 2008; Ritchie et al., 2014). Given the
close relationship between DNA replication, cell division, and cell cycle progression, it
has been difficult to decipher whether meiotic/mitotic defects stemming from ATRX loss
are primary or secondary to replicative stress. Issues during replication, such as underreplication of DNA sequences, failure to repair DSBs, or telomere uncapping can
manifest as anaphase bridges and/or micronuclei (Burrell et al., 2013; Gauthier et al.,
2012; Hampel et al., 2013; Incles et al., 2004; Kim et al., 2003; Sofueva et al., 2011;
Tahara et al., 2006). At the same time it is possible to envision mitotic defects, such as
congression and cohesion failure, to be capable of inducing DNA double-strand breaks
and issues during replication. For instance, mutation- or drug-induced mitotic spindle
disruption can induce DSBs that are found in centromere-containing micronuclei (Dalton
et al., 2007; Guerrero et al., 2010; Quignon et al., 2007). Moreover, chromosomal
instability can result from chromosome missegregation during mitosis (Dobles et al.,
2000).
Current evidence in the literature supports a model wherein ATRX functions to promote
replication fork processivity through notoriously difficult-to-replicate repetitive genomic
regions, thereby preventing fork stalling and collapse into DSBs that can aberrantly affect
cell division (Figure 5-1). This is substantiated by the findings that ATRX targets
repetitive DNA (Law et al., 2010), that Atrx-null cells exhibit replication defects (Clynes
et al., 2014; Leung et al., 2013), the particular sensitivity of Atrx-null cells to replicative
stress-inducing drugs (Clynes et al., 2014; Conte et al., 2012; Leung et al., 2013; Watson
et al., 2013), and that DNA damage foci in Atrx-null cells colocalize with late-replicating
heterochromatin (Huh et al., 2012; Watson et al., 2013). Further evidence for this model
of ATRX function is presented below.
ATRX genomic binding sites are predicted to adopt non-B form secondary structures
(Law et al., 2010), which have been shown to impede replication fork progression leading
to fork stalling or collapse into DSBs (Paeschke et al., 2011; Sarkies et al., 2012; Sarkies
et al., 2010). It is tempting to speculate that ATRX may facilitate replication by resolving
G4-DNA structures, an idea supported by the particular sensitivity of Atrx-null cells to
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replication stressors and the G4 ligand telomestatin (TMS) (Watson et al., 2013).
However, although recombinant ATRX can interact with G4-DNA oligonucleotides in
vitro (Law et al., 2010), it performed poorly in a G4-DNA unwinding assay compared to
the Bloom Syndrome helicase protein BLM (Clynes et al., 2014), suggesting that ATRX
does not directly unwind G4-DNA. ATRX may, however, indirectly overcome these
secondary structures by incorporating H3.3 into chromatin to maintain B-form DNA, or
alternatively through template switching. The ATPase domain of ATRX is similar to the
homologous recombination (HR) protein Rad54 (Picketts et al., 1998), which stabilizes
Rad51 onto presynaptic filaments to enable HR repair (Alexiadis and Kadonaga, 2002;
Golub et al., 1997; Tan et al., 1999) and to resolve stalled replication forks (Maher et al.,
2011). Atrx-deficient cells have decreased Rad51 levels (Huh et al., 2012), suggesting
ATRX may also function to stabilize Rad51 in some capacity.
We now know that ATRX interacts with the MRN complex (Clynes et al., 2014; Leung
et al., 2013), although the functional implications of this interaction are unclear. MRN is
required for DNA damage detection, signaling, and repair (Dinkelmann et al., 2009; Rass
et al., 2009; Taylor et al., 2010; Xie et al., 2009), as well as for promoting fork restart
after replicative stress (Bryant et al., 2009; Falck et al., 2012). MRN localizes to
telomeres in S and G2 phase, Mre11 can interact with G4-DNA in yeast (Ghosal and
Muniyappa, 2005; Leung et al., 2013; Verdun and Karlseder, 2006; Zhu et al., 2000), and
MRN is implicated in the alternative lengthening of telomeres (ALT) phenotype,
providing additional parallels with ATRX functions (Jiang et al., 2005; Zhong et al.,
2007). Human mutations in MRN components cause a spectrum of disease. For instance,
MRE11 mutations cause ataxia telangiectasia-like disorder (A-TLD) characterized by
ataxia and neurodegeneration, which shares similarities to A-T resulting from mutations
in ATM (Gatti et al., 1988; Stewart et al., 1999), and mutations in NBS1 cause Nijmegen
breakage syndrome (NBS) characterized by microcephaly, immunodeficiency, and cancer
predisposition (Carney et al., 1998; Rodrigues et al., 2013; Varon et al., 1998). The
parallels between ATR-X and NBS, like microcephaly, are intriguing since ATRX
interaction with MRN appears to be mediated by NBS1 (Leung et al., 2013), suggesting
that the overlapping phenotype may result from cooperative functions of the proteins.
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Chapter two of this thesis describes a requirement for ATRX in preventing accumulation
of endogenous DNA damage in the embryonic brain. The first indication that genomic
instability was linked to cellular proliferation came with the finding that the postreplicative juvenile Atrx-null mouse brain does not exhibit elevated DNA damage (Figure
2-9). However, Atrx-null cells do not display a typical response to replicative stress in
that mutant cells exhibit increased activation of ATM (pATMS1981) rather than ATR
(pATRS428) (Figure 2-1). A mouse model of Seckel syndrome carrying a hypomorphic
Atr mutation demonstrated that replicative stress activates an ATM-dependent DNA
damage response resulting in increased γH2AX levels (Murga et al., 2009). There is also
extensive cross-talk among the ATM and ATR kinases in NPCs (McKinnon, 2013). In
fact, telomere dysfunction in NPCs results in ATR-to-ATM-dependent signaling (Lee et
al., 2014), evoking the possibility that ATM and ATR may both be activated in Atrx-null
cells. Since ATR is phosphorylated on a number of different residues to mediate its
activation, it will be worthwhile to assess activation status of downstream targets of
ATR-dependent signaling like Chk1 and RPA in Atrx-deficient NPCs (Durocher and
Jackson, 2001; Shiloh, 2001). In human HCT116 cells, deletion of ATRX resulted in
reduced phosphorylation of Chk1 on serine 317 (Leung et al., 2013), suggesting ATRX is
required for correct checkpoint signaling downstream of ATR. Therefore, our observation
of increased ATM signaling in Atrx-null NPCs may result from defective ATR signaling
in response to the replicative stress induced by ATRX loss. The exact molecular details
of ATRX function in DNA damage signaling are clearly not completely understood and
require further examination.
The novel role for ATRX in genomic stability requires a thorough evaluation of the DNA
damage response in patient cells. Indeed, ATR-X patient lymphocytes exhibited
increased γH2AX and p53 phosphorylation suggestive of an increased DNA damage
response (Huh et al., 2012). However, it remains unclear whether patient cells exhibit
evidence of replicative stress or increased occurrence of unresolved secondary structures
like G4-DNA. With the recent generation of a G4-DNA-specific antibody (Biffi et al.,
2013) it will be possible to test this hypothesis in cellular models of Atrx deficiency as
well as in ATR-X patient cells.
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Figure 5-1 Model of ATRX function in genomic stability
ATRX is critical for stability of heterochromatin, presumably via incorporation of histone
H3.3 to maintain heterochromatin function. H3.3 incorporation may also help resolve G4DNA structures, which have the propensity to form at telomeres and GC-rich ssDNA
exposed during replication or transcription. The consequences of ATRX loss is (1) failure
to incorporate H3.3 at heterochromatin, resulting in dysfunction, DNA damage, and
mitotic defects and (2) failure to resolve G4-DNA structures, resulting in their overabundance that could cause replication stress and transcriptional dysregulation. The
relationship between H3.3 incorporation and G4-DNA resolution is not well
characterized.
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5.2 ATRX is a novel telomere-binding protein
This study is one of many to identify ATRX as an important component of telomeres
(Goldberg et al., 2010; Huh et al., 2012; Watson et al., 2013; Wong et al., 2010). In 2010,
two groups demonstrated that ATRX is required for H3.3 deposition at telomeric
sequences (Goldberg et al., 2010; Wong et al., 2010). The functional significance of H3.3
incorporation at telomeres remains unclear, especially in light of conflicting findings
regarding the effect of ATRX loss on transcription of the non-coding telomeric transcript
TERRA (Goldberg et al., 2010; Levy et al., 2014) and given that H3.3 enrichment was
generally observed in regions of active transcription (Hake et al., 2006). ATRX is also
involved in restricting the repressive variant macroH2A incorporation at telomeres
(Ratnakumar et al., 2012). Therefore, ATRX may be required to balance active and
repressive modifications at chromosome ends to promote their stability, a phenomenon
that has been observed at centromeres wherein a dual open and closed chromatin state is
necessary for stability (Chueh et al., 2009; Nakano et al., 2008; Wong et al., 2007). Loss
of this balancing act may render telomeres hypercondensed, leading to defects in TERRA
transcription or DNA replication. Furthermore features intrinsic to repetitive elements,
such as DNA bending and the propensity to form of G4 structures, can adversely affect
nucleosome occupancy and telomeres have decreased tendency to form nucleosomes in
vitro (Cacchione et al., 1997). The ATRX-DAXX complex may function to re-establish
H3.3 containing nucleosomes at these elements to help maintain proper nucleosome
density for heterochromatin formation, serving as a specialized chromatin assembly
pathway for repetitive regions such as telomeres, centromeres, and other regions of
constitutive heterochromatin. Defects in nucleosome assembly pathways, like the ATRXDAXX pathway, may therefore lead to increased DNA damage and genomic instability.
Telomere damage and mitotic fusions imply disintegration of the shelterin complex that
protects telomere ends from being recognized as DSBs (de Lange, 2005), therefore it
would be interesting to assess telomeres in Atrx-deficient cells for the presence of the
protective components.
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This thesis also describes a role for ATRX in PCH stability. PCH is AT-rich and
therefore not enriched for G4-forming sequence, suggesting that the mechanism
underlying destabilization of the major satellite repeats in an ATRX-deficient context
differs from that of telomeric repeats. The common link between telomeric and
pericentromeric heterochromatin is enrichment of H3K4me0-K9me3 and the requirement
for ATRX in H3.3 deposition (Drane et al., 2010; Goldberg et al., 2010; Lewis et al.,
2010). Therefore the mechanism underlying ATRX-dependent stability of repetitive
elements may more broadly involve H3.3 deposition rather than specific resolution of
G4-DNA structures. The recent discovery that ATRX can tolerate the histone H3K9me3S10ph modification is intriguing since other H3K9me3 readers, such as HP1, are unable
to bind this signature and become displaced (Kunowska et al., 2015). H3S10ph is induced
during late G2 and remains associated with chromatin during mitosis (Jeong et al., 2010;
Nigg, 2001). It is possible that ATRX functions at heterochromatin are particularly
relevant in actively cycling cells due to its ability to remain bound to H3K9me3-S10ph
residues, when other proteins required for heterochromatin stability are displaced.
Telomeres and PCH also express non-coding RNA transcripts that act as structural
components implicated in heterochromatin formation and maintenance (Azzalin et al.,
2007; Bulut-Karslioglu et al., 2012; Nergadze et al., 2009; Schoeftner and Blasco, 2008).
Given that ATRX can interact with RNA (Sarma et al., 2014), the non-coding transcripts
originating from telomeres and PCH may play a role in ATRX targeting and/or
suppression of the DDR at these structures in the absence of ATRX. Indeed,
dysregulation of PCH transcripts results in mitotic dysfunction (Bulut-Karslioglu et al.,
2012) and alterations in TERRA levels causes activation of the DDR at telomeres (Deng
et al., 2009; Deng et al., 2012b).
The mechanism of ATRX recruitment to telomeres is unknown. Telomeric chromatin is
enriched for inactive histone post-translational modifications recognized by the ATRX
ADD domain, such as H3K9me3 (Dhayalan et al., 2011; Eustermann et al., 2011; Iwase
et al., 2011; Mitson et al., 2011), providing one explanation for ATRX recruitment to the
genomic structures. ATRX interaction with G4-DNA, at least in vitro (Law et al., 2010),
provides another explanation. Moreover, ATRX recruitment may also be mediated or
stabilized by protein-protein or protein-RNA interactions, as ATRX was recently
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identified as an RNA-binding protein (Sarma et al., 2014), and interacts with telomereenriched proteins such as the MRN complex (Verdun et al., 2005), HP1 (Fanti et al.,
1998; Fanti and Pimpinelli, 2008), the cohesin complex (Remeseiro et al., 2012).
Moreover, the ATRX partner MeCP2 interacts with TERRA RNA (Deng et al., 2009),
indicating the possibility that ATRX recruitment may occur via MeCP2. Future studies
aimed at identifying the ATRX protein domains required for targeting to telomeres will
be pivotal in furthering our understanding of ATRX contributions to telomere biology
and genomic stability.

5.3 ATRX functions as a tumour-suppressor protein
Somatic loss-of-function mutations in ATRX were first described in pancreatic
neuroendocrine tumours (PanNETs) and later in CNS tumours such as glioma and
astrocytoma (Chen et al., 2014; Jiao et al., 2012; Jiao et al., 2011; Kannan et al., 2012;
Liu et al., 2012; Molenaar et al., 2012; Schwartzentruber et al., 2012). Genomic
instability is a hallmark of the early stages of tumourigenesis (Negrini et al., 2010).
Exacerbation of the DNA damage phenotype in cells lacking ATRX and p53 highlights
the tumour suppressive functions of p53 in mediating cell death to protect against
acquisition of genomic instability (Seah et al., 2008; Watson et al., 2013). Moreover, the
data fit well with the finding that ATRX/DAXX mutations commonly occur in conjunction
with mutations in the tumour suppressors p53 or IDH1 (Liu et al., 2012;
Schwartzentruber et al., 2012) and support a model wherein epigenetic factors like ATRX
may act as “backseat drivers” in a tissue-specific manner to suppress oncogenic pathways
upstream of master regulators common to a broad range to tumours, like p53 (Elsasser et
al., 2011). Studying mice and human cells lacking ATRX and p53 will improve our
understanding of the mechanisms underlying ATRX mutations promote tumourigenesis.
ATR-X syndrome patients do not display increased cancer susceptibility (Gibbons,
2005). This is likely due to the differential mutational landscape observed in ATR-X
syndrome versus ATRX-null tumours: ATR-X syndrome mutations are hypomorphic and
result in reduced activity or levels of the protein (Argentaro et al., 2007; Higgs et al.,
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2005), while mutations identified in cancers render the protein non-functional. Perhaps
decreased quantity or activity of ATRX protein renders specific cell types, like NPCs and
myoblasts (Huh et al., 2012; Watson et al., 2013), susceptible to DNA damage-induced
apoptosis during development, while cancer progression requires additional mutations in
tumour suppressors like p53 to prevent apoptosis and/or drive tumourigenesis.
Tumours harboring ATRX/DAXX mutations often utilize the alternative lengthening of
telomeres (ALT) pathway to confer immortality (Bower et al., 2012; Heaphy et al.,
2011a; Lovejoy et al., 2012; Schwartzentruber et al., 2012). The mechanism by which
ATRX mutations result in the ALT phenotype and drive cancer progression is largely
unknown. While my data demonstrates that ATRX loss causes telomere dysfunction,
deletion of ATRX alone is not sufficient to drive ALT (Clynes et al., 2014; Flynn et al.,
2015; Lovejoy et al., 2012), suggesting that additional genetic or epigenetic changes are
necessary to establish the phenotype. Accordingly, ATRX loss in NPCs did not
dramatically affect telomere FISH signal intensity (a surrogate for telomere length),
although this was not assessed in ATRX/p53 mutant cells.
Interestingly, ALT is associated with the appearance of large PML-NBs (referred to as
ALT-associated PML-NBs, or APBs) that contain telomeric DNA, the DNA repair MRN
complex, replication factor A (RPA), and telomeric-repeat binding proteins TRF1 and
TRF2 (Luciani et al., 2006; Wu et al., 2003; Wu et al., 2000; Yeager et al., 1999). The
appearance of APBs is a robust marker for tumours that utilize ALT, and APBs rapidly
assemble upon ALT induction (Costa et al., 2006; Henson et al., 2005; Perrem et al.,
2001), suggesting that APBs may be involved in the mechanism underlying ALT. PML
or MRN knockdown results in disassembly of ALT-associated PML-NBs, leading to
inhibition of telomere elongation in ALT cells (Jiang et al., 2005; Jiang et al., 2007; Wu
et al., 2000; Yu et al., 2010a). This is intriguing since ATRX/DAXX/H3.3 are PMLassociated factors (Chang et al., 2013; Ishov et al., 2004; Luciani et al., 2006), ATRX
interacts with the MRN complex (Clynes et al., 2014; Leung et al., 2013), and mutations
in this pathway drive cancers with a high frequency of ALT. It is possible that defects in
the ATRX/DAXX pathway results in a loss of heterochromatic features at telomeres,
such as H3.3 enrichment, increased TERRA transcription, and persistent RPA-ssDNA,
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leading to increased homologous recombination rates that are associated with ALT
activity. However it remains unclear as to how PML-NBs fit into this picture exactly.

5.4 Future Directions: ATRX Functions in Genomic Stability
Several questions remain unanswered with regards to ATRX function in promoting
cellular survival through genomic stability. These questions along with strategies to
address them are discussed below.
First, where exactly does DNA damage localize in Atrx-null cells? Is it concentrated at
telomeres and PCH, or does it also occur genome-wide? While my data provides
evidence that damage occurs at repetitive elements like telomeres and PCH, it is unclear
if these are the only regions susceptible to DNA damage in the absence of ATRX.
Evaluation of γH2AX occupancy genome-wide by ChIP-sequencing would identify the
landscape of DNA damage accumulation in Atrx-null cells. Given that ATRX targets
repetitive DNA (Law et al., 2010), the prediction would be that damage is enriched at
these sites if indeed ATRX plays a direct role in preventing γH2AX accumulation.
Next, what role, if any, does H3.3 incorporation play in the DNA damage phenotype
stemming from ATRX loss? While heavily speculated upon, the role for H3.3
incorporation in ATRX-dependent genomic stability is largely unknown. HIRAdependent H3.3 deposition is required for replication fork restart after UV damage
(Adam et al., 2013). It is possible that other pathways of H3.3 deposition, like ATRXDAXX, are responsible for replication fork restart after endogenous replicative stress.
Although H3.3 is only unique in five amino acids relative to H3.1 (Maze et al., 2014), the
recent generation of H3.3-specific antibodies allows for analysis of H3.3 enrichment
genome-wide. Our group recently demonstrated a requirement for ATRX in H3.3
deposition within gene bodies to promote transcriptional elongation (Levy et al., 2014).
Therefore it would be worthwhile to test whether ATRX is required for H3.3
incorporation at specific sites of damage, which can be induced using lasers or rarecutting endonucleases (Jasin, 1996; Kim et al., 2007a). An additional hypothesis that has
gained much attention is that ATRX resolves G4-DNA structures to facilitate
transcription and replication (Clynes and Gibbons, 2013; Clynes et al., 2013). The recent
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generation of a G4-DNA antibody demonstrated the in vivo occurrence of these structures
(Biffi et al., 2013), and provides a useful tool in testing the aforementioned hypothesis.

5.5 Hormone signaling from the CNS: Implications for understanding
aging?
A surprising finding from chapter two was that Foxg1Cre-mediated deletion of ATRX
from the forebrain and anterior pituitary causes systemic defects manifested by decreased
body weight and length, kyphosis, degeneration of subcutaneous fat, cloudy lenses that
resemble cataracts, altered relative organ sizes, and decreased bone mineral density. We
determined that the systemic defects correlated with altered endocrine signaling, as the
mutant mice displayed decreased thyroxine (T4) and insulin-like growth factor 1 (IGF-1)
levels compared to age- and littermate-matched controls (Figure 2-6). Moreover, the
mutant mice exhibited reduced lifespan even when controlling for competition amongst
littermates (Figure 2-4). Overall, the systemic phenotypes we described for the
conditional knockout (cKO) animals were characteristic of aged mice and resembled
mouse models of accelerated aging.
Numerous accelerated aging syndromes are caused by defects in the cellular response to
DNA damage, including Cockayne syndrome, Werner syndrome, and ataxia
telangiectasia (Hasty et al., 2003). Most of these syndromes are segmental, in that they do
not fully recapitulate all aspects of normal human aging, making the relevancy of these
disorders to human aging controversial (Kipling et al., 2004). However, the segmental
nature of the syndromes is congruent with the DNA damage theory of aging that posits
that aging results from DNA damage accumulation (Gensler and Bernstein, 1981;
Kirkwood and Holliday, 1979; Szilard, 1959), since damage is stochastic and each tissue
has different requirement for repair mechanisms and damage thresholds (Kirkwood,
2005).
The most consistent determinant of lifespan is the IGF-1 pathway (Bartke, 2005; Kenyon,
2005). IGF-1 is typically regulated by the action of growth hormone (GH), however T4
has been demonstrated to regulate IGF-1 during prepubescent development, particularly
in the context of bone development (Xing et al., 2012). The regulation of IGF-1 by T4
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was especially relevant in our study, since we did not observe changes in GH that could
explain the dramatic reduction in IGF-1 levels. This study was one of the first to
acknowledge a potential link between T4 and aging-like phenotypes. Moreover,
thyroxine is critical for development and maturation of the CNS, particularly neuronal
differentiation, migration, and myelination (de Escobar et al., 2004; Oppenheimer and
Schwartz, 1997; Porterfield and Hendrich, 1993). It is therefore possible that many of the
congenital neurological defects resulting from ATRX mutation or deletion in humans and
mice could be caused by thyroxine deficiency. This intriguing concept could be tested by
administering thyroxine to mouse models of Atrx-deficiency, as well as by measuring
thyroxine levels in ATR-X patients. Intriguingly, ATR-X patients display kyphosis,
muscle hypotonia, and delayed ambulation (Gibbons, 2006), however it is currently
unknown whether this is relevant to the endocrine defects observed in the cKO mice
described herein.
A key observation is that the somatotroph axis is suppressed in the ATRX cKO mice,
which correlates with increased DNA damage. This is consistent with genetic deletion of
the nucleotide excision repair factor ERCC1 (Niedernhofer et al., 2006), SIRT6
(Mostoslavsky et al., 2006), and overexpression of the short isoform of p53 (Maier et al.,
2004). Furthermore, chronic exposure of wild-type mice to genotoxic stress can also
dampen the somatotroph axis (Niedernhofer et al., 2006). Collectively, these studies
provide strong evidence of a link between genome maintenance and somatotroph axis
signaling. Our findings are unique in that deletion of ATRX, resulting in DNA damage
accumulation, occurred only in the forebrain and anterior pituitary. This suggests that
damage restricted to these regions can result in defective endocrine signaling and
promotion of systemic aging-like characteristics. Furthermore, telomeres are heavily
implicated in aging and cellular attrition (Sousounis et al., 2014), and this study links
telomeric dysfunction with specific features of aging. However, it remains unclear
exactly how telomere dysfunction fits into the systemic defects observed in ATRX cKO
mice. Short telomeres have been linked to premature aging-like phenotypes, which can be
rescued by reintroduction of telomerase (Samper et al., 2001). If the systemic defects in
the cKO mice are due to abnormal telomere shortening, then overexpression of
telomerase may constitute a means to rescue those phenotypes.
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5.6 CTCF regulates NPC proliferation, differentiation, and survival
Prior to my studies, virtually nothing was known regarding CTCF functions in the
context of brain development. In fact, CTCF activities had rarely been approached in an
organismal context. Given the critical role for CTCF in development (Fedoriw et al.,
2004; Heath et al., 2008; Moore et al., 2012; Soshnikova et al., 2010; Splinter et al.,
2006; Wan et al., 2008; Watson et al., 2014) and the finding that human CTCF mutations
cause autism and schizophrenia (Gregor et al., 2013; Iossifov et al., 2014; Juraeva et al.,
2014), CTCF has emerged as a critical regulator of brain development. In particular, my
data indicates that CTCF regulates brain size by balancing NPC proliferation,
differentiation, and survival.
CTCF deletion in mouse NPCs results in microcephaly. I discovered that the
microcephaly phenotype of mutant mice could not be fully explained by increased cell
death in the absence of CTCF, since rescue of caspase-mediated apoptosis through Puma
deletion failed to restore brain size at birth. A contributing factor to the microcephaly
phenotype is the fact that CTCF influences timing of NPCs differentiation. Ctcf deletion
causes precocious differentiation of NPCs into early-born deep layer cortical neurons,
resulting in premature depletion of the progenitor pool and a failure to sustain the correct
number of later-born superficial neurons. Together, aberrant differentiation timing and
increased apoptosis of NPCs likely accounts for the neurodevelopmental abnormalities
observed in NestinCre-mediated Ctcf deletion. The phenomenon of a premature switch
form symmetric to asymmetric NPC divisions has been observed in many mouse models
of microcephaly, and more recently induced pluripotent stem cell (iPSC)-based 3D
neuronal culture models (Gilmore and Walsh, 2013; Lancaster et al., 2013), indicating
that alterations in division mode can affect brain size.
An important distinction from the work presented in this thesis is that mutations
identified in intellectual disability/microcephaly patients are de novo and only affect one
copy of the CTCF gene (Gregor et al., 2013), as opposed to complete loss of CTCF.
Detailed analysis of the consequences of three patient mutations indicated that frameshift
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mutations resulted in an approximately 50% reduction in CTCF levels, while a missense
mutation in the ZF domain did not affect transcript or protein levels (Gregor et al., 2013).
This suggests that both the reduction of CTCF levels and alterations in its targeting or
functions can cause neurological abnormalities. Further investigations into the functional
consequences of human CTCF mutations will be necessary to fully resolve CTCF
contributions to brain development and function.
Fate determination of NPCs is orchestrated by intrinsic and extrinsic mechanisms. Many
studies indicate an essential role for centrosomes in neurogenesis (Doxsey et al., 2005;
Higginbotham and Gleeson, 2007; Knoblich, 2008; Wang et al., 2009), functioning to
maintain the neuroprogenitor pool while inducing the neuronal fate. CTCF has been
positioned at the centrosome in HeLa cells (Rosa-Garrido et al., 2012; Zhang et al.,
2004), raising the intriguing possibility that centrosomal activities of CTCF may regulate
neurogenesis. However my analysis of CTCF localization in NPCs indicated enrichment
at the mitotic spindle rather than at centrosomes per se (data not shown). Future
experiments aimed at uncovering CTCF activities at the mitotic spindle and/or
centrosomes will likely provide important insights into fate determination of NPCs.
Given that CTCF is a well-documented transcriptional regulator, it is also possible that
altered NPC fate results from dysregulation of cell cycle regulators or other genes that
play important roles in fate determination. Preliminary transcriptional profiling of the
Ctcf-deficient embryonic brain has indicated altered expression of several cell cycle
genes such as decreased expression of Cdkn2a and upregulation of cyclin D1 and Cdk6,
which is predicted to promote the G1 to S phase transition and fits with the slight increase
in the proportion of Ctcf-null S phase NPCs (Figure 4-4a). The Ctcf-null neocortex was
characterized by an increase in the basal progenitor (BP) population, similar to what is
observed after overexpression of cyclinD1 in neural stem cells (Lange et al., 2009).
CDK6 mutations cause microcephaly in humans, and were shown to affect progenitor cell
proliferation (Hussain et al., 2013). Furthermore, alterations in the retinoblastoma (Rb)
and Cdkn1a (p21) cell cycle regulators cause neurological phenotypes that resemble
CTCF loss (McClellan and Slack, 2006; Seoane, 2004; Slack et al., 1998). Global
transcriptional analysis failed to detect differences in the mRNA levels of Rb or p21,
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however these genes have been documented as direct CTCF targets in the literature (De
La Rosa-Velazquez et al., 2007; Filippova, 2008; Qi et al., 2003). In vivo analysis of cell
cycle progression failed to indicate any overt differences between control and Ctcf-null
cells (Figure 4-4), but a more detailed investigation of cell cycle parameters including
BrdU pulse-chase experiments and calculations of individual phase lengths may indicate
subtle differences in Ctcf-null NPCs that could have dramatic consequences on brain
development and growth.
Microcephaly can also result from increased cell death during brain development. Indeed,
CTCF deletion using two separate Cre driver lines caused increased NPC death.
Investigation of the mechanism underlying cell death indicated an increase in Puma
transcript and protein levels. PUMA is a potent activator of the mitochondrial cell death
pathway (Nakano and Vousden, 2001). Ctcf deletion in the developing limb bud also
caused increased Puma levels (Soshnikova et al., 2010), and analysis of Puma regulation
in HCT116 colon carcinoma cells indicated a p53-independent role for CTCF in
suppressing Puma transcription (Gomes and Espinosa, 2010a, b). This led to the
hypothesis that loss of CTCF-specific Puma repression causes ectopic induction of
apoptosis in a p53-independent manner. Analysis of p53 activation as well as generation
of Ctcf/Puma double mutant mice demonstrated that this hypothesis does not accurately
describe the complexity of apoptotic induction downstream of CTCF loss. Ctcfdeficiency resulted in evidence of p53 activation such as increased total p53 protein
levels and its translocation to the Puma promoter (Figure 3-3). Caspase-mediated
apoptosis is PUMA-dependent in Ctcf-null NPCs, as caspase activation was inhibited in
the Ctcf/Puma-deficient forebrain. However, the microcephaly phenotype at birth was not
restored in the double mutant brain, presumably due to upstream activation of p53.
Generation of Ctcf/p53 double mutant mice would be helpful in delineating apoptotic
from cell cycle defects downstream of CTCF loss.
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5.7 Towards understanding CTCF functions in cellular survival
Genotoxic stress triggers activation of p53/PUMA-dependent signaling in NPCs (Jeffers
et al., 2003). Since CTCF is regarded as an important organizer of global chromatin
structure (Ong and Corces, 2014), and Ctcf-null NPCs activate the p53/PUMA-dependent
signaling axis, I hypothesized that CTCF may regulate genomic stability to promote NPC
survival. Indeed, Ctcf mutant cells display elevated endogenous DSB levels and
sensitivity to exogenous stressors, particularly replicative stress-inducing agents. Further
analysis indicated a correlation between endogenous damage and active proliferation,
suggesting CTCF may protect cells from replicative stress. Despite this relationship, the
exact mechanism of CTCF function in preventing damage accumulation remains
enigmatic. My data suggests that CTCF is not involved in replicative stress signaling or
repair, however more thorough analysis is required to substantiate this claim. Given the
existing links between CTCF and replication (Cleary et al., 2002; Cleary et al., 2010;
Libby et al., 2008), the protein may play a more indirect role in preventing genomic
instability by facilitating DNA replication or the organization of replication timing
domains.
CTCF binding upstream of repetitive tracts is hypothesized to slow the replication fork
before progressing through difficult-to-replicate regions (Cleary et al., 2010). This idea is
similar to the proposed role for CTCF in alternative splicing regulation, wherein CTCF
binding downstream of weak exons promotes RNAPII pausing and exon inclusion
(Shukla et al., 2011). Therefore CTCF may be required globally to slow polymerase
progression, which in the context of replication may have important consequences for
repeat stability. In particular, CTCF depletion causes a telomere dysfunction phenotype
in U2OS cells (Deng et al., 2012a), indicating that at the very least CTCF is required for
telomeric stability.
The downstream consequences of Ctcf deletion using two different Cre driver lines were
remarkably distinct. In both instances, CTCF loss in NPCs resulted in elevated
endogenous DNA damage levels, Puma upregulation, and apoptotic induction. However,
deletion of CTCF from early progenitors at approximately E8.5 via Foxg1-cre was more
severe than deletion at approximately E11 using Nestin-cre. This result is reminiscent of
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inactivation of the replicative stress-signaling protein TopBP1. Deletion of TopBP1 in
early progenitors using Emx1-cre results in profound loss of forebrain structure, while
deletion in progenitors later in development using Nestin-cre causes a milder apoptotic
phenotype (Lee et al., 2012a). Moreover, irradiation-induced DNA damage results in
similar levels of DNA breaks in early and later progenitors, however apoptosis is elevated
in response to radiation in early progenitors versus later-born progenitors (Lee et al.,
2012a). Together, these data indicate that NPCs early in development trigger apoptosis
to prevent the propagation of damaged genetic material to daughter cells. Furthermore, it
provides a mechanism underlying the disparate phenotypes associated with CTCF loss
using two different Cre driver lines.
DNA lesions activate PARP1, triggering the synthesis of ADP-ribose and PARylation of
DNA repair proteins (Davies et al., 1978; Durkacz et al., 1980). Furthermore, PARP1
activity is required for efficient reversal of stalled replication forks (Ray Chaudhuri et al.,
2012). CTCF is poly(ADP-ribosyl)ated by PARP1 (Yu et al., 2004) and activates PARP1
by acting as a link between DNA and poly(ADP-ribosyl)ation (Farrar et al., 2010).
However, the CTCF and PARP1 interaction has primarily been studied in the context of
chromatin insulation and transcriptional regulation. My findings suggest a reevaluation of
the interaction between CTCF and PARP1 in the DDR and during replication fork restart.
The CTCF gene is located on chromosome 16q22.1, a deletion region well documented
in several human cancers (Filippova et al., 1998; Rakha et al., 2006). Ctcf functions as a
haploinsufficient tumour suppressor protein in mice (Kemp et al., 2014), strengthening
the link between CTCF loss and cancer progression. Ctcf+/- tumours exhibited widespread
DNA methylation changes, however it was unclear whether this effect was a primary or
secondary cause of CTCF loss, and if it is the direct upstream source of Ctcf+/- tumour
formation. My findings provide an additional avenue by which CTCF loss may promote
tumourigenesis. Indeed, genomic instability and replicative stress are potent mediators of
cancer progression, suggesting that replication-associated DNA damage may drive
tumour formation in the absence of CTCF. Furthermore, there are existing links between
DNA methylation status and genomic instability (O'Hagan et al., 2008; Robertson and
Jones, 1997), suggesting that altered methylation profiles could explain damage
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accumulation in the absence of CTCF. It is possible to test this by profiling global DNA
methylation in Ctcf-null NPCs by next-generation bisulfite mutagenesis sequencing.
However, it will be important to assess genomic stability in cells heterozygous for Ctcf as
well as in tumours harboring CTCF mutations.

5.8 Future Directions: CTCF Functions in Genomic Stability
The body of work described in chapters three and four of this thesis demonstrates that
CTCF is required for NPC survival through suppression of genomic instability. CTCF
impinges on the p53 signaling network to mediate survival and likely to control cellular
proliferation (Figure 5-2a). Several questions remain unanswered regarding CTCF
activities in preventing endogenous DNA damage accumulation, namely, is CTCF
directly or indirectly involved in the DDR?
Preliminary evidence suggests that CTCF is not required for timely repair of replicationassociated damage, as Ctcf-null NPCs were able to resolve aphidicolin-induced γH2AX
foci to baseline levels 24 hours post treatment (Figure 4-5). A more detailed analysis of
DNA repair capabilities in the absence of CTCF will be required to exclude a role for
CTCF in repair, especially given its localization at damage foci. The DR-GFP HR assay
would be an excellent method to assess whether Ctcf-null NPCs are repair-competent,
especially since replication-associated damage is typically repaired via HR (Jasin, 1996;
Pierce et al., 1999). DR-GFP consists of two expression plasmids: (1) containing two
tandem GFP genes, the first is a full-length GFP gene mutated with the 18 bp SceI
endonuclease recognition sequence and the second is a truncated GFP that can be utilized
as a template for repair, and (2) an SceI expression plasmid. Expressing both of the
plasmids in cells results in a SceI-mediated DSB in the full-length GFP gene. If cells are
capable of HR repair, they will utilize the truncated GFP for repair and will express the
GFP reporter (Pierce et al., 1999). It would also be worthwhile to induce damage with
different types of stressors, such as γ-irradiation or mitomycin C, to test whether CTCF is
required for the repair specific types of lesions.
An equally plausible scenario is that CTCF loss causes global chromatin dysregulation,
resulting in endogenous DNA damage. Global analysis of DNA damage sites via γH2AX
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ChIP-sequencing in mutant cells will be informative in understanding the role of CTCF
in suppressing endogenous damage accumulation. CTCF depletion causes global
chromosome compaction (Tark-Dame et al., 2014). Intriguingly, chromatin condensation
can lead to DDR signaling (Burgess et al., 2014), raising the distinct possibility that
global changes in chromatin organization artificially signal activation of the DDR
downstream of CTCF loss. Alternatively, changes to global chromosome architecture or
subnuclear domain organization may cause changes to the replication timing program
that can induce replicative stress (Cornacchia et al., 2012; Pope et al., 2014) (Figure 1-3),
a possibility that can be tested by profiling replication timing in Ctcf-deficient cells.
CTCF may instead function more directly during DNA replication, which is supported by
the finding that CTCF binding upstream of the repetitive DM1 locus is required for its
efficient and correct replication (Cleary et al., 2010) (Figure 5-2b) and my findings of
altered replication dynamics in NPCs (Figure 4-3h). Moreover, the work herein
demonstrates an interaction between CTCF and PCNA, albeit indirect, which would
support the model that CTCF binding upstream of repetitive elements is required for
polymerase fidelity (Figure 5-2b). Alternatively, CTCF may be involved in organizing
replication factories with cohesin (Figure 5-2c), which is supported by the interaction
between CTCF and the cohesin complex, namely the SA1 subunit that has been
implicated in telomere replication and stability (Remeseiro et al., 2012). Evidence also
points to a role for CTCF in organizing TAD boundaries (Dixon et al., 2012; Narendra et
al., 2015; Nora et al., 2012), which have recently been shown to regulate replication
timing (Pope et al., 2014). Profiling the timing (early and late-replicating) of control and
Ctcf-null cell DNA replication is the most direct method to test whether CTCF is required
for replication timing (Ryba et al., 2011) (Figure 5-2d). Together, my data suggests that
CTCF is required to prevent replication-associated damage in NPCs, however the
upstream molecular mechanism is currently unknown. The interaction between CTCF
and PCNA requires further examination, especially since the interaction appeared to be
enhanced under conditions of replicative stress. This finding may indicate a requirement
for the partnership between CTCF and cohesin in postreplicative repair (Figure 5-3e), as
cohesin is a well-established postreplicative repair factor (Sjogren and Nasmyth, 2001).
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Figure 5-2 Possible mechanisms underlying CTCF-dependent suppression of DNA
damage and p53-dependent signaling
(A) In NPCs, CTCF is required to suppress DNA damage and p53-dependent signaling.
Potential mechanisms of CTCF-dependent DNA damage suppression supported by the
literature and this work are presented in panels B-E. (B) CTCF binding upstream of
repetitive elements such as the DM1 locus (Cleary et al., 2010) and telomeres (Deng et
al., 2012a) is required for fork/polymerase slowing, as represented by green arrows, prior
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to progression through the elements to prevent fork slippage and collapse. (C) CTCF may
help organize replication factories through its ability to mediate higher-order chromatin
organization and interact with the cohesin complex and PCNA. (D) CTCF may be
required for the establishment of TADs, which play important roles in regulating
genome-wide replication timing domains (Pope et al., 2014). The diagram highlights
CTCF binding at TAD borders, which demarcate the boundaries between earlyreplicating active euchromatin (green) within the nuclear interior and passive replicating
regions (red arrows) that represent the transition regions between early- and latereplicating (heterochromatin found at the nuclear exterior; red) domains. (E) CTCF may
interact with cohesin and assist with postreplicative repair of DNA damage acquired
during S phase.
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A key finding of this work is that proteins that regulate higher-order chromatin structure
are essential for correct brain development through the balance of NPC proliferation,
differentiation, and survival. Deficiency of either Atrx or Ctcf in the embryonic brain
causes profound neurodevelopmental abnormalities, providing some insights into the
pathologies stemming from human ATRX and CTCF mutations.
The physiological ramifications of aberrant chromatin structure are still widely unknown,
however alterations in epigenetic regulators appear to particularly affect brain
development and cognition (Kleefstra et al., 2014). A high proportion of ID disorders are
caused by heterozygous de novo mutations in epigenetic regulators, suggesting that gene
dosage is critically important for correct brain development and functioning. Mutations in
ATRX and CTCF both cause intellectual disability disorders characterized by
microcephaly and autistic features (Gibbons et al., 1995b; Gregor et al., 2013; Iossifov et
al., 2014). Phenotypic similarities observed in these disorders may reflect common
molecular pathways affected by mutations in different genes.
The overlapping phenotype associated with Atrx- and Ctcf-deficiency, namely
accumulation of endogenous replication-associated DNA damage, indicates that the
proteins may function together to regulate NPC survival. Given that ATRX is required
for nucleosome remodeling and CTCF recruitment to imprinting control regions (ICRs)
(Kernohan et al., 2014), it may be worthwhile to assess whether ATRX is required for
CTCF localization in NPCs. Interestingly, CTCF sites are enriched for H3.3 (Jin et al.,
2009) and H3.3 deposition at CTCF sites facilitates H3K27me3 removal in HeLa cells
(Weth et al., 2014). Moreover, CTCF binds to human and mouse subtelomeric sequences,
and its depletion results in decreased TERRA transcription and telomere dysfunction in
U2OS cells (Deng et al., 2012a). ATRX may therefore facilitate CTCF recruitment to
subtelomeric regions to promote telomere stability. ATRX loss is correlated with
increased TERRA levels, however, suggesting that the relationship between ATRX,
CTCF, and telomere stability is not straightforward. It is also important to interpret
telomeric data derived from U2OS studies with caution since the cells do not express
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ATRX and exhibit ALT (Lovejoy et al., 2012). Nevertheless, investigations of telomeric
stability in Ctcf-null NPCs will provide insight into the genomic regions that acquire
damage in the absence of CTCF and may point to the underlying molecular mechanism
responsible for endogenous DNA damage downstream of CTCF loss. Unlike ATRX,
however, CTCF binds to numerous genomic locations (Kim et al., 2007b), suggesting
that CTCF function in preventing endogenous DNA damage is likely not telomerespecific. More global approaches, such as γH2AX ChIP-sequencing, will be required to
determine if specific DNA sequences are more susceptible to damage acquisition in the
absence of CTCF.
The finding that both Atrx and Ctcf deficient cells exhibit replication-associated damage
may simply be a consequence of the loss of genomic stability factors in rapidly
proliferating cortical NPCs. In other words, the genomic instability observed in Atrx- and
Ctcf-null cells may be enhanced by the highly proliferative nature of NPCs. This idea is
supported by the differences in cell viability after deletion of the genes using a Foxg1-cre
or Nestin-cre driver line (Berube et al., 2005; Watson et al., 2014), which likely reflects
the differential susceptibility of early and late NPCs to DNA damage (Lee et al., 2012a).
However, it is not supported by the selective sensitivity of Atrx- and Ctcf-null NPCs to
replicative stress-inducing agents. Furthermore, it is not supported by the finding that
ATRX localizes to late-replicating heterochromatin foci, the majority of DNA foci in
Atrx-null NPCs localizes to late-replicating foci, and the proposed model of ATRX
functions in remodeling heterochromatin in G2. It is also not supported by the finding
that Ctcf-null NPCs in the same regions of the embryonic cortex exhibit cell cycledependent DNA damage that correlates with PCNA staining. In conclusion, ATRX and
CTCF may not be involved in preventing replicative stress per se but rather are critical to
suppress DNA damage; the consequence of loss of these proteins being p53-dependent
apoptosis in the quickly dividing NPC population. Alternatively, the phenotypes observed
downstream of ATRX and CTCF loss may indicate critical cell cycle-dependent roles for
these proteins. Future experiments aimed at uncovering the exact biochemical
mechanisms of function for these proteins in different phases of the cell cycle will be
instrumental in dissecting their true actions in protecting the genome from DNA damage.
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Moreover, deficiency of either Atrx or Ctcf in NPCs causes precocious differentiation
early in corticogenesis, resulting in depletion of the progenitor pool and a failure to
sustain generation of late-born neurons (Ritchie et al., 2014; Watson et al., 2014).
Selective lengthening of the cell cycle, particularly the G1 phase, is hypothesized to
causally contribute to progenitor switching from proliferative to neuron-generating
divisions (Calegari et al., 2005; Calegari and Huttner, 2003). Replication errors or
unresolved replication intermediates generated during S/G2 phase can be converted into
DSBs during mitosis and are repaired in the subsequent G1 (Lukas et al., 2011), which
can induce G1 lengthening. If G1 lengthening is causal in promoting neurogenic divisions
of progenitors, then G1 lengthening may be responsible for the precocious differentiation
observed in the Atrx- and Ctcf-null neocortex (Figure 5-3).
The most common disease linked to replication stress is cancer (Bartek et al., 2012). This
fact is currently being exploited to induce synthetic lethality in tumour cells. For
example, PARP inhibitors have been used to block repair of ssDNA breaks that are
processed into DSBs during S phase, and results in apoptotic induction of HR-deficient
tumour cells (Jackson and Bartek, 2009). Along the same lines, ALT-positive tumour
cells, such as those with inactivating ATRX mutations, are sensitive to ATR inhibition
(Flynn et al., 2015). Further investigation of the exact mechanism underlying
tumourigenesis downstream of CTCF mutation will be necessary to advance cancer
therapeutics, especially given the high occurrence of 16q22.1 deletions in various human
cancers (Filippova et al., 1998; Rakha et al., 2004).
Replicative stress has also been associated with human neurological diseases such as
Seckel (OMIM# 210600), Aicardi-Goutieres (OMIM# 610333), Meier-Gorlin (OMIM#
224690), Nijmegen breakage (OMIM# 613078), and Wold-Hirschhorn (OMIM# 194190)
syndromes (Zeman and Cimprich, 2014). These syndromes feature overlapping
characteristics with ATR-X syndrome and patients with mutations in CTCF such as
intellectual disability and microcephaly, suggesting similar molecular mechanisms
underlying disease pathogenesis. However, analysis of patient cells and/or generation of
effective animal models of the disorders will be necessary to confirm or refute this claim.

225
The findings documented in this thesis broadly illustrate the importance of higher-order
chromatin regulation for correct brain development. They also support the genome-wide
association studies indicating that epigenetic pathway alterations play a major role in the
pathogenesis of neurodevelopmental and neuropsychiatric disease (De Rubeis et al.,
2014; Pinto et al., 2014). Collectively, the data positions two important epigenetic
regulators, ATRX and CTCF, at the intersection between chromatin structure and
genomic stability, and demonstrates the importance of higher-order chromatin
organization in safeguarding the genome to support correct brain development.
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